var title_f36_61_37840="Dapsone: Patient drug information";
var content_f36_61_37840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dapsone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=see_link\">",
"       Dapsone (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/51/1844?source=see_link\">",
"       Dapsone (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10981 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37840=[""].join("\n");
var outline_f36_61_37840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=related_link\">",
"      Dapsone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/51/1844?source=related_link\">",
"      Dapsone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37841="Mutations entry inhibitors";
var content_f36_61_37841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Mutations in the envelope gene associated with resistance to entry inhibitors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAmIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqjDq+mz6pLpkOoWcmpQrvktEnUyovHJTOQPmXkjuPWgC9RUctxDFLDHLNGkkzFIlZgC5ALEKO5wCeOwNJc3ENtGJLmaOFC6RhpGCgszBVXJ7liAB3JAoAloqK2uIbmMyW00cyB3jLRsGAZWKsuR3DAgjsQRUNlqdhfXF1BZXtrcT2r7J44ZVdoW54cA5U8Hg+hoAt0VUvdTsLG4tYL29tbee6fZBHNKqNM3HCAnLHkcD1FW6ACiqlxqdhbXBt7i9tYpwquY5JVVtrNsU4JzgsdoPc8daluLu3tpIY7i4iiedikSu4UyMFLEKD1IVWPHYE9qAJqKjt5orm3int5UlglUPHJGwZXUjIII4II71JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV5F8W9Xaw8eeG7e41CS10+a0mZkOtS6bGziWEBiyA7yAW+Q9QTyMUAeu0V4prHjnxVP4d1aQS6ZafaLDWJrOSC3k82AWUvlncTJgswPBAAUgHDfdqZ/HeraFp82gR3OmS+IYrvT7OwW885muEuEi3SsrSl2Ad3G7dj5QCc9QD2WivD7/AOJes3elWev21nFBaxC68qOTzU3zw6bPLKJFDgMglUIAR/yzYjnaRJ4r8TeJdNl8QpqmsacwHhpdQt7W2gltiZN0u7y3E2/KgLuYEcFeE6kA9sorwDxz8TdcsNZsprSeyaW01S8t30WJXW4SNI5UWW4/eBXQjEoGFXAGGOCR2vgLWvFXiq8stUkutNj0W3mmguY7aWJ/tQ2ZjdQhmCkMwBUTHOM8Yw4B6VWL/wAJTo//AD+f+Qn/AMK2q8WpN2MatRwtY9P/AOEp0f8A5/P/ACE/+FH/AAlOj/8AP5/5Cf8AwrzCilcy+sSPT/8AhKdH/wCfz/yE/wDhR/wlOj/8/n/kJ/8ACvMKKLh9Yken/wDCU6P/AM/n/kJ/8KP+Ep0f/n8/8hP/AIV5hRRcPrEj0/8A4SnR/wDn8/8AIT/4Uf8ACU6P/wA/n/kJ/wDCvMKKLh9Yken/APCU6P8A8/n/AJCf/Cj/AISnR/8An8/8hP8A4V5hRRcPrEj0/wD4SnR/+fz/AMhP/hR/wlOj/wDP5/5Cf/CvMKKLh9Yken/8JTo//P5/5Cf/AAo/4SnR/wDn8/8AIT/4V5hRRcPrEj0//hKdH/5/P/IT/wCFch4cv5dK1+RX1a1/sEtdzGNFcyTSzT+ajMpiypUM6kiQhsKdornmIVSWIUAZJPavONH8T38+vWlq95LPYNMyRSboN9z82P4FKuF6nYVwDySQRTuVGrOW1j37WdV02+1jQLuK/jEen3Uk8oaOTLBoJYwF+Xrlx1xxml8XappeteG7+xtr9I7t0320jxPtjnQh4nOFzgOqnj0rxHxBrNxDqWswWepTjyLQSLHGYGKTllVIx8rFdxIBDjJ3fLwDWj4hv7jS4tDh+3ub2W4hhZR5X78FkEjFCNxABP8Aq8YJBOB0Lh7Wemx7B4W1XSNF8O6fp8l+sk0MIE0ixPiSU8yP93+JizfjXOeDriHSdbhS+mthaafp5s7e5gVyboNLuLSKVBRwEU4G4EyMd3avOPA+sXWo+Gr661S9O6JiDcHy18seSjMcgBRtLNwR8uMNnBJzvD/iDVLvWdGie5M9tc+blSYSxRWuBvfZz/BCAyfuzluTlaLsPaT120PWPHdxDqFxczaZNbXMd9aR6fOJFdZLdBLuMsWVwxAdjtJXlFwT0ruP+Ep0f/n8/wDIT/4V85eI/EWp23iea0jeWz09YkUytb4C/voA84dlK4CSuOcgFckdK6/QLie70LT7m7GLiW3jkk+Xb8xUE8due3ai7B1ZpX0Nvxtptnr3iuDWrLVoIHhWxjAdJcyRxXLSyxthehBjYf7UYBwOa1PiL9h8TwaWLDVYraewuXu45Hjk+WQQyLGcBTkCRkLDjK7hXjmu+KLyDUteglvZNMSFIVsDJCqK8haRfmeRSpViAcg/dUkYIatfxTrlzYazo9ukklvYTFzc3SxZXHlOVw5BVcFdxz2wem6i7H7SfkezeFdY0zSPC+j6bcXyPPZ2cNvI0cchUsiBSRlQcZFav/CU6P8A8/n/AJCf/CvFfB19NqPh+C5uJWld5JVV22ZZFkZVJKfITtA5Xg9Rkc1t0rkOvJOx6f8A8JTo/wDz+f8AkJ/8KP8AhKdH/wCfz/yE/wDhXmFFFw+sSPT/APhKdH/5/P8AyE/+FH/CU6P/AM/n/kJ/8K8woouH1iR6f/wlOj/8/n/kJ/8ACj/hKdH/AOfz/wAhP/hXmFFFw+sSPT/+Ep0f/n8/8hP/AIUf8JTo/wDz+f8AkJ/8K8woouH1iR6f/wAJTo//AD+f+Qn/AMKP+Ep0f/n8/wDIT/4V5hRRcPrEj0//AISnR/8An8/8hP8A4Uf8JTo//P5/5Cf/AArzCii4fWJHp/8AwlOj/wDP5/5Cf/Cj/hKdH/5/P/IT/wCFeYUUXD6xI9P/AOEp0f8A5/P/ACE/+FH/AAlOj/8AP5/5Cf8AwrzCii4fWJHp/wDwlOj/APP5/wCQn/wo/wCEp0f/AJ/P/IT/AOFeYUUXD6xI9P8A+Ep0f/n8/wDIT/4Uf8JTo/8Az+f+Qn/wrzCii4fWJHp//CU6P/z+f+Qn/wAKP+Ep0f8A5/P/ACE/+FeYUUXD6xI9P/4SnR/+fz/yE/8AhR/wlOj/APP5/wCQn/wrzCii4fWJHp//AAlOj/8AP5/5Cf8Awo/4SnR/+fz/AMhP/hXmFFFw+sSPT/8AhKdH/wCfz/yE/wDhR/wlOj/8/n/kJ/8ACvMKKLh9Yken/wDCU6P/AM/n/kJ/8KP+Ep0f/n8/8hP/AIV5hRRcPrEj0/8A4SnR/wDn8/8AIT/4Uf8ACU6P/wA/n/kJ/wDCvMKKLh9Yken/APCU6P8A8/n/AJCf/Cj/AISnR/8An8/8hP8A4V5hRRcPrEj2miiiqOsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuY/4QrTv+e13/32v/xNdPRQTKKlucx/whWnf89rv/vtf/iaP+EK07/ntd/99r/8TXT0UrC9lDscx/whWnf89rv/AL7X/wCJo/4QrTv+e13/AN9r/wDE109FFg9lDscx/wAIVp3/AD2u/wDvtf8A4mj/AIQrTv8Antd/99r/APE109FFg9lDscx/whWnf89rv/vtf/iaP+EK07/ntd/99r/8TXT0UWD2UOxzH/CFad/z2u/++1/+Jo/4QrTv+e13/wB9r/8AE109FFg9lDscx/whWnf89rv/AL7X/wCJo/4QrTv+e13/AN9r/wDE109FFg9lDscx/wAIVp3/AD2u/wDvtf8A4mj/AIQrTv8Antd/99r/APE109FFg9lDscx/whWnf89rv/vtf/ia57RbTRNV1ifT44tYgdHuEjlmMXlz+RKIpSm3JGGZfvBSc5GecekVwXhKyhtvH2vQH7SGtGkkt1uZhkrcsk0rxIIlzGZPl3F3IMZHy9yweyh2INVsdB0zVl065fU/tL/Z/K2mPEvnTGL5eOdhG5vRSCM8gS+LdL0LwtoFzq+pS6i1tBtDLDsZ2LMFAAwM8sK6fVPDtjqfiDRtYufNN3pXnfZwrYQ+YoVtwxzjAI9DXOfFe40iNPDdt4ijuW0661QRO0Nw0IRjDLtLlfmK7scArzg5IG0uweyj2NJPBmmOiulxdMjDIYOpBH/fNc/4ZtdD8Q32o2ttHrFu9keWnMQWVfNli3IV3cb4JBhsHgHHNbvwo1OPV/h5ol1DBc28QhMCRXMgklVYmaMb2CrlsJzwKt+GvCWm+Hb++u9N81JL4lrgHbiRzLJJvOFHzAysuf7oUHO0UrB7KHY5zXrHQdEvre1u21NpJ0DqYzGQAZ4YecgfxTofoD7A7v8AwhWnf89rv/vtf/ial8S+D9L8RalYX2pK7XFjjyCAvyESxS7hlSQcwqMjHysw78dFRZB7KHY8/v8AR9NtPEmnaN9l1iaS9ikmW4jeDyo1QqG3biG43p0U/e9jhvifTNI8PpZmWHWLx7qRo0jtTEWG2N5GJ37RgLG3TJPQA12lxpkE+tWWpu0guLSGaFFBG0rIYy2RjOf3a459apeJ/DsPiBLMS3l5ZvayNIj2pQMd0bxsp3K3BWRumCOoIp2D2Uexm2fhPSL2zgurW6upLeeNZY3DLhlYZB+76Gpv+EK07/ntd/8Afa//ABNdDZ20NnaQWtrGI7eBFjjQdFVRgD8hU1Kweyh2OY/4QrTv+e13/wB9r/8AE0f8IVp3/Pa7/wC+1/8Aia6eiiweyh2OY/4QrTv+e13/AN9r/wDE0f8ACFad/wA9rv8A77X/AOJrp6KLB7KHY5j/AIQrTv8Antd/99r/APE0f8IVp3/Pa7/77X/4munoosHsodjmP+EK07/ntd/99r/8TR/whWnf89rv/vtf/ia6eiiweyh2OY/4QrTv+e13/wB9r/8AE0f8IVp3/Pa7/wC+1/8Aia6eiiweyh2OY/4QrTv+e13/AN9r/wDE0f8ACFad/wA9rv8A77X/AOJrp6KLB7KHY5j/AIQrTv8Antd/99r/APE0f8IVp3/Pa7/77X/4munoosHsodjmP+EK07/ntd/99r/8TR/whWnf89rv/vtf/ia6eiiweyh2OY/4QrTv+e13/wB9r/8AE0f8IVp3/Pa7/wC+1/8Aia6eiiweyh2OY/4QrTv+e13/AN9r/wDE0f8ACFad/wA9rv8A77X/AOJrp6KLB7KHY5j/AIQrTv8Antd/99r/APE0f8IVp3/Pa7/77X/4munoosHsodjmP+EK07/ntd/99r/8TR/whWnf89rv/vtf/ia6eiiweyh2OY/4QrTv+e13/wB9r/8AE0f8IVp3/Pa7/wC+1/8Aia6eiiweyh2OY/4QrTv+e13/AN9r/wDE0f8ACFad/wA9rv8A77X/AOJrp6KLB7KHY5j/AIQrTv8Antd/99r/APE0f8IVp3/Pa7/77X/4munoosHsodjmP+EK07/ntd/99r/8TR/whWnf89rv/vtf/ia6eiiweyh2OY/4QrTv+e13/wB9r/8AE0f8IVp3/Pa7/wC+1/8Aia6eiiweyh2CiiimWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUIdIs4tZn1VUla+mjETO8zuFQY+VFJKoDgE7QMkZOTV+igArjfixDpP/CIy3eu6dbahb20iBY7m5a3iUysISzyAHaoEpJODgc9ea7KqWtaXaa1p0ljqKO9tIUYhJXiYFWDKQyEMpDKDkEdKAI/D0Fvb6NbfY44I4pgbkiCYzRl5WMjlXIBZSzsQcDg9B0rRqO3hW3t4oYzIUjUIpkdnYgDHLMSWPuSSe9SUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGY3iDRk0+6v31bT1sbWQw3FwblBHC4IBR2zhWyQMHnJFadfOmr/DLxXNoWr6XbWaGy1J7vUJ4jcRgtdLLcCBR82MOskD57eTg46V0OuaN8Q7/AMS6ibWK+stNuJQha31NgDGLuAh0LXDbSYVlJCxxdWXDZFAHtVQyXVvHdw2sk8S3Mys8ULOA7quNxVepA3LnHTI9a8f8daB48vfEYi8NfbrLT7cKkN0mpyMJVSAlfM33HJMoVW/dZI5MhBYU/W/DvjnULXSLhJdQgvbqSae/jg1EJ9kWS6tCsKNuHCwRyjK8E7+74IB7HRXmd9onimPxapsJdSNrHd2xtrptQLWsVmiKJYpYWk3SSsQ53kMTuB3Lgiq/gnwfqx8R6RrHiCK+ivtOgkW6mur/AO0/bblgVWSJQxEcSq82F+THmY28EkA9UrK/t22/uTfkP8a1a4ak3YicmtjpP7dtv7k35D/Gj+3bb+5N+Q/xrm68pi0nxlpVgLXwvANPthPcuomhtpJZspH5ZnIkx97zB5gLMQqblPNK5Cm2e9f27bf3JvyH+NH9u239yb8h/jXifiTRPEWq+CdNhnE19q6faUmMiw27kS288KsVWQoADIhO1jwCQM8VLNH45/4SSNLeWePRo7o5fyrVzJF8mF2lgypw+XyzkkfIBxRcfM+57P8A27bf3JvyH+NH9u239yb8h/jXgXjHwx4s1bQ9Kkike41ePSLiG7EjxJ5ksxiDRHbtXAHmEEDGY1yTnJt3Nv8AEGWJZUluFuIppCqbrYKxMEoBwOsIk8rAb58FiRkKQ7hzPue5f27bf3JvyH+NH9u239yb8h/jXEeGl1BNCs11mV5tQCfvXkiSJmOT1VGZQcY6MR9OladK4udnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dJ/btt/cm/If40f27bf3JvyH+Nc3RRcOdnSf27bf3JvyH+NH9u239yb8h/jXN0UXDnZ0n9u239yb8h/jR/btt/cm/If41zdFFw52dzRRRVGwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUf7Jsv8Anj/4+3+NXqKBNJ7lH+ybL/nj/wCPt/jR/ZNl/wA8f/H2/wAavUUrByrsUf7Jsv8Anj/4+3+NH9k2X/PH/wAfb/Gr1FFg5V2KP9k2X/PH/wAfb/Gj+ybL/nj/AOPt/jV6iiwcq7FH+ybL/nj/AOPt/jR/ZNl/zx/8fb/Gr1FFg5V2KP8AZNl/zx/8fb/Gj+ybL/nj/wCPt/jV6iiwcq7FH+ybL/nj/wCPt/jR/ZNl/wA8f/H2/wAavUUWDlXYo/2TZf8APH/x9v8AGj+ybL/nj/4+3+NXqKLByrsUf7Jsv+eP/j7f40f2TZf88f8Ax9v8avUUWDlXYo/2TZf88f8Ax9v8aP7Jsv8Anj/4+3+NXqKLByrsUf7Jsv8Anj/4+3+NH9k2X/PH/wAfb/Gr1FFg5V2KP9k2X/PH/wAfb/Gj+ybL/nj/AOPt/jV6iiwcq7FH+ybL/nj/AOPt/jR/ZNl/zx/8fb/Gr1FFg5V2KP8AZNl/zx/8fb/Gj+ybL/nj/wCPt/jV6iiwcq7FH+ybL/nj/wCPt/jR/ZNl/wA8f/H2/wAavUUWDlXYo/2TZf8APH/x9v8AGj+ybL/nj/4+3+NXqKLByrsUf7Jsv+eP/j7f40f2TZf88f8Ax9v8avUUWDlXYo/2TZf88f8Ax9v8aP7Jsv8Anj/4+3+NXqKLByrsUf7Jsv8Anj/4+3+NH9k2X/PH/wAfb/Gr1FFg5V2KP9k2X/PH/wAfb/Gj+ybL/nj/AOPt/jV6iiwcq7FH+ybL/nj/AOPt/jR/ZNl/zx/8fb/Gr1FFg5V2KP8AZNl/zx/8fb/Gj+ybL/nj/wCPt/jV6iiwcq7FH+ybL/nj/wCPt/jR/ZNl/wA8f/H2/wAavUUWDlXYo/2TZf8APH/x9v8AGj+ybL/nj/4+3+NXqKLByrsUf7Jsv+eP/j7f40f2TZf88f8Ax9v8avUUWDlXYo/2TZf88f8Ax9v8aP7Jsv8Anj/4+3+NXqKLByrsUf7Jsv8Anj/4+3+NH9k2X/PH/wAfb/Gr1FFg5V2KP9k2X/PH/wAfb/Gj+ybL/nj/AOPt/jV6iiwcq7FH+ybL/nj/AOPt/jR/ZNl/zx/8fb/Gr1FFg5V2KP8AZNl/zx/8fb/Gj+ybL/nj/wCPt/jV6iiwcq7FH+ybL/nj/wCPt/jR/ZNl/wA8f/H2/wAavUUWDlXYKKKKYwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoory3/AIXh4X/4Qb/hKfs+qfYvtv2D7P5Ufn+Zs35278bdvOc0AepUVxut/EPSdHj8VPdW9848OfZ/tfloh3+cqsvl5YZwGGc4/GqNn8ULObVNUsrjw/4gsjpcPn301zDCsdunls6sxEpPzBDjAPNAHoFFecTfFzSE8Ew+KodJ1u50tmkSfyoY/MtGRguJQZABkkYwT+FWU+KWkpDq7ajp2sadcaZ9nWW1uYEM0jzlhEiKjtuY7OnHUe+ADvqK8+v/AIraNp2i6zfanp+sWVxpKwyXFhcQItwY5XCI6DftZdx5IbjBz2zLd/FHQYFujFHfXRiFl5IgjVjdNdhjCsWWGSQpzu2getAHeUVU0q8OoadBdNa3Nm0q7jBcqFkj9mAJGfoTVugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+c/wDhQ2t/2N9k/tDTd39meX5fmSbPtudnmZ2Z2+TxnGc9sV9GUUAeT+Nfh1rms6t4oj06901NI8TfZPtrXG/z7fyQqnywBtbIUdSMGneMPh3reuan4vFrfWdtYeIn06GV97ebHbwh/OwNuNxyoAzgjOSK9WooA8Zuvhb4gj8LeMvD9rq9neWespBJbSXI8lo5lKh9yxptClUXkckjkc5rV8SfDnUtU8R+I9Xtr20gnuLnTL7TS25gs1oH4lXA+U7scE+vbB0NV+IT6P4y1TSbvT57yKN7K3so7GMGaSWeO4chi7quMQYHTGefUVU+M/hd4bmbbepDb2UV67yLGmVk2hFAZwScuoJA2A8FhQBneIPh74j8TJrWoazc6RHrF3BZ2VvDbNJ5EUEN0s7lnK7mZiDj5cDgd8inZfCjUNMHjG2hg0TVdK1Sa2+w2moSyoIYYzKxQsi5UqZAFIJ4Hateb4y6VNpt1c6NpGq6jJBp8uoOIxF5cSo0qkSSByAMwtyu4EEbd2cVJZ/FeH7ZeW1/o98t1GI3itLfZJKY/ssc8jtlgoCeYBwxJ4wCTigDrfh/ot74d8HaZpWqXxvry2jKvPknOWJCgnkhQQoJ5woroK4fQPiZo2u65badYW2oGO6kaGC8aNBBK4gWfaDu3f6tgeV/pXcUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUdxNHbW8s87iOGJS7seiqBkk1JUdzBFc28tvcxRzQSqUkjkUMrqRggg8EEcYoA8L8B/GS5vNC8W6rqckGoNaxPqdlZxssbxW/mtH5LEDIIwjZIJIkHXtp6x8W9ThtxEdEisLh7x7RJPtQuBvhvIIJ127V42y/K2eo6evqdzoOkXSKlzpVhMiwG1USWyMBCcZjGR9zgfL04FNm8PaLMVM2kadIVkeYF7ZDh3dXZunUuqsT1JUHqBQB5wvxhlDok3h8IbouliftwKyst4LU+YSg8pdzA5+bjPtnok8fo3ga615rKOO5t7trA2rzlkedZvKISREYuCeQVQk+ldK3h3RXiMT6PpzRFHiKG2Qgo773XGOjOAxHc8nmpJNE0qTSP7Kk0yxbSwoX7G0CGHAOQNmNuM89KAPJbv4yXeo+FtTvtC0qK3ms9Oa7mkurjmN98saqkZQGUboTknZgHkZ4rW0f4iXmteOtJgSOHT9CkTUQ2+4R3m8iREDyLtBiwQ+Bkghvbjun8J+HJI4o30DSGSFHjjU2UZCK5JdQNvAYs2QOu4561DqPgzw3qLXT3Wh6eZro5nmSFY5ZPmVjudcMclVzzzjByKAOZ8ffE+DwTr1pp+q6a3k3U8Kx3AnwDAwbzZSNvWMqMrnkMDkdK5vW/idrAudHnjh/s+zu4NLvXgCiWTy57uRHXJA+9Gq9gQScHvXreq6NperiMatptlfCMME+0wLLtDDDY3A4yOD6iiTRdLlmjlk02yeWIRqjtAhZBG26MA44CsSV9CcigDzbwV8S59W1PVrrV4mt7CS2057G1t1a62NcLM/ztFGWXIRM7hhSMZ55qaN8WtVFpYx61oVqb/UZ5oLAWt222eVLsQGIgplCqtuzzlVJwM4HqWk6HpOjNO2kaXYWDTkGU2tukRkwSRu2gZxubr6n1rMl8GaO/iOy1hbdYZrSSS4SGGONI3nddrTPhdzPt4yW7DjIBoA8/t/jbnR4b268P7Hu7OO7tY4Lwz7g86w7ZNseUIZs8KxIBwM8V6P4P8Qp4i0OzvpLaSwup0Z2s58iRNrlCcMA2MjgkDgjgVV8NeBPDvh/QF0m10y1mtzCsE8lxBG0lyo6eaQoD/iKsaj4P0K+tLSA6dDbfYxi0ksx9nktv+ubJgqM9hwe4NAG/RXHeb4n8NA/aEfxNpi9JIVWO+iX/aThJfqu1v8AZat3Qdf0zXoHk0u7SYxnbLEQUlhb+7IhwyH2IFAFe58KaLc63/a81lu1HzYZ/N81x88SSJGduccLNIOnO7nOBjLi+GvhOOJYv7KLxJbfZI0luZpFij+XhAzkIfkU7lw2QDmuwooA4fTNB0hfFet6P9gElsNEtoXeaeWWSWKaa83xuzucjIJz975jkkYAnk+GnhSSJkk0yRixBMhvJzIcRCLG/fu2lFClc4IHINalnYXMfjjV9QePFnPp1lBHJuHzPHLdM4xnIwJU5Ixzx0ON2gDn7DwdoGn3cFzZackEtvctdxbHcKkrQiAkLnGPLAXGMDGQM810FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBd3dvaIr3dxDAjMEVpXCgsegGe59KnrivH3h/U/Et3a2lsIYrGCGSUyzfMGmYbVAUEEFQSwPTJHWsyHSPFN/eRXGoSalab7i3WWKK/CqsQgxKQFbAzIB055yO5rojRi4p8yuYurJStynoaXEMlxLAk0bTRBTJGGBZAc4yOozg4+lS15lp2h+Kmt8Xr3kc0r2CzSpdqH2IXEx3Buu0r9fenWmleMUksxNLeMyMojkN4uyJRM5bzlz+93R7cdfwNN0I9JoSrS/lZ6XUUlxDFNFFLNGksxIjRmALkDJCjvgc8VyPjS28Rz6xYPoSSi3i2M7pcbQT5g3BlLqCNvqG9MDrWFNovi2SG3Mf2tdSia4MtzJeq0blonCmNc/IMlQBgYJB7ZpQoxkk3JDlVadlFnpcdxDLNLFFNG8sJAkRWBKEjIDDtkc80SXEMU0UUs0aSzEiNGYAuQMkKO+BzxXG+E9L1Wxh8RTS2lzFPc7WtlurtZpHKxbfmkBPcdT0H0rnV0PxXKbR7+2v5hb3LyKIr9UlRWh2kLI0jEfN7+vTNNUIttcy0/wAhOrJJPlPVEuIZLiWBJo2miCmSMMCyA5xkdRnBx9KlrzLTdD8UweIbK6uPPLstoLm5S6URsqBvMV0zlzggA465PvVf+wfGkNrpflXt8ZTDmffdeY0c2/qcyKGXaFGPmH3uMnNP6vG/xoXtpfys9QubiG1hMtzNHDECAXkYKoJIA5PqSB+NSMQoJYgAdSa85n0LxNJb6nBLPczRwNHFZZucmdPtIkZ3y33lQBeecA+tUrjQfFWo2Grw38VwUk8maCH7bkGRZssATIf4PXauccAgGkqEH9tf1YHWl/Kz0+C4hnMogmjlMTmOQIwbYwwSpx0PI496lrzC50bxUr3rWqXyQyzSvBGl+qPG5SII7tuO9QVcFc5J5xzV0aR4oXUp7hrq+PmS3KEJcrsEZtx5bIhbAPm5x6d8Ch0I/wAyGqsv5WehVClzA9zJbpNE1xGAzxBwWUHoSOoBrmvBtpq9sLYazHd+akEimR7vzFP7wbdyFm+cjnIJAGQDzisq307V9K1I+JruNWMrzPe2sajzY4CvygvvKvs8tMAAdW61Pso3a5vTzK9o7J2PQKjimilaVYpUdom2OFYHY2AcH0OCDj3Fcp41XW9Q0qzbQLW4WSSNpCRMYpInKjYCBKgPJOc7gMfdNZGr6X4mW21AadayCe5u5LgSQ3GxgfIiVTgSoMFg/wB7djaPlINEKKkleSQpVWnornoc0scEMks8iRxRqWd3ICqoGSST0FOVgyhlIKkZBB4Nee3Oi+I2sp5UlvWvJ5L5XjN7lBG0cnkhVLbV+bZjHIzzgdJp9I8Sq9zcWlzdLdvcskYe6zCkP2bAbZnH+tx2zxnpnL9jH+ZB7WX8rO9qpc6lY2t3Da3N7bQ3M2PKiklVXfJwNqk5PPHFcf4Ug1ey1K2h1kam7THcgeUmOMrGwcsfOk3AllwCQM8gCrc0dzomtavf3Gkm/tZ3W5+1xvHvhREAKlWIPy7SRtznPrSdJKVr3D2javax2FFc3riX97JpFzbW9+1ltZ7i2guBbyhmVdm4714X5sjd36HFcmYNe1Fb/wDsy8vLuCxuTb2xhuyFuASzt5j71JC7o0ypJG08HkUQoqSu3YJVeV2senhlYsFYEqcEA9D1/qKZHPFJJLHHLG8kRCyKrAlCQCAR24IP415rqXh/xBDq182mpfLbT3MkzvDeFt4aNAuAZozlWD5yRwV+8AAL0Wha/cauxvbm/FoYTl4rvyd8vkQKCQjZHzrIcdM57Hl+xha/Mhe1ltynoFVdQ1Gy02NZNQvLa0jY7VaeVYwT6Ak1w+nWnia11OK91ia7a1htEaVYmDKcW+HQgS/f8wEghDk4+YDitXV7a8lg8M3dtpk96LU75baSZPMAaBl+ZpCAxBYZOc0vZJNK9x+0bV7HVxSJLGskTq8bDcrKcgj1Bp1c14PWTTYV0m5t3jn2yXhWPBhgWSVisQb1HPbHB56Vyz2HjCVLtmgvIt7xyJDHeHaWHmbl3GcsE5TlSvQYTggiopya5rA6rSTsenUV5vpy69c3d7cWMd7K8d7fIzT35+zyIC6pEqbsqQ23DALgDr2FnQtG16e7t01qTUIrJJLhiqXzodpWHywSsrMfmEv8Zxz2IFN0Ut5ISrN7RO+RldQyMGU8gg5BpFZWyVYHBwcHvXmdnpHiWz0/Q7OzsrqAWojEz/bSQT5n7wYEwXZtHHyseSAFpJ/D3iK23waWb+CD7ZdSF1ud7MHfMTjMy5wM5DdSclX6h+wj/Ohe2l/Kz0+is3RZvON+2y5XbdMmZmJDFQoJQH7qZBwPqe9aVc7VnY3TvqFFFFIYUUUUAFFFFABRRRQAUUjMqqWYhVAySTgAV5N4N+LqanoviXV9YtkjsLANeWYtRmSazEjxgkM2C4aM55A+ZfXkA9aory7WPjBY2lhrHk6TqUGo2ENw4ivY1RHkhEZePcjNg7ZY2+jeuRV+D4saHIl5JLZ6pbxQRSSxvLCmLkJcC3Ijw5JPmsq84+8PfAB6FRXKL4508+GdS1l7a8hGnTm1urWYxRyxSgqNpJfyx99TnfjB61zN78YtNm8N3up+H9Pvb9rWya8lZlRYoPmkVVkYMeWaJwNgYdDnHNAHqNFcFaePxqXxDtNA060l+w5vobi6mjwHmtzGCsRDcgF2DZX0xUdx8WNCtbq+hvLXU7cW0txAkjwqVuZIZVidIsMSTudMbgv3vrgA9BorzuP4saPNqzaQlnqEOqqkxkguREgheMElGO/5jjBxHv4YHpWNp3xfmudT0e1udCktYLuKxlmvGmUxxi4tpZjgA7uPKwOOcPnbhdwB67RXnK/FvSH+xJHpOtvdXxhNnbCCMSXMcqyNHKmZANh8phyQQcZAHNdp4b1m18Q6DYavp5f7JeQrNH5gwwB7EetAGlWbcaHplxrFtq0tlF/aduCI7lRtkAIwVJH3lwehyK5msfxR4gt/DtnBPcwXFw08wgiitwpZm2s38TKB8qMeT2pgdX4CgvrLSrqz1GwntXivrp0eR42WZJLiSRWXYzEDaw4YKc9q6WvH/C3jjSvE181vpi3ODEZopZFUJMqsFcrgk/KzAHIHXjIrqKAOL8NfBK10j4xXniPEZ0WLF1Y24P3LhicjHomMj/eX0Ne2Vw9FFhXO4oryK68Zada3+uWs8c6/2PEJbh90Z3blVlVE37yTvAB2gE5Gc1taPfxarpNlqNsrrBdwJcRhwAwV1DDOM84NIZ6HRXD0U7CudxXNeLYL46r4avLGwnvks753nSB41ZUa3lj3fOyggM65AOcdAazK5K68eabbNdiS11DNpcywT/uQuxY1RnmOWH7sCVOepzwCKLDPZaK8v8MeILXxFYvdWcc8SKyjbMAGIaNJEbgnhkdT684IBBA6bRP+QnD/AMC/9BNIDqqKKKACiiigAooooAKKKKAOO8Wanf2/iTTbK0ubyGCaB5HFrHCzFg6AEmXgDDHpz04rf8QamNI0t7vyvNYOkaIW2As7BRljwoyRkmoNSi0m/wBatrDUdPgu7nyHuI3mgRwiqyqQCeQSWHT0qneW2lWGlf2DPObWzMDzNPK8RAAkXdu8zIOWfnKkc/St1ytRVv8AgmOq5nf/AIBiXfjW8g1SJZrWOKOGea0nhjnDq7BrZQ4cqCMec3GBnHPtd1HxZcxatHFbw2iWcN9Na3Es05GVjt/NJ4U7cZPryuOM5BZ2/hXRtJv40kstQ8uKW8liPkvIyFFLbUUBQpVE4AA4FaAHhQ2r2TpoiQoBcyWrrEAnyj52TsQuOT2rV+zX2DNc/wDMY0Xjy4mu/skOko90WXAM8kaFTHJJuy8St0jP8ODkYJqaDxw0lo0klhFDO0cE0ETTu5lSVXZfuRM24BCSApHvWyIfDOkucR6NZOkgjPyxRlXKnC9sEq549GPrVb7T4XngjivY9Ih3ERJb3JhyRG7xoAMkYBDhR25HByKn929oOw/fW8jGh8c3ZjvL5rGJrBLW0lijWVjJumZlAOEPGeuOmBgMWwOn8P6tPqsSyTWRtBsyUkdg4YOykbWVTt+UEE4znGBiopI/DTSyQSJo5kto1t3jYRZiRjgRkfwgkgAdyapNeaN4f12Wxs7KUahcQwmO3tkUB03OAqDICgYdiTgDOc0pKE1aMbMceaLvKV0J8Ob7UdS0JLzVZbyWSVVZWniiRDxyU2ckf73NY+s+OLxdGupre0itjIbqG2mW4ErrJCGOWQrgAhfU9uMEGuo1CHTdBin1owMiWdmYRHCAAsQO4hV4AycfkKoWtp4T0y1LSS6Sy3Pmsbi4aItKrSEsC3G5QW2/kKalByc+W/8AX/DCakko8xTvfG9xaXBsZNHZtTWR1aCOV5VwsaScMkZJJEgGNuMg845qKfx3dR28t0uiMbZZRCN1xtlMnkecVKbOMLkdeuPw2bq58N3YkGqx6WhkuHTbeGEmV4z5ZYZJyeAPUDAOOlPvW0EJc2QvNPsp4v3z+W0KyQELt8zDAgEL8uSOnFC9npeH5g+fpIxrnxixurS6t/LXTJFuxGXYkXOx4kRsqjMMszAAA5465GI4vGkktzDcFUgh+y3G63k3YaZJ441wfLL87jgbM88jPTdistHgmsfD7WEcwjs3aLzYldRErIrAk9ySpPHOMntT9TtdF0yygSbS7U28sqWixpbptHmyKMEdNu7aT9M8mjmp6Ll/4Ydqmr5jn08fTS29zPDpKtFZ25uLndclCoErxkKDHkn5M8heuDg09/GF3bNdolibz7Ob2eRpLhY9kUEu3CgJzwRgHn1J61vWSeG2jkt7JdIMch+yvHCI8MfmbyyB1P3zt+p9ajurzw9DHdHOmSyCCd3hRot8iZJlGCRkEqd2eMjnpReneygFp2u5GZbeNJbzUJ4LPSneFHmiWeR3RN8YJ+dvL2KDg4IYnpkDNWfFmpXkGqWNhaXLWaTQyzeaixs8rJtxGnmfID8xPPYU6a38KatNLE39kteuuZRG0YnCqRkMV5wNuD+IrTeXRdchiieTTtRhkLNGhKTKxXGSBznGRn0yKTcItNRGlJppyIbHWYj4Qj1hmmmiSz+0MXRVkcKmSSBwCcdBxXOX3i7UmdLeKygt7rzLKQeXdCVZEmkxsJKDaSOM4PXI7Eu/t7w9pun+JLyGG5gFvOLG4ijRA3yDy18pc7dvDEZ9G4rT0fw1pGk2lzeBhtmjSVpp44UEQTLKwCoqKVJ3Zx15PSqUYQu5R9PwJblKyi/Up6b42fVLq2g0/TkYzLnfNc+WqsqK8qE7Dyu9R05O7piq3/CaXdu+rr9gF1Fp5lmlkkuAjCMTyRhVUJyQEyMn6nPJ1tLh8LvaRacl1pmpHzHuMTSRSu7kkvJgcZznkAY9qWbV/CaMqfaNIk+3yG3byzG4kJ3MQ+O2Sc57t6mj3L2UH+Ie/a7kRaf4smv9Tu7WDTHWKGVoknlZ0RikqowJKbQeSQATnGDtJp3iPXLzTNfhgt7e5uoXsJpTFbohKuHQByWI4AJHB79D2rQX3hfWIrXUbeK1a6mnt5HWNolnDFxs83DZOG2nGT0GAa3JNU0MyzTyX2mmS3BhlkaaPMYYjKsc8AkDg9SBUtKMtIjTbXxFH+07v/hW/wDavnf6f/ZP2nzdo/1nk7t2MY684xism48WahC0EFxYlLuN4maO3nVxOrwTOFyUGDmLBA9sMRnOrDJ4ftJrgo9p9jv7cM0hlj+zmJNsQQDONvzAYAxyRnkCrM1x4buYUuJ5tHmhnYQpK7RMshAZQoJ6kB2GPRj6mhcq3jcHzPaRzl14u1KaNpbe3tYoRpd3dOFnbzI5ImC4G+L7wP8ACV7nPQAwar4x1Boo5bSNYLVDeRtIJVaWRobeRuVKEL8ygg89BkYOD0OuyeHtN8PveXGn2d1YWLGERQQRyeWWcIyqvQcnBH1qXT4dB1W+vmg0yzkmh2xyTtbofMWSIMMN1IKPjn3HSrUqaXNyaa/1+KJam3bm7GXL41e18+S504mxgka3M6zgyPILfzvubQMYGM56kfhe8OeJbnWJlWTTDaplTvkd1DKyMwKb41LEFcEDjByCa0ZZNEiu3tpX01LlCblomKB1ITBkI6/c43entWfYxeFI9SspdOl0mK5+ZoEtpI08wsNpYKv3jgMAee9Q+Rx0jqX76fxHS0Vmtr2jrHJI2q2ASN/KdjcphXwTtJzweDx7H0qQ6vpoluYzqFmJLYbp189cxD1YZ+UfWsOWXY15l3L1FZDeI9JDxbb+0eCQOTcLcR+WhXZwTu6nzF6Z6jOMjMw1vSTbxTjU7EwSv5ccn2hNrt/dBzgn2o5Jdg549zRoqOKeKZpVhlSQxNskCsDsbAOD6HBBx7ipKkoKKKKACiiigAooooAKKKKAMfVNT0O4t9X06/1KxCW8BF/EbpUaCJ16vhgYwVOQTj1BrAt/h94FfTGnsdI0+OwurA2zzWkhjjntm2tlmRgHztU7ySe+ea898d/DvxNq3jzxBfabbAaZrMsNtdMZkHmWyQ27ZALZH7yF06Zw5OMc1ieMtH8c6R4SiWWKe00iy0COyuR9uDRNmwaN0Mfm7d3nEKMRsSdpD9qAPa9Q8BeGNTe7lu9NExvDM0zCeQbzMsayHhuMrDH06beMZOYb/wAH+D7GyxqNpawWrxy2YNxcsqkTziZkBZvvNKAw7g4246V5/DofxDaG/wDIfUEd7K8WOUagFidGt8WscUW4GKVJMZcheh+Y542/GHh3UotE8Gwt9v1QWt1ILtZpDPJ5s0EqJIzd1SSQDPQAjsM0Adba+EvDV34XXT7S3WfSbmRb5ZY7qRmlkJDrMJw28twpD7s9OcVlr8P/AAM8V1Zx2kWy1ie3u447+UFUk3SlZsPk/wCtZhv5G7IxxXn2geFvHlhpGn2rW2uxabbQWkVzYR61GJ5XSGVXaCQPiKMMYPk3LnYeD3B4P+IEdneteC4uprue3a8FlepBJdbdPWIHeWHyrMBuBxuAPBHUA9O0jRPB6+K11fS2tH1u6he8QxXrP5kUu3dKse8rtbC/OFwT35qlpfwx0GCTWZdUgXUp9TubqZ2lLgRpNL5mxV3EKQQvzrgnaDxgY87tfAXi3S7TztOtL1byTTNJsX8vVGTZ5cTicALMmdrrFgB1GGbaTlgbsGh/Ex9FuUvJNRbWH0+3jtZ01FVigKgCZJEWQbpWw2JBnG4fMuKAPRYvh74Xt5IJf7PcmFnkXzbuZwXcMGkYM5DSYYje2Wx0PAqRfh/4ZW90y7XTMTadDFBbfv5dqpGrJGGXdtcqrsAWBOGPNcjqvhTxFqnwbXS9Qe/vNbjukuFia58mUotyG8tnEzBiI84LSNztJORkcL9s8SzadezRatrE9jaa1a6PZeRqLCS6R7re4aXdguFeOHfkgbWGetAHs+m/D7wxptxbz2elhJbeZJ4WM8jGNkV1QLljhQJHwg+UbulPj8AeEUtLS2fw3pNxFaxLBCbq1Sd0jGcLvcFiOT1PevNtJ0L4j2/iLR7q8u9TXSIJd5ga7W5kjhE8jGKb96okYxFF3bZTkcY5z6r4KE48KaWbuC9t52gVmivpzPOmeQJHPJbB5z06dqAOD/4Qvwt/0LWif+AEX/xNQ6n4I0O80ibTbaxtdOtpnV5RZ2kC+ZgEDIZGHc4OMjsRXrtcf8TfEx0Dw7fRWE7R63NZXEtmEjEhjMcZYyMCCAoO0ZIxllHOaYHH+F/BGleGr97nTDcBfKaGKF2BSFWYM4XgH5mUE7ienGK6iqPw18Waz4k8S6vHqcX2e0trO2EcBj24nDSpcnJGTiWN064/d5HU16NQBw9FdxRRcVjybWvCVjrepfa9UmvJgkeyGFZfKWE7o2LKyBXzuiQ8scEcYrU0TTYdH0ey021aVoLSFIIzK25iqjAyfw+npiuo8RX9zZ6x4Xgt5NkV7qLwTrtB3oLS4kA5HHzRocjB4x0JrdouM4eiu4oouKxw9cvqngrTtRnupZZ7xGupnlnEbqBIrxxxvEcqfkYQpnvkcEV7BXM+MdU1HTrvRE0pFlkuJp0aBsATFbWaRELYJXLonI/+tQM5Xwx4ftfDti9rZyTyozKd0xBYBY0jReAOFRFHrxkkkknptE/5CcP/AAL/ANBNV9F1TxvdaJp8954d0WG+eL/SoptUkh2SBiCAqwSDaQAR8x645xk3PtvjL/oA+Hv/AAdzf/IlIDpqK5n7b4y/6APh7/wdzf8AyJXmnxgt/G3iK50awg8PyAWBl1OR9MuvOjEioVtyJJUiBYSFiYxk7cEdeAD3GivGNZ1bxvrdzrsFjFrNnaXWgm4tI4bTyGtbnyVbymeSLLOzllGx8rzwpAasSbxD8ToEu00+LUpLeGwzbefprmWQiBSHx9nx5nmZBVnGR0TjcQD6Corw65l8eaH4zuY4LjVNStZdUt1mkjsNv2mL7PACUby3ijRSX3cpkhsMCMVX8E+HvF2r213o97qeteGoLS4ubmxMNs6JMrzXHzO4KksJHR9hOCqqQCGJAB7zRRRQBh6xp95/aSappbRNeR2zWqRTKdmHkjJckEHgKeO9Q+JfDZ1m6E63EcTLbtAoeJnwTJG4cFXUgjy+MHvntg43jvQm1nXbR5pTa2VvYzSSXZhL+UQ8Z+U5G18ZIPPAPBq/4p1iZV0B9NurqG2v5jve2tvNlMflM4wjKT2B6ZHoeldMVL3XB669Njnk4+8pLTQp/wDCCSNYvZy6qZIcTurtb/vTLLEUZmcN8y/MTtAHYEnFMb4eRO90sl+zwTecyhlk3RtKpUkfvNmOf7me2e9Vba88WzWtxPJJexeTFFtjFmm6QNK4Z9pXJcRhW2AjkjjsamtJrd9byStbXd2I7e/jt5JrPDyIRDs3x7QNxIcAFRkLnFbL2t7c6Mn7O1+VnQweFL6PV21ZtWgk1FpGYsbP93taNEICb85xGMHPrwaZ/wAIQhs9SgN6Cby1e2DmDmPdPLLn73P+sAxx93P0q3Nz4phMtxbNcTs9zexR20lsqoiIshhbIXdyVUAk4OQO+aueD9S1G5uIrfWLqf7SVklWJoChaMeWMvuijIIYsBgAHJ64zUN1Ur8y0/T5Fr2bdrMbb+E7jTdXlvbC4jm864LETiQmKN5VkkAy5U/d4woOcEkkVf1nwy19ro1e2vmtb6OGOKBxHuCbXctuGRuVg+CvHTOa5G4hNvqcKS2N2viebVcx3xVhG8XmbsB+hTygRs68dK6zXNXkuNHsLvRZp/stxdKks9vbmSRYvm3MiFSTyAPungk4NElUTTT/AK/yCPJZqxZvtPvda0HVdP1F4bc3JkhheJS22PorMM8k9cZHXFc5F4NuLx9SnaRtPeS632fmDe9tH87EpscBSXkc9SMYBB6DL0LUdcuLqfVl+13Kr5MLTi1G6SFLyUOAijBYJ1A5H1q697rcl7Z6nKmteUPt6pbRWoUkBwYQwKHBK8Zb+6MdTupQqU7xTX/BJcoTs2ma8ngpJPtxe9DtcwXsQLQA7DcPu3DnqvI7Zz26VUPgu6sbmW7068inm82SWJLlZCEaT5XP+s2YwWP3MngZrLh1PxfcRT7P7QhWGK5lRmtAzSlY4mjQ7oUzli44VSeRzjNWdSl8Rxg/u7m6uLR5nguTaKWybFmGAFxxKdowOfunPdpVVo5IL03qos6nVtIvbjWrXUtOv4rWWKB7dlltvNDqzK395cH5RRPp15rGjWKaq0VveR3EVzIIASo2SBgoOc5wAM5681zOqXfiuyEsNvLd3MebZjcm2G9A6yeYFCRNkBlT+FiA3vkaT3F1qvgrXkkklur4WbwPEkOAs32cblQbQxyW6HkEkdqy5JJLVf1/w/U05otvRlfTvAj6dFAbXUl+0W00ckMskUjjaiyKFdTLg8SH7uwD0p2m+Cbix0/VrNdVjkj1NJRcM1phg7hwCpD8Abhxg5weRmoPA1qfD+sXdhfxR2016kLWyW8TJDIFRi+Bzhxg7sn+76im+K9Y8R2+s3UWj2uoGJIpFXEAkRj5DMrriI/x7RzIeRjbzVt1ZTcVK/W+hCVOMVJx8i9J4Hhl09LR7whRPdTM6RbWbz0dMde28c8524xVvwzoN3ot35ZlgmtmRpJZQJN7ynYo++7kDanPPPHHFYmvanrml3NjEb67OVtQGFojCd5JiJFkIXEeFwFAxn1JziCJ/EsFjfGz+12wtbeWeG3js02zSm6n+XlMnKBDheTkHPPI41JR1krMLwjLSLujQvPh/Hc3F5K2oMBci5LJ5Xy75DLsYjPJQTP9fat240+8vtN1bS7hoYrOW2+y20qqWcho8M7DOOp4HHT3rlpG8RxG/Fh9ptY4v7RulWOzU+fIs37pTlf4gSeOWHPvUltrGux3WsS6zLPZWMaSeWVtyTGd6iIx5i2sSD0LtknouMUpRqS+0nYacI6WaNC98EQ3YuFN2Y0mmWRtkQBCi2MBUHPfJbP4Y71Hp/guWzMEq6hG11DPDMJWilfcI0dArB5W7SHoQBjpTfFlmx8X6Te29pPezp5aeU9qzwovmEmQSjiNxyeeoAq74l1a5n8O21/4cluJBJMP9RAWeRBuBC5RguSB8zLj3Gc0uao0kpbj5aabbWxWi8EJGuhhb0A6ZFHHxBjzds0cuevGdhHf72fqyLwKB9hSa/SSCxKJAn2YAmMTLKVkO75ydgGeAMk4OTWfLqHi6S71RFE0AEwSJVti+xTcRqGQmLaw8ssT87evy4xViWHXl8U31vaT3lvaMHdrpLSMmZkggCZYptJLF+g7EDGOL/e9Zrv/AFp5k/u+kX/X/DFy48ELNI5a+GxpJH2GHIw91HPt+922bfxz7VHq/gVNQvLi4+27fOnlkaNkfYUkSNWU7JFJ/wBWDnODnBBwKp6Zq/iU6pBJqwe0sBapLMGgYKB9n3O2fKIDCTPDOOmNp61oeLNMh1zwlYTPbNqFyptmjkkhHmbWkj3kqBxlclgOBz6VN6kJJOW/bzHanKLaj/SNOXSrrUvD/wBj1CSKG4a4WYmJdwAWcSKvbJ2qAT6knmqnh/w/c+HtRkSwkjm067neaXzFw0CBAscac84x1I6DHvSa2Fv/AABdr4YeVEFu6WwtV2lguRtUEZwcEccnsa51m8QWEGrX2lPqMv2i6kCRS2QDP/oeVmIKA53qgxgLnIxzilCMpRavbfR/1/VhycYtO1/M39Z8JT6prTXs2p77fDhLWeJnRd0JjIwJAuPm3fdDdRu9M6x8G366u32q/wDMtI1tWMzR7pJjHK8m1WLlkC/KMnJI75GalvLnxPba1pVtDJLNbGKJpZZIeJXLnzFcpEQmFxjlcdSW5FUo7/xXMII0kv0kl8lbp5LBVFtI0yqwjyuHQIWO75uADkZwLj7W1uZW/ry/r1Jfs735Xc0dP8Ezw6vb399rD3kkMscn7yNiW2CUDJZ2wf3ueAAMcAZqtrng2+uLm5vzqdxeygloICm4jMqOBh5BGQNgG0BQQOeeagu5fEf2hXijuftUSzWy3f2NS7L9thUMflxzHubAwCAW7ZBq194ttZHt7V7iSOO6lRLp7bLOoSNo9wSJsrlpBlQuduNy45a9rzJ8yv8A15Cfs0rcrFsvBl7qYmudYlS1mkvZLjyhCp3KzW7cgOQP9QRjc33s5Pe/q/gVNQvLi4+27fOnlkaNkfYUkSNWU7JFJ/1YOc4OcEHArpNCulvbFrhJ3nRppQrMoXADkbRgDKjGATyQMmtGsJYiopb2saqjTa2uUdLju0+1fbPKG6djCI+vlgALuPdjjJ+tXqKKwbu7myVgooopDCiiigAooooAKKKKACiiigAri/H/AI0n8Lahptpa6bBeyXltd3Jaa8FuqLbqjMM7GySHOOnT0yR2lYHiDwlpHiDV9Nv9YtkuzYRzRx28yJJC3m7MllYHJHlrjpjnr2AOFsfi7c6k8P8AZ/hxfKubkWtrLdagIVZ/sy3DB8odmEYeuTx64y1+NN99pluBoUcunXEFi1jEs0nnmScSN84WNiVxEwyqnBC/e3/L61ceH9GubSa1uNI06W1mlE0sMlsjJJIAFDspGC2FAyecAelNvfDmh3xzfaNptyfJFt++tUf90CCI+R93IB29MgUAeeT/ABiWO/sLdNAuXa6t1cwiRhPFM1u0yxMpj2AkADlw3zA7cc0zQvjH/aus6Vpy+H7jzLlo0ujE0r/ZGeV4gGBhX7rId24pjtuwa9Cl8K+Hpplll0HSZJUjEKu1nGWCBSoUHHQKSuOmCRToPDGgwPZPBomlxvZZ+yslpGDb5JJ8vA+Xkk8Y60Acn4m+JaaH4iu9POmedb2k8FrNN9oCyebMhePbHtO5MdWyMc8HBrnH+KOs6mujfYdJWyuprmzlNstyswuoLm1uZY4y5jGwloRkgEjjnqK9WudE0q61BL+50yxmvkQxrcyQI0iqc5UMRkDk8e9RN4e0kIv2fTrK2ljREhmitow8OxWSMplSBsV3C8YAYjoSKAPH/EXxh1F9CtvEfh61jXT0drVoJzvFxMbNpzwAGHlOoQ4bBy3TAx7B4Xn1a40K1l8Q20VrqjBvOiixtX5jt6MwBK4JAZgCSMnGaz9A8E6NokelC2hkkl00zvBNK/zb5jmRyFwpY5IzjgEgYHFdDcTRW0Es9xIkUMSl3dzhVUDJJPYAUAUPEes22g6TLfXYdwpCRQxjLzSMcJGg7sxIA/wrN8IaLdWrXOr64Uk1/UApnKnKW8Yzsgj/ANlcnJ/iYlu/FDw5BL4o1eLxPqMbpYQgjR7VxjCEYNy4P8bjhR/Cnuxx2lABRRRQAUUUUAcz4t/5D/gr/sLyf+kF3XTVzPi3/kP+Cv8AsLyf+kF3XTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+I9e/se+eO+iifTpbGWVMjLPKnWM9sMpGBjsasS3q2WnaPca5bR/a3kjiLRRjbbyupXIycquTtyCfve9XtV0qy1VbddQt1nW3mWeMMSNrr0PHXr0PBqvJokF1p19ZanJLfW93M0jrK5+UEgqi4OQFwMY78962UoWV/mZNTu7fIof8Jjp4Olbo50XUmVYCzRhsM+1W2b95B4IIB4Izis3RvGrz29o13ayT3FzFbbIbSIA+ZKsrHl3xjER64x6nt0E/hzSp7u3uZLYiWARhNkrov7ttyZUEBtp6ZBpLXw1pNpJbvb2gRrfy/LPmOdvlq6p1POBI/X156Cq5qKT0ZPLVvuZaePNIa6sbcidJbohdr7AYmMhjww3ZPzKfu7sDk4HNTeINel0m1tNRktBFbSRS+cJlHmxuIy6KcEjBKsCOeSOfW4fDWmqyyW0cttOgbZJFPIuCzs/IDYYB2ZgGyBmpptCsbrQI9Hvo2urNY0jYSOdz7cYJIIOcjOaXNSTTS0HapZ3epz3hTxFceIrmztr21tBNBFJPeDyyRHKsu2PZk8cBmzz26VN4p1ey0+6Gnajogu9Lhs3vGOyJ1UIVAwjEdN2PqRjjJGtN4etFTUDp5ksLi+eNp54HIY7SOnPy8ZHGOtTavoWnawytqEDSERvDlZXTKNjcp2kZHA4PcZp89PnvbQXJPltfUxZPFunaTaSQvpl7Zm2QMLMRRq2wxvJuVQ2MARvnkYIxSS+Myb6ytYNIvvNmmjjdZTEpVJEdkYfOc52Nx22nODgG1rXhhdW1C+u5541eawksIMQ8xBwdzE7vmPPA+Xgkd81PbeFdKghjUQytIrxy+abiXfuRSqkNuyAAzDaDjBPFO9G12tRWq3t0KL+OLBLUXDWd+IpEEludif6SpkWPKfN6upw2Dg5xVa48cLDqjRnTrv7PBBO92mxDLA0ZjJJIfbt2vngknIx6Ve1DwbplxYz29tGbYymMFt7uERZVkKIC2EBK9FwO/arkXhjSI0nVbVj58UsMrPNIzSLJjfuYtkk7V5znjg0KVBa2YNVX1M7U/HWl6ddzW86Ss0aO4MUkLlgqFz8ofcvAP3gBWnpOtRX0jxRWF3BKk3lzpIiAwkoHDPhjwQR0ycnnHNVpvBuhSlzJZuyu0jFPtMuwF1KuQu7AJBOcCrraLb/2wmoxtLHLvaSRVY7ZXMYjBYeyjAA9c1MnStaNykql9TKvNV1NPE6aUlnbPPIwlt7oodsdtx5u7nO4EADBAO5T2NW9Z1+bTtatbJdNubiKW3mnMkTJk+WF4UFgT97vjqMZ5xb1fR49Q3SJNNa3hiMC3MLlXWMurMBzxnYOeoqW/wBOhu7iC6I23lsH8iXc4CFsZyFYbl4GQeuKXNDS6Hyy1sznU8Q6Jqet2Ji0t7u5K7orwwxEQrsR2O9myNolUnHqRyadP480+FbdpbO/QXSiS2LrGgmQnAcEuAo6feKn5hxzWj4d8NWWjWtmqqslzbiXEwUoCZGBfC5xj5VAznAAGaY3g/RDG8f2SQRsNpUXMoATnKABuEOTlB8p9OBV81G9nexPLVtdWuUn8Zw2xnW4tbq4aJ7pmNvEoEcUMm1mbc/bjkdfQdKnsvGGk6jrv9kQ7nmMjxqxKFWeMZI27twxg4JUA44NX/8AhHNJxOBaACeOaKTDsMpM26QdeMkdunbFNXw1pivM0cU8Yl3b0jupUQlhgnaGADH1AzS5qPZjtV7o2abFGkUaxxIqIowqqMAD0Ap1Fc5sFFFFACMoZSrAFSMEEcGlHHSiigBsUaRRrHEioijAVRgAewp1FFABRRRQAUUUUAIiqihUUKo6ADAFLRRQAUUUUAFFFFABRRRQAUUUUAFfNpufHum+IfEvibT/AA9rUUuuQ3KQOYBKY/Kx9mzEMsp2I6/OoyXGM5r6SooA8G8U3HxD+y+JNOMmrajbGK+t4HTTxGx2JbvFIjRoCSxllUY4Pl9yCa0NU1j4j2lzqE1kl/dxy3GoxxQNp6Yt4oriMQyIQoLMYmkKhiQ+wYB5J9D8aeJ5PD8mk21pZR3l7qdw1vCs1wLeJdsbOS0m1scLwMHJritQ+Mf2VXkj0HzYpZZIrP8A00B5DHdR27+auw+VzJlc7s47ZoA0rXWfFCfDnXL2SDVLi/huXj09zZrHdzwbkAkaHZgMMvx5ecLnaTweCvtY+IWq+GNVtdTi1+Gb7BOloltphzdSCSYZkkESshCCIrtWPcT05xW5cfFHWf8AhITNPp62mlaTY6jPqNrBcLK8slvKIcBmiyV3FcY2/eJJ+Xa1pPjFfS21w8PhKYy2tjdX9wst00AEcAQ7k8yJWYHzF52g9eDigB+jt4kv/jNBNrFvqH2OxbUYoSbLZbRQMYfKKzAfOXC5IJOCMDFRWPiLxvb3c8t9b6tc2dvrkaSNFpuBJZsk2VjjMQk+VvJDNlh3DYzSH4qa5D4jksJfD0Dyz20M0Fob0L5QMVzKxaUId2UhUgbRgkjmtXTviuuo65pFlbaR/o189nG00l2FeNri2NwuI9p3KFABORyaAPOtA1D4i2s+pXyw6zDrOoSWbzLNoxa3kAtEWWViEyGQqMIpGSMYJ6aWszeOdQ8O6ZeXb+Jlnk0vVraaGC1/1k+zEDlEhV0D87dyqRtGMEkt2fiv4o3Og63qtjH4ee7hs7uCxjuEuGPmzSwrKqmNI2cDaX5AblRx83GZc/Fq8ubK7FvpDaVdRpY3ES3pcySxzTwRyEJsC4Hmsud5O4cqKAMzSb/xtoOo3nnf8JDd2737M0JsDOqxNYnyfLbZnAmAVgD8uxd2NzFqco8dyajp9zcv4gubm6g0O5+ztbFbdZBIDchyiARFSfmUkZV2yCFG3pNN+Keqaprmh2sej2WnxT6jLaX8V5dOJoEWEygnMYUEqNwwWDYABG7cK9l8aZ7+7+xWHh1JrxsOgN68cbRmCWYOGaEE/LC3RSDkYY0AU9M1b4j6hcaVatNq1tDcT2yX11LpUcb2rtHOZo4wyFWiUrFiQg8kDcc4rr9I0/XfF/hfwwPFIFtbNbrcarbPGY5riZSNsbpgBUzlmHcgLgDNZCfGJZ9DvNYttEZrGEW0SBrk+c886wsqmNUZhGBN98ZJK4Ckmu/8H623iLw5Z6o9lPYvOGDW86sGjKuVI+YA4yuRkDgjgUAbIGBgcCiiigAooooAKKKKAPlX/hFPFnk/YP7K1T7B/a39u/6h/wDXfbvI2Yx/zy/e/wC783Tmu18I3fj+1ukSQarHYQapDGbaWxDCWGe+uBKxdl37UjEbZBwAVPTro2fxoubq10xk8NRtdapFBLZwx6kGDeZOIMO3ljYQzDHXIz0wQGa78YdRh0K/uLDQ7aK4FvdS2plvPMwbeRY5fNjVQV5OVGfmx1WmBUh1v4l3csNuq6lbSTzQR3kr6WmyxdrkIyw5XEsQiJYuS2MD5hnAl+LFhqF14os7SZZ7+YabaGyKRH95MuoQm5dVHAbyxGxx0Xd2zWrD8X2Nzq8NzoLwrp6uhuPOkaBp0dI2j8zycYLSAKV3FuPlBIBpP8bo4rWC7uvD00Vv5VyZJWlfHnQmTMKZiBLER7vnEeATxkEUgOZ/4Sjxl4fgjtbq41PTz9qUWsbWSyrcebqUquJXdSyfu9uwDGRyM9Qv2Lx1Y+GXsbGbXra0Y3F75VtZASRMuqDKq2wu2+KR5duSWCjAK5B7uPxbpd/4SuvG2r+FYo9T0uYWsXnw/vMlk2GOWWNXVCZQd20Y+Y44qhffGKe0e+i/4R5JJtMjuJNQ2ah8kYheJW8tvL/ef65ccLyCDjrQBzGrN4z0C68UanoEOvT3uo6lK0Up05GLRRW8bRA/uGYqTI6gYUZjI3IxYts6t4h+IX2LUJIINThv/tyr9nj07MMFnjiWKTyZC8hONy4cjJ+UYzVy0+J9/p9/d6dqFi1/cXOq3lnpjiQR+ayXghEOAhxtR1fcc5CnPTNS/Dfxn4q1zxdc6LdQWl5pultLDe6jsCPIRNcRo4wwHPkqMKmOWOVwAQCz4uXxXdeE/BN2L/UrLURcwnUzpltv2hoXy7RMhbCvtypGBuORwCOOsvHHjK+stGubzUL6zjvb2TT3j0/T4rqZjb2zebIibDu3TKxwM4C/UV9AyxpNE8UqK8bqVZGGQwPUEdxVO30jTbaOyjt9Ps4kscm1WOFVFvkFT5YA+XIJHGOCaAPFh4p+I9vdxTeIUl0vTk00S3EkVl5mD9mZmcfumUTCXGEaRQThdpzke36e0jWFs0xkMpiUuZVCvnAzuA4B9QOKsUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9U0yw1e1+zarY2t9bbg3lXMSypkdDhgRmqx8OaIZ7mY6NppmuWVp5PsqbpSrBlLHHzEMARnoQDWrRQBQj0XS4ppJY9NskllEiu6wIGcSNukBOOQzAFvUjJqvbeGdBtYHgtdE0uGF4pIGjjtI1Vo5CC6EAcq2BkdDgZrXooAzm0PSXu1um0uxa6VQgmNuhcKFZQA2M4Cu649GI7msOTwBoj+KtP13y2SXT0RLa2jSNIYtqFFxhN2AGOF3bR1xXW0UAZ95omlXsd3HeaZY3Ed4yvcrLbo4nZQFUuCPmIAAGegAqvD4Y0CHzfJ0PS4/NEYk22kY3+WQUzxztKqRnptGOlbFFAGRD4Z0GG1S2h0TS47ZJxdJEtpGEWYdJAMYD/7XWm2XhXw9Yy+bZaDpNvJkndDZxoeQwPIHo7j6M3qa2aKAMc+F9AO7Oh6Wd1uto3+iR8wrjEZ4+4Nq4XpwPStGxs7XT7SK0sLaG1tYhtjhhQIiD0CjgCp6KACiiigAooooAKKKKAOY8MeBfD3hzSbWwstMtZPs4j/ANImgjaaRozlHdgoywOCD2PStVdB0dZ72ddKsBNeqUupBbJuuFPUSHGWHsc1pUUAYq+FPDqrMq6BpIWaFbaQCzjw8S4xG3HKjauFPHA9KWDwr4et5o5bfQdJiljV0R0s41Kq2dwBA4B3HI75PrWzRQBn2miaVZ6ZJp1npljb6fJu32sVuiRNu65QDBz34qBPDOgx2otk0TTFtxC1uIhaRhPKYhmTGMbSQCR0JArXooA5658I6Xca9p+qGMxtYySzw28SIkXny53zMAu4udx5z15xnmtPQ9Js9D0q307TIfJtIAQilixySWJJPJJJJJPUmr1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the International AIDS Society-USA. Johnson VA, Brun-V&eacute;zinet F, Clotet B, G&uuml;nthard HF, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD. Update of the Drug Resistance Mutations in HIV-1: December 2010. Topics in HIV Medicine 2010; 18(5):156-163. Updated information (and thorough explanatory notes) are available at",
"     <a href=\"file://www.iasusa.org\" target=\"_blank\">",
"      www.iasusa.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37841=[""].join("\n");
var outline_f36_61_37841=null;
var title_f36_61_37842="Amiodarone skin pigmentation";
var content_f36_61_37842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amiodarone-induced pigmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Amiodarone causes a striking slate-gray pigmenation in a photodistribution of the face. The blue color (ceruloderma) is due to the deposition of melanin and lipofuscin contained in macrophages and endothelial cells in the dermis. The pigmentation is reversible, but it may take up to a year or more to complete resolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick TB, Johnson AB, Wolff K, Suurmond, D. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 4th ed, McGraw-Hill, New York 2001. Copyright &copy; 2001 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37842=[""].join("\n");
var outline_f36_61_37842=null;
var title_f36_61_37843="Multiple actinic keratoses";
var content_f36_61_37843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple actinic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperkeratotic lesions are present on the dorsal hands and forearms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37843=[""].join("\n");
var outline_f36_61_37843=null;
var title_f36_61_37844="Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information";
var content_f36_61_37844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/51/29492?source=see_link\">",
"    see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/39/5748?source=see_link\">",
"    see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10514505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Feiba NF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Activated Prothrombin Complex Concentrate (aPCC);",
"     </li>",
"     <li>",
"      Antihemophilic Agent;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Control of bleeding:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Considered a first-line treatment when factor VIII inhibitor titer is &gt;5 Bethesda units (BU) (antihemophilic factor may be preferred when titer &lt;5 BU)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      General dosing guidelines:",
"     </i>",
"     50-100 units/kg (maximum: 200 units/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Joint hemorrhage: 50 units/kg every 12 hours; may increase to 100 units/kg every 12 hours; continue until signs of clinical improvement occur (maximum: 200 units/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucous membrane bleeding: 50 units/kg every 6 hours; may increase to 100 units/kg every 6 hours up to 2 doses only (maximum: 200 units/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soft tissue hemorrhage (eg, retroperitoneal bleed): 100 units/kg every 12 hours (maximum: 200 units/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other severe hemorrhage (eg, intracranial hemorrhage): 100 units/kg every 12 hours; may be used every 6 hours if needed; continue until clinical improvement (maximum: 200 units/kg/day unless severity of hemorrhage justifies higher doses).",
"     <b>",
"      Note:",
"     </b>",
"     If total single dose exceeds 100 units/kg or total daily dose exceeds 200 units/kg/day, monitor closely for DIC and/or coronary ischemia.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F135846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/39/5748?source=see_link\">",
"      see \"Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Feiba NF: ~500 units, ~1000 units, ~2500 units [heparin free; contains natural rubber/natural latex in packaging; exact potency labeled on each vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     For I.V. injection or drip infusion only; maximum infusion rate: 2 units/kg/minute. Following reconstitution, complete infusion within 3 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemophilia A &amp; B patients with inhibitors who are to undergo surgery or those who are bleeding",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7740564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acquired hemophilia with factor VIII or factor IX inhibitor titers &gt;5 Bethesda units (BU)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure decreased, MI, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Hypoesthesia (including facial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (including anaphylaxis), anamnestic response, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation; use in patients with normal coagulation mechanism; significant signs of disseminated intravascular coagulation (DIC); treatment of bleeding due to coagulation factor deficiencies in the absence of inhibitors to coagulation factors VIII or IX; acute thromboembolism (including myocardial infarction)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Allergic reactions (including severe anaphylactoid reactions) have been observed following administration. Discontinue immediately with signs/symptoms of hypersensitivity. Appropriate medication including epinephrine should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Thrombotic and thromboembolic events (including venous thrombosis, pulmonary embolism, disseminated intravascular coagulation [DIC], myocardial infarction and stroke) have been reported following administration of anti-inhibitor coagulant complex, particularly with administration of high doses and/or in patients with thrombotic risk factors.",
"     </b>",
"     Administer to patients at risk of DIC or venous or arterial thrombosis only if alternative therapy is not available. Use with caution when administering to patients with liver disease, postoperative patients, neonates, elderly, or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications. Observe closely for signs and symptoms of intravascular coagulation or thrombosis. Single doses should not exceed 100 units/kg and daily doses should not exceed 200 units/kg unless the severity of bleeding justifies use of larger doses. Large doses should be administered only as long as absolutely necessary to control bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antifibrinolytic agents: Thromboembolic events may be increased with concurrent use of an antifibrinolytic (tranexamic acid, aminocaproic acid); avoid or delay use of antifibrinolytic for at least 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Factor VIII: Product contains minute amounts of factor VIII which may cause an anamnestic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Patients with signs/symptoms of infection (eg, fever, chills, drowsiness) should be encouraged to consult healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Product packaging may contain natural rubber latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should only be used to control bleeding in patients with inhibitors resulting from coagulation factor deficiencies. Tests used to control improvement, such as aPTT,  whole blood clotting time (WBCT), and thromboelastography (TEG), do",
"     <b>",
"      not",
"     </b>",
"     correlate with clinical efficacy. Dosing to normalize these values may result in DIC.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2869874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2869871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Reproduction studies have not been conducted. Administer to pregnant women only if clearly indicated.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2869876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for control of bleeding; signs and symptoms of DIC (blood pressure changes, pulse rate changes, chest pain/cough, fibrinogen decreased, platelet count decreased, fibrin-fibrinogen degradation products, significantly-prolonged thrombin time, PT, or partial thromboplastin time); hemoglobin and hematocrit; hypotension; have epinephrine ready to treat hypersensitivity reactions.",
"     <b>",
"      Note:",
"     </b>",
"     Tests used to control efficacy such as aPTT, WBCT, and TEG do not correlate with clinical improvement. Dosing to normalize these values may result in DIC.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Autoplex (JP);",
"     </li>",
"     <li>",
"      Autoplex-T (IL);",
"     </li>",
"     <li>",
"      Feiba Tim 4 (KP, TW)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Huth-Kuhne A, Baudo F, Collins P, et al, &ldquo;International Recommendations on the Diagnosis and Treatment of Patients With Acquired Hemophilia A,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2009, 94(4):566-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/61/37844/abstract-text/19336751/pubmed\" id=\"19336751\" target=\"_blank\">",
"        19336751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd Jones M, Wight J, Paisley S, et al, &ldquo;Control of Bleeding in Patients With Haemophilia A With Inhibitors: A Systematic Review,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2003,  9(4):464-520.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/61/37844/abstract-text/12828680/pubmed\" id=\"12828680\" target=\"_blank\">",
"        12828680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ma AD and Carrizosa D, &ldquo;Acquired Factor VIII Inhibitors: Pathophysiology and Treatment,&rdquo;",
"      <i>",
"       Hematology Am Soc Hematol Educ Program",
"      </i>",
"      , 2006: 432-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/61/37844/abstract-text/17124095/pubmed\" id=\"17124095\" target=\"_blank\">",
"        17124095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monahan PE and Aledort LM, &ldquo;Factors Affecting Choice of Hemostatic Agent for the Hemophilia Patient With an Inhibitor Antibody,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2004,  77(4):346-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/61/37844/abstract-text/15558804/pubmed\" id=\"15558804\" target=\"_blank\">",
"        15558804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tjonnfjord GE, &ldquo;Activated Prothrombin Complex Concentrate (Feiba&reg;) Treatment During Surgery in Patients with Inhibitors to Factor VIII/IX: The Updated Norwegian Experience,",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2004, 10(Supp 2):41-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/61/37844/abstract-text/15385045/pubmed\" id=\"15385045\" target=\"_blank\">",
"        15385045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8434 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6AB2C9D7C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37844=[""].join("\n");
var outline_f36_61_37844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10514505\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135834\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135835\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135851\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135836\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135846\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135837\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673193\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673194\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135824\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135810\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135826\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135825\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7740564\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135850\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135828\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135813\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298760\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869874\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135820\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869871\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869876\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135822\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276659\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8434|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/51/29492?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/39/5748?source=related_link\">",
"      Activated prothrombin complex concentrates (factor VIII inhibitor bypassing activity): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37845="Common breastfeeding problems";
var content_f36_61_37845=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Common breastfeeding problems (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/61/37845/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37845/contributors\" id=\"au4693\">",
"       Richard J Schanler, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37845/contributors\" id=\"au1765\">",
"       Lisa Enger, RN, BSN, IBCLC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/61/37845/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37845/contributors\" id=\"se4702\">",
"       Steven A Abrams, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/61/37845/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37845/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/61/37845?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BREASTFEEDING PROBLEMS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Breastfeeding a healthy infant is often accompanied by challenges. These challenges can be difficult to deal with, especially when combined with the normal anxieties of parenting a newborn infant.",
"    </p>",
"    <p>",
"     Problems associated with breastfeeding can include engorgement, sore or painful nipples, plugged ducts, and infection of the breast (mastitis). Because these problems can cause distress, mild discomfort, or significant pain, many women stop breastfeeding after a few weeks. However, these problems can be treated effectively, allowing the woman to continue breastfeeding, which benefits her and her infant's health.",
"    </p>",
"    <p>",
"     The management of common breastfeeding problems will be discussed here. Additional breastfeeding topics are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"      \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"      \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ENGORGEMENT",
"     </span>",
"    </p>",
"    <p>",
"     Engorgement refers to swelling within the breast tissue, which can be painful. In some women with engorgement, the breasts become firm, flushed, warm to the touch, and feel as if they are throbbing. Some women develop a slight fever (eg, less than 101&ordm;F or 38.3&ordm;C).",
"    </p>",
"    <p>",
"     The best treatment for engorgement is to empty the breasts frequently and completely by breastfeeding. It may be more difficult for an infant to latch-on (form a tight seal around the nipple and most of the areola) when the breasts are engorged because the nipples become flattened. A correct latch-on allows the infant to obtain an adequate amount of milk and helps to prevent nipple soreness and injury. Instructions for latching-on are described separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If the breasts are engorged, expressing milk by hand or breast pump can help to soften the areola and allow the baby to latch on more easily. However, it is important to avoid overstimulating the breasts with hand",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     pump expression because this could worsen engorgement. Information about the use of a breast pump is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Hand expression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hand expression of milk between feedings may be necessary to avoid engorgement. Milk ducts open in several areas on the nipple; after let-down, milk should squirt easily from multiple openings when you gently push the area behind the nipple (",
"     <a class=\"graphic graphic_figure graphicRef72583 \" href=\"mobipreview.htm?8/30/8674\">",
"      figure 1",
"     </a>",
"     ). There are a number of techniques to express milk by hand.",
"    </p>",
"    <p>",
"     One suggestion is as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hold the hand in a c-shape, with the thumb on top. The fingers should be 1 to 1.5 inches behind the nipple. Keep the fingers together to avoid cupping the breast and apply gentle pressure with the thumb on top of the breast, pressing straight back against the chest.",
"      </li>",
"      <li>",
"       While pushing against the chest, roll the thumb and fingers towards the nipple. Work around the entire breast. It may help to use both hands (",
"       <a class=\"graphic graphic_figure graphicRef73810 \" href=\"mobipreview.htm?37/13/38111\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Continue pressing inward and rolling the fingers over the breast tissue. You may need to apply pressure closer to or further away from the nipple to find the right area.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Breast pump",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is also possible to use a breast pump to relieve engorgement, although you should not pump for more than about two to five minutes, as this could stimulate even more milk production. Pumps are often inefficient at removing milk during early engorgement. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      \"Patient information: Breast pumps (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is important to use the correct size flange if a breast pump is used. The flange is the piece that is held against the breast and draws the nipple in to pump milk. Using a flange that is too small can injure the nipple and cause pain. In addition, using a flange that is too small may decrease milk supply because it does not allow for adequate milk to be removed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Cold pack or showers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use of a cold compress or ice pack can be helpful in relieving the discomfort of engorgement. Heat packs or hot water bottles are not recommended to treat engorgement because this can increase tissue swelling. However, using heat and massage just before a nursing session may improve milk flow. Standing in a warm shower, allowing the spray to fall on the breasts, can promote milk release.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Massage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Massaging the breast gently prior to a feeding may promote milk flow and help to soften the breast. Using the fingertips, gently knead the breast in a circular motion, working from the chest wall and moving towards the nipple.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Reverse pressure softening",
"     </span>",
"     &nbsp;&mdash;&nbsp;Reverse pressure softening can help to move some of the swelling away from the nipple so that the infant is able to latch on the breast more easily [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/61/37845/abstract/1\">",
"      1",
"     </a>",
"     ]. Lying down while performing reverse pressure softening can enhance the technique's effectiveness.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Place the middle three fingers of each hand on the left and right side of the nipple. The fingertips should be touching the edges of the nipple (",
"       <a class=\"external\" href=\"file://www.health-e-learning.com/resources/articles/41-reverse-pressure-softening\">",
"        file://www.health-e-learning.com/resources/articles/41-reverse-pressure-softening",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Push the fingers back firmly but gently against the base of the nipple, towards the chest wall, and count to 50. This may need to be repeated.",
"      </li>",
"      <li>",
"       Once the",
"       <span class=\"nowrap\">",
"        nipple/areola",
"       </span>",
"       is softened, try to latch the baby to the breast.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Pain medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acetaminophen (Tylenol&reg;) or ibuprofen (Advil&reg;, Motrin&reg;) are safe to take while breastfeeding and may be effective in treating the discomfort related to engorgement.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      SORE OR PAINFUL NIPPLES",
"     </span>",
"    </p>",
"    <p>",
"     The nipples normally become more sensitive during pregnancy, with the greatest sensitivity occurring around the fourth day after delivery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       \"Normal\" nipple soreness occurs for the first 30 to 60 seconds of breastfeeding, but then improves.",
"      </li>",
"      <li>",
"       Nipple injury (such as a bruise, crack, or blister) usually causes pain throughout the nursing episode. Nipple bruising, cracking,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       blistering may develop if the infant fails to latch on correctly or does not take a large portion of the area behind the nipple into",
"       <span class=\"nowrap\">",
"        his/her",
"       </span>",
"       mouth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In general, normal nipple sensitivity completely resolves within about seven days after delivery. Pain that continues beyond the first postpartum week is more likely to be due to nipple injury. Women with injured nipples are at risk of developing a skin or breast infection.",
"    </p>",
"    <p>",
"     If pain continues throughout a nursing session, does not improve over the first week, or if there is any concern about an infection, talk to a lactation consultant or healthcare provider who is knowledgeable about breastfeeding. To locate a lactation consultant in your area, (see",
"     <a class=\"local\" href=\"#H30\">",
"      'Finding a lactation consultant'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Potential causes of nipple soreness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nipple trauma usually is due to incorrect breastfeeding technique, particularly poor position or latch-on. Nipple abrasion, bruising, cracking,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     blistering may result when an infant fails to achieve a proper latch-on. Infants with ankyloglossia are at increased risk for inadequate latch-on. Ankyloglossia, also known as \"tongue-tie\", occurs when the frenulum connecting the tongue to the floor of the mouth is tight and limits extension of the tongue. A review of correcting latching-on and positioning is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other contributing factors to sore nipples include plugged ducts, infections (eg, candidiasis), harsh breast cleansing, use of potentially irritating products, and skin disorders.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sore nipple treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The management of mothers with nipple trauma includes the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Identification of any underlying nipple condition and, if present, treatment for the specific problem. In particular, assessment of infant positioning and latch-on with correction of improper technique should be performed.",
"      </li>",
"      <li>",
"       Nipple ointment &mdash; A topical ointment may be recommended for treatment of sore nipples. One combination treatment includes a mixture of an antibiotic ointment, steroid ointment, and antifungal powder, known as \"All Purpose Nipple Ointment\" (APNO). This combination requires a prescription and can be specially made by a pharmacy. A thin layer of the ointment is applied to the nipples after feeding [",
"       <a class=\"abstract\" href=\"mobipreview.htm?36/61/37845/abstract/2\">",
"        2",
"       </a>",
"       ]. The ointment does not need to be wiped off before nursing.",
"      </li>",
"      <li>",
"       Moist healing &mdash; Moisture may help sore nipples to heal. A purified lanolin (eg, Lansinoh, Purelan) or hydrogel dressing (eg, Comfortgels&reg;, Soothies&reg;) may be applied after feeding; these are available without a prescription in some pharmacies. A thin layer of lanolin ointment should be applied to the nipple after feeding, and it is not necessary to wash the lanolin off before the next feeding. The hydrogel dressing should be removed before nursing and may be stored in the refrigerator between uses. It is best to alternate the use of an ointment or cream with the hydrogel pads rather than using them together.",
"      </li>",
"      <li>",
"       Use of breast shells to protect the nipples from friction between feeds.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PLUGGED DUCTS",
"     </span>",
"    </p>",
"    <p>",
"     Plugged ducts are areas in the breast where the flow of milk is blocked, usually by plugs of skin cells and milk. As the milk duct fills and stretches, the surrounding breast tissue becomes tender. Signs of a plugged duct include a tender or reddened lump in the breast. This usually occurs in one breast, develops gradually, and the discomfort is mild. Fever is not a typical sign of a plugged duct. Repeated episodes of plugged ducts can lead to the development of a galactocele, an enlarged area containing a thick, creamy, cheesy, or oily material within the duct (",
"     <a class=\"graphic graphic_picture graphicRef70540 \" href=\"mobipreview.htm?24/21/24927\">",
"      picture 1",
"     </a>",
"     ). Galactoceles often appear quickly and may be quite large (up to the size of an egg).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Plugged duct treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of a plugged duct includes frequent and complete emptying of the breast. Nursing from the affected side first may help to more fully empty that breast and begin the flow of milk. Positioning the infant with the nose pointed toward the plugged area may facilitate drainage of the affected area. Massage and a warm shower often promote milk release. Plugged ducts that do not resolve within 72 hours should be evaluated by a healthcare provider.",
"    </p>",
"    <p>",
"     If plugged ducts occur repeatedly in the same area of the breast, it may be helpful to change nursing positions at each feeding or to avoid bras and other clothes that compress the breast (eg, an underwire bra). Massaging the breast while breastfeeding is also suggested. Instructions about positioning are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      MASTITIS",
"     </span>",
"    </p>",
"    <p>",
"     Mastitis is inflammation of the breast, and is thought to be caused by infection. It typically causes a hard, red, tender, swollen area of one breast, and fever &gt;101&ordm;F (38.3&ordm;C). Other symptoms include muscle aches, chills, and feeling ill.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Mastitis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of mastitis includes continued nursing and a medication for pain control (eg, ibuprofen). If symptoms do not resolve promptly, an antibiotic course is generally given for 10 to 14 days. Breast massage during nursing or pumping afterwards may help to reduce discomfort. Stopping breastfeeding is not recommended during mastitis treatment; consult with a healthcare provider if you are concerned. There is little to no risk of passing the infection to the infant as a result of breastfeeding during an episode of mastitis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      BLOODY NIPPLE DISCHARGE",
"     </span>",
"    </p>",
"    <p>",
"     A small percentage of women have bloody nipple discharge in the first few days after delivery, resulting in bright red or rusty colored colostrum. The condition is related to an increase in blood vessels in the breast ducts during pregnancy and typically resolves within a few days. It is not necessary to stop nursing or to substitute infant formula, if blood is seen in the colostrum or breast milk, although you should consult with your healthcare provider.",
"    </p>",
"    <p>",
"     Blood may appear in breast milk as a result of cracks in the nipple, trauma to the breast, or other conditions. Blood is often detected because the infant's stool becomes bloody. The color of the milk can range from pale pink to bright red.",
"    </p>",
"    <p>",
"     If blood is seen during breast pump use, the pump settings and length of pumping should be modified. Using a high vacuum setting or pumping for long periods can cause bleeding in the breast tissue, which may cause the milk to appear bloody.",
"    </p>",
"    <p>",
"     If no obvious source is identified, you may be asked provide a milk specimen for microscopic examination. This is important because, in rare cases, blood in the breast milk is a sign of breast cancer. If the examination is normal, the bleeding usually resolves spontaneously and you can continue nursing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      OVERACTIVE MILK EJECTION REFLEX",
"     </span>",
"    </p>",
"    <p>",
"     Milk production increases rapidly between three to four days after delivery until approximately two to four weeks postpartum. The amount of milk you produce depends in part upon how frequently your breasts are emptied.",
"    </p>",
"    <p>",
"     As milk production increases, milk ejection may occur too rapidly for an infant to swallow. This can cause the infant to gag, cough, or push away from the breast shortly after latch-on. It may appear that the baby does not like breastfeeding or breast milk. However, it is usually the milk's flow rate, and not the taste, that is bothersome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Management",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several options are available to manage an overactive milk ejection reflex",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nurse the infant in a semi-upright position and allow the infant to interrupt nursing frequently.",
"      </li>",
"      <li>",
"       Reduce the flow of milk by gently compressing the base of the nipple during the first several minutes of nursing to slow the initial milk flow.",
"      </li>",
"      <li>",
"       Hand express until the initial let-down occurs and then allow the baby to latch onto the breast.",
"      </li>",
"      <li>",
"       Nurse frequently to minimize the amount of milk that collects. Having less milk collected in the breasts will reduce the force of milk flow.",
"      </li>",
"      <li>",
"       Use a nipple shield to create a reservoir for the milk.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pumping is not recommended because this will stimulate milk production and potentially worsen the problem.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      NIPPLE COLOR CHANGES",
"     </span>",
"    </p>",
"    <p>",
"     Women who have Raynaud phenomenon or unusual cold sensitivity may develop a narrowing (constriction) of the blood vessels of the nipple related to breastfeeding. This can cause the nipple to become painful and whitened (blanched) during, immediately after, and between feedings. Some women have a two-part color change (white and blue) while others have a three-color change (white, blue, and red) of Raynaud phenomenon. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=see_link\">",
"      \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Blanching can also occur as a result of nipple compression due to poor positioning and latch-on. Nipple compression is a more common cause of blanching and nipple pain than Raynaud phenomenon, and can be addressed by adjusting the position of nursing and latch-on.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Management",
"     </span>",
"     &nbsp;&mdash;&nbsp;Measures to alleviate blood vessel constriction include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Increase the air temperature and wear warm clothing. Reusable wool breast pads may be helpful.",
"      </li>",
"      <li>",
"       Apply a warm compress just before and after nursing.",
"      </li>",
"      <li>",
"       Stop smoking.",
"      </li>",
"      <li>",
"       Avoid medications that constrict blood vessels (eg, pseudoephedrine, a decongestant).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If your nipple pain that does not improve with these measures, you may benefit from a medication typically used to treat high blood pressure, called nifedipine [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/61/37845/abstract/3\">",
"      3",
"     </a>",
"     ]. A two week trial of nifedipine is usually recommended, followed by a period of time without the medication. If pain returns after the drug is discontinued, the medication may be resumed for an additional two-week course. It is uncommon to need more than three two-week courses of nifedipine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      INFANT STOOLS",
"     </span>",
"    </p>",
"    <p>",
"     Meconium is the sticky dark-colored stool that infants normally produce for the first few days after birth. An infant's stool should transition from the dark sticky meconium to a greenish-brown color to a stool that is mustard yellow to light brown, often with visible milk curds, by the third to fifth day. Most infants have four or more stools per day by the fourth day, although fewer stools may be normal. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"      \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Continuing to have meconium stools after day four may indicate that your supply of breast milk is low or that the infant is not taking in an adequate amount of milk (even if abundant milk is available). If an infant's stools are not pale yellow and seedy by the fifth day, even if the infant is otherwise healthy, contact the infant's healthcare provider to determine if further evaluation or treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Stool frequency",
"     </span>",
"     &nbsp;&mdash;&nbsp;During the first few weeks after delivery, breastfed infants generally pass gas or stool during or after each nursing session. Stool frequency usually decreases after approximately four to six weeks. The decrease in frequency may be abrupt. In some cases, a healthy breastfed infant may stool as infrequently as once every two weeks. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"      \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If a breastfeeding infant is otherwise healthy and gaining weight appropriately, changes in stool frequency are usually normal. However, contact your child's healthcare provider immediately if your child has less frequent stools as well as decreased sucking strength, decreased interest in feeding, or if the infant seems irritable.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Green frothy stools",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stools that appear green and frothy sometimes develop when food passes especially rapidly through the baby's digestive tract. This is more likely to occur if you switch the infant from one breast to the other before the infant is finished with the first side. It may also occur if you have an overabundant milk supply because the infant is less likely to get as much of the hind milk.",
"    </p>",
"    <p>",
"     Thoroughly emptying one breast allows the baby to consume hind milk, which has a higher fat content than milk available at the start of a nursing session. The higher fat content of the hind milk helps to slow digestion and reduce excessive gas and frothy stools. Allow the infant to finish nursing on one breast before switching to the other, even if the child does not take the second breast.",
"    </p>",
"    <p>",
"     Women with an overabundant supply may need to decrease their milk supply by allowing the baby to nurse on just one breast for two or three feedings in a row. This signals the breast to slow milk production. You may partially empty the other breast if needed, just until the discomfort is eased.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      BITING",
"     </span>",
"    </p>",
"    <p>",
"     Infants normally begin to have visible teeth at six to ten months of age. Infants who bite during breastfeeding can cause pain and injury to the nipple. However, it is not possible to bite and nurse at the same time.",
"    </p>",
"    <p>",
"     To teach your infant not to bite, immediately remove the infant from the breast as soon as a bite begins. Place the infant on a safe surface, such as a blanket on the floor. You can then offer a teething toy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     If you are unable to breastfeed due to engorgement, pain, or difficulty latching your infant, help is available. Talk to your obstetrical or pediatric healthcare provider, nurse, lactation consultant, or a breastfeeding counselor (see",
"     <a class=\"local\" href=\"#H30\">",
"      'Finding a lactation consultant'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784887186\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11479718\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/25/17813?source=see_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=see_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11479726\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=see_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/43/17075?source=see_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=see_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/62/22498?source=see_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44615?source=see_link\">",
"      Ankyloglossia (tongue-tie) in infants and children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=see_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=see_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43864?source=see_link\">",
"      Maternal nutrition during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/44/28362?source=see_link\">",
"      Nutrition in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6727?source=see_link\">",
"      Nutritional composition of human milk for full-term infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link\">",
"      Principles of medication use during lactation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17304?source=see_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38745?source=see_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/23/29050?source=see_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/breastfeeding\">",
"      www.cdc.gov/breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/Breastfeeding\">",
"      www.womenshealth.gov/Breastfeeding",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www2.aap.org/healthtopics/breastfeeding.cfm\">",
"      www2.aap.org/healthtopics/breastfeeding.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bright Futures Lactation Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.bflrc.com/resources.htm\">",
"      www.bflrc.com/resources.htm",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Finding a lactation consultant",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certified lactation consultants, or LC s, are available at most hospitals as well as privately, and can be an invaluable resource for instructions about breastfeeding, pumping, milk storage, and bottle feeding breast milk. The websites listed below have information about finding a lactation consultant or breastfeeding counselor.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       La Leche League",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lalecheleague.org/\">",
"      www.lalecheleague.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Board of Lactation Consultant Examiners",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.iblce.org/\">",
"      www.iblce.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 703-560-7330",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Lactation Consultant Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ilca.org/\">",
"      www.ilca.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;phone: 919-861-5577",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/61/37845/abstract/1-10\">",
"      1-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/61/37845?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Cotterman, KJ. Reverse Pressure Softening. Available online at: www.health-e-learning.com/articles/RPS_JCotterman_ver2005.htm (Accessed on July 30, 2007).",
"    </li>",
"    <li>",
"     Newman J. Treatments for sore nipples and sore breasts. Available online at: www.kellymom.com/newman/03b-treatments_sore_nipples_breasts.html#apno (Accessed on September 10, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/3\">",
"      Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. J Hum Lact 2002; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/4\">",
"      Roberts KL, Reiter M, Schuster D. Effects of cabbage leaf extract on breast engorgement. J Hum Lact 1998; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/5\">",
"      Ballard JL, Auer CE, Khoury JC. Ankyloglossia: assessment, incidence, and effect of frenuloplasty on the breastfeeding dyad. Pediatrics 2002; 110:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/6\">",
"      Dollberg S, Botzer E, Grunis E, Mimouni FB. Immediate nipple pain relief after frenotomy in breast-fed infants with ankyloglossia: a randomized, prospective study. J Pediatr Surg 2006; 41:1598.",
"     </a>",
"    </li>",
"    <li>",
"     La Leche League. Is thrush causing my sore nipples? Available online at: www.lalecheleague.org/FAQ/thrush.html (Accessed on July 30, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/8\">",
"      Snowden HM, Renfrew MJ, Woolridge MW. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev 2001; :CD000046.",
"     </a>",
"    </li>",
"    <li>",
"     Newman, J. Blocked Ducts and Mastitis. Available online at: www.bflrc.com/newman/breastfeeding/mastitis.htm (Accessed on June 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37845/abstract/10\">",
"      Mennella JA, Jagnow CP, Beauchamp GK. Prenatal and postnatal flavor learning by human infants. Pediatrics 2001; 107:E88.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_61_37845=[""].join("\n");
var outline_f36_61_37845=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BREASTFEEDING PROBLEMS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ENGORGEMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           SORE OR PAINFUL NIPPLES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PLUGGED DUCTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           MASTITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           BLOODY NIPPLE DISCHARGE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           OVERACTIVE MILK EJECTION REFLEX",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           NIPPLE COLOR CHANGES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           INFANT STOOLS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           BITING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8674\" title=\"figure 1\">",
"           Breastfeeding anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/13/38111\" title=\"figure 2\">",
"           Hand expression PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/21/24927\" title=\"picture 1\">",
"           Galactocele PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37846="Paronychia and ingrown toenails";
var content_f36_61_37846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paronychia and ingrown toenails",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37846/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/61/37846/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PARONYCHIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paronychia is an inflammation involving the lateral and proximal fingernail folds. Predisposing factors include overzealous manicuring, nail biting, thumbsucking, diabetes mellitus, and occupations in which the hands are frequently immersed in water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/1\">",
"     1",
"    </a>",
"    ]. Paronychia has also been reported in association with antiretroviral therapy for HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and with use of epidermal growth factor inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paronychia may be either acute or chronic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute paronychia is characterized by the onset of pain and erythema of the posterior or lateral nail folds, with subsequent development of a superficial abscess (",
"      <a class=\"graphic graphic_picture graphicRef70107 graphicRef80162 graphicRef60833 \" href=\"mobipreview.htm?20/24/20872\">",
"       picture 1A-C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In digits without exposure to oral flora, acute paronychia is most commonly caused by skin flora (such as Staphylococcus aureus and Streptococcus pyogenes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In digits exposed to oral flora, acute paronychia may be caused by either skin or oral flora. In this setting, organisms include both aerobic bacteria (such as streptococci, S. aureus, and Eikenella corrodens) and anaerobic bacteria (such as Fusobacterium, Peptostreptococcus, Prevotella, and Porphyromonas spp) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Candida is frequently isolated from the proximal nail fold of patients with chronic paronychia (",
"      <a class=\"graphic graphic_picture graphicRef53529 graphicRef63272 \" href=\"mobipreview.htm?35/55/36727\">",
"       picture 2A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. However, it is not clear that Candida infection is actually responsible for the onset and maintenance of the disease. On the other hand, there is substantial evidence that chronic paronychia represents an eczematous condition with a multifactorial etiology (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/10-13\">",
"       10-13",
"      </a>",
"      ]. Acute bacterial paronychia can exacerbate the chronic swelling and erythema of the proximal nail fold associated with chronic paronychia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical appearance of swollen, tender posterior or lateral nail folds should confirm the diagnosis of paronychia. A purulent fluid collection is often present in acute paronychia (",
"    <a class=\"graphic graphic_picture graphicRef70107 graphicRef80162 graphicRef60833 \" href=\"mobipreview.htm?20/24/20872\">",
"     picture 1A-C",
"    </a>",
"    ). Retraction of the proximal nail fold, loss of the cuticle, and nail dystrophy are common features of chronic paronychia (",
"    <a class=\"graphic graphic_picture graphicRef53529 graphicRef63272 \" href=\"mobipreview.htm?35/55/36727\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The differential diagnosis of paronychia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal onychomycosis &mdash; In onychomycosis, the nail plate is friable and the nail folds are not predominantly involved (",
"      <a class=\"graphic graphic_picture graphicRef81063 \" href=\"mobipreview.htm?3/1/3089\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=see_link\">",
"       \"Onychomycosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpetic whitlow &mdash; Acute onset is associated with vesicles, vesicopustules, severe edema, erythema, or pain (",
"      <a class=\"graphic graphic_picture graphicRef75510 graphicRef52029 \" href=\"mobipreview.htm?9/42/9892\">",
"       picture 4A-B",
"      </a>",
"      ). The patient should be asked about exposure to herpes simplex virus (HSV). Tzanck staining of vesicles will demonstrate multinucleated giant cells. Immunofluorescence staining and viral culture can also be used to confirm HSV infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Skin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pustular psoriasis &mdash; Acrodermatitis continua of Hallopeau, a rare variant of pustular psoriasis, presents with pustules, erythema, scale, and crusts involving the distal digit (",
"      <a class=\"graphic graphic_picture graphicRef69799 \" href=\"mobipreview.htm?42/42/43694\">",
"       picture 5",
"      </a>",
"      ). Unlike acute paronychia, pustules are sterile. In addition, nail destruction is a prominent feature.",
"     </li>",
"     <li>",
"      Pseudomonal nail infection &mdash; The nail plate has a blue-green tint (",
"      <a class=\"graphic graphic_picture graphicRef74676 \" href=\"mobipreview.htm?39/7/40049\">",
"       picture 6",
"      </a>",
"      ). Prolonged exposure to water is a predisposing factor. In some cases, this condition may occur simultaneously with chronic paronychia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paronychia must also be distinguished from felon, an infection of the digital pulp (",
"    <a class=\"graphic graphic_picture graphicRef55298 \" href=\"mobipreview.htm?9/22/9581\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69094 \" href=\"mobipreview.htm?25/36/26191\">",
"     figure 1",
"    </a>",
"    ) characterized by severe pain, swelling, and erythema in the pad of the fingertip that is typically more dramatic than the onset of paronychia. Treatment of felon is an emergency situation and requires incision and drainage to prevent the development of osteomyelitis, permanent nail deformities, and ischemic necrosis of the fingertip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acute paronychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of acute paronychia without abscess formation includes local care (warm compresses or soaks to the affected digit for 20 minutes, three times per day). Oral antibiotic therapy may be helpful in more severe cases. Topical antibiotics with or without topical corticosteroids have also been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/16\">",
"     16",
"    </a>",
"    ]. Although topical antibiotics have not been well studied in this setting, we typically have patients apply an antistaphylococcal antibiotic (eg, triple antibiotic ointment or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ) after each warm soak.",
"   </p>",
"   <p>",
"    Acute paronychia with abscess formation is treated with incision and drainage in addition to the above management. Incision and drainage is performed after appropriate local anesthesia (digital block or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14370?source=see_link\">",
"     ethyl chloride",
"    </a>",
"    spray) by the insertion of a number 11 surgical blade under the affected cuticle margin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    .) Extension of the incision along the lateral nail bed is indicated if the infection is unilateral. Another method that can be used when the abscess is superficially located is to use a large-gauge needle and run it (bevel down) along the nail and into the abscess; some patients will tolerate having this performed without local anesthesia. Frequent warm soaks will help to maintain the patency of the incision and assist wound drainage. Given the increasing prevalence of MRSA, we suggest that cultures be sent from all drained paronychia.",
"   </p>",
"   <p>",
"    Drainage is sufficient for many cases of paronychia with abscess formation. For more severe cases, oral antibiotic therapy can be used after drainage.",
"   </p>",
"   <p>",
"    Antibiotic treatment is typically given for five days after surgical drainage and for seven to ten days without drainage. When available, culture and susceptibility results should be used to tailor antibiotic therapy. Empiric antibiotic therapy should be selected based on antibiotic activity against potential flora:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a digit that has not been exposed to oral flora (paronychia of a toe or of a finger in a patient with non-oral trauma to the digit and who definitively denies oral contact with the digit), an antibiotic with coverage of skin flora is appropriate. An antistaphylococcal agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      (250 mg four times daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      (500 mg three to four times daily) is appropriate in areas with a low prevalence of methicillin-resistant Staphylococcus aureus (MRSA). In areas with a high prevalence of MRSA, an oral agent likely to cover local strains of MRSA (eg, TMP-SMX two double-strength tablets twice daily) is a reasonable choice in patients with risk factors for MRSA who fail to respond to coverage for methicillin-sensitive Staphylococcus aureus (MSSA). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a digit that has been exposed to oral flora (nail biting, finger sucking), antibiotic coverage should include S. aureus, E corrodens, H. influenzae and beta-lactamase producing oral anaerobic bacteria (",
"      <a class=\"graphic graphic_table graphicRef80408 \" href=\"mobipreview.htm?3/59/4028\">",
"       table 1",
"      </a>",
"      ). Considerations regarding coverage for MRSA are the same as those discussed above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chronic paronychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised to keep their hands as dry as possible and to use gloves for all wet work. Given the possible association between chronic paronychia and eczema, patients with known contact allergies should also be advised to avoid irritant or allergen exposure.",
"   </p>",
"   <p>",
"    In addition to these protective measures, topical therapy is typically used to treat chronic paronychia. Antifungal agents have traditionally been used because the pathogenesis of the disorder was thought to be fungal. However, one study has found that topical corticosteroids are more effective than antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/13\">",
"     13",
"    </a>",
"    ]. In this report, 45 patients with chronic paronychia were randomly assigned to receive one of three treatments: oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    200 mg, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    250 mg, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    aceponate 0.1% cream (a high potency topical corticosteroid). Trial participants given oral medications used a placebo cream, and patients receiving methyprednisolone aceponate were given an oral placebo. Patients were treated for three weeks and then followed for six more weeks. Topical methylprednisolone therapy was associated with a significantly higher cure rate compared with systemic antifungal therapy (85 versus 49 percent of nails, respectively). Only 18 patients had Candida cultured from the proximal nail fold at the beginning of the study, and of these, Candida eradication was associated with clinical cure in only two.",
"   </p>",
"   <p>",
"    These findings further support the idea that chronic paronychia is an eczematous process and that Candida infection is a secondary phenomenon. Thus, the treatment of choice should be protective measures as outlined above plus a topical corticosteroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ). If the lesions remain unresponsive to therapy, it may be reasonable to try a course of antifungal therapy and to perform a Gram stain and culture to identify a possible bacterial superinfection.",
"   </p>",
"   <p>",
"    Although more expensive than topical corticosteroids, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be another therapeutic option. Topical tacrolimus 0.1% ointment was similar in efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    17-valerate 0.1% ointment and superior to placebo in one randomized unblinded trial of 45 patients with chronic paronychia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INGROWN TOENAIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingrown toenails occur when the lateral nail plate pierces the lateral nail fold and enters the dermis (",
"    <a class=\"graphic graphic_picture graphicRef60056 \" href=\"mobipreview.htm?19/25/19857\">",
"     picture 8",
"    </a>",
"    ). The great toenail is most commonly affected. Characteristic signs and symptoms include pain, edema, exudate, and granulation tissue. Predisposing factors include poorly fitting shoes, excessive trimming of the lateral nail plate, pincer nail deformity (",
"    <a class=\"graphic graphic_picture graphicRef59295 \" href=\"mobipreview.htm?14/21/14676\">",
"     picture 9",
"    </a>",
"    ), and trauma. The diagnosis is based upon clinical appearance and rarely is difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of ingrown toenails depends upon the severity of the lesion. All patients should be educated about proper nail trimming; the lateral nail plate should be allowed to grow well beyond the lateral nail fold before trimming horizontally. Patients should also be educated about the importance of well-fitting shoes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mild to moderate lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate lesions are characterized by minimal to moderate pain, little erythema, and no discharge. Two options for conservative treatment are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a cotton wedging or dental floss underneath the lateral nail plate to separate the nail plate from the lateral nail fold, thereby relieving pressure.",
"     </li>",
"     <li>",
"      Soak the affected foot in warm, soapy water for 10 to 20 minutes, three times per day for one to two weeks, pushing the lateral nailfold away from the nail plate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/21\">",
"       21",
"      </a>",
"      ]. Alternatively, a solution of water mixed with 1 to 2 teaspoons of Epsom salts can be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/22\">",
"       22",
"      </a>",
"      ]. A medium to high potency topical corticosteroid can be applied after soaking to reduce inflammation (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 70 percent of patients respond to conservative therapy. Nonresponders may need to undergo more aggressive therapy (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Moderate to severe lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe lesions are characterized by substantial erythema and pus (",
"    <a class=\"graphic graphic_picture graphicRef60735 \" href=\"mobipreview.htm?22/28/22990\">",
"     picture 10",
"    </a>",
"    ). Treatment consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform an appropriate digital block with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent without epinephrine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      .) EMLA (eutectic mixture of lidocaine [2.5 percent] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      [2.5 percent] in a cream base) has not been proven helpful in reducing the pain of injection.",
"     </li>",
"     <li>",
"      Using nail-splitting scissors or a hemostat, insert the instrument under the nail plate and remove the involved nail wedge with nail clippers or scissors.",
"     </li>",
"     <li>",
"      Remove any granulation tissue with a curette",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      sticks.",
"     </li>",
"     <li>",
"      Dilute",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      1:1 with tap water and cleanse the surgical site with cotton swabs two or three times a day, followed by application of either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      ointment.",
"     </li>",
"     <li>",
"      Many elect to treat secondary infections with oral antibiotics. However, in a study of 54 patients with ingrown toenails (patients who were immunocompromised, had peripheral vascular disease, or had cellulitis were excluded), the use of antibiotics in association with nail border resection did not decrease healing time nor postprocedure morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Follow-up in three to four days to assess treatment and possible spicule formation with nail regrowth. Remember to educate the patient that when the lesion heals and the lateral nail fold is no longer edematous, they should allow the lateral nail plate to grow beyond the lateral nail fold.",
"     </li>",
"     <li>",
"      An additional option is the placement of a soft plastic tube stent along the affected nail edge (gutter method).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Recurrent ingrown toenail",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who suffer recurrent ingrown toenails, consider permanent nail ablation of the lateral nail horn. This is best achieved with the combination of surgical excision plus phenol ablation (chemical matricectomy). In one study, for example, 163 patients (204 ingrowing nail edges) who had not had previous surgery were randomized and treated by total nail avulsion, nail edge excision, or nail edge excision with phenolization of the germinal matrix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/24\">",
"     24",
"    </a>",
"    ]. Recurrence rates one year postoperatively were 73, 73, and 9 percent, respectively.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis concluded that nail avulsion combined with phenol leads to a 75 to 91 percent reduction in the recurrence of ingrowing toenails compared to excisional techniques alone, although there is a higher rate of postoperative secondary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/25\">",
"     25",
"    </a>",
"    ]. One study described more rapid healing with the use of sodium hydroxide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/26\">",
"     26",
"    </a>",
"    ], but until additional studies are performed demonstrating efficacy, safety, and ease of use, we continue to use phenol.",
"   </p>",
"   <p>",
"    To perform the procedure, surgical nail avulsion of the involved lateral nail is performed prior to the application of phenol. The central nail plate and uninvolved lateral nail plate is usually left in place. The procedures for partial nail avulsion and chemical matricectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12758?source=see_link&amp;anchor=H6#H6\">",
"     \"Nail surgery\", section on 'Nail avulsion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12758?source=see_link&amp;anchor=H9#H9\">",
"     \"Nail surgery\", section on 'Chemical matricectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of partial regrowth, including nail spicules should be discussed with the patient.",
"    <br/>",
"    <br/>",
"    Surgical ablation with electrocautery, radiofrequency, or carbon dioxide laser are alternatives to destruction of the nail matrix with phenol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37846/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/3/19505?source=see_link\">",
"       \"Patient information: Ingrown toenail (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/25/23953?source=see_link\">",
"       \"Patient information: Paronychia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H478700\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term paronychia refers to inflammation involving the proximal or lateral nail folds. Acute paronychia results from bacterial infection of the nail fold, and can present with pain, erythema, swelling, and abscess formation. Common features of chronic paronychia include periungual erythema and swelling, loss of the cuticle, and nail dystrophy. The cause of chronic paronychia may be multifactorial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Paronychia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In mild cases, acute paronychia can be managed with warm compresses or soaks. If an abscess is present, incision and drainage should be performed. In severe cases, antibiotic therapy may also be required. The choice of the appropriate antibiotic is based upon the possibility of exposure to oral flora and the results of microbial cultures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute paronychia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic paronychia appears to be an eczematous process that can be complicated by secondary Candida infection. Avoidance of environmental triggers is an essential component of treatment. Patients should wear gloves during wet work and should avoid contact with irritating substances. Topical treatment consists of the application of a medium or high potency topical corticosteroid (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 2",
"      </a>",
"      ). If patients do not improve with these measures, a course of antifungal therapy also can be tried. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chronic paronychia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ingrown toenails occur when the lateral nail plate pierces the lateral nail fold. Patients may present with pain or swelling surrounding the nail. Mild lesions can be treated conservatively, with soaks several times per day and the use of cotton or dental floss to separate the nail plate from the nail fold. Surgical intervention may be required for more severe cases. In patients with frequent recurrences, permanent nail ablation can be beneficial. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ingrown Toenail'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/1\">",
"      Shroff PS, Parikh DA, Fernandez RJ, Wagle UD. Clinical and mycological spectrum of cutaneous candidiasis in Bombay. J Postgrad Med 1990; 36:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/2\">",
"      Alam M, Scher RK. Indinavir-related recurrent paronychia and ingrown toenails. Cutis 1999; 64:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/3\">",
"      Tosti A, Piraccini BM, D'Antuono A, et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 1999; 140:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/4\">",
"      Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007; 56:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/5\">",
"      Rigopoulos D, Larios G, Gregoriou S, Alevizos A. Acute and chronic paronychia. Am Fam Physician 2008; 77:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/6\">",
"      Brook I. Paronychia: a mixed infection. Microbiology and management. J Hand Surg Br 1993; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/7\">",
"      Brook I. Bacteriologic study of paronychia in children. Am J Surg 1981; 141:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/8\">",
"      Rockwell PG. Acute and chronic paronychia. Am Fam Physician 2001; 63:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/9\">",
"      Barlow AJ, Chattaway FW, Holgate MC, Aldersley T. Chronic paronychia. Br J Dermatol 1970; 82:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/10\">",
"      Kanerva L. Occupational protein contact dermatitis and paronychia from natural rubber latex. J Eur Acad Dermatol Venereol 2000; 14:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/11\">",
"      Tosti A, Guerra L, Morelli R, et al. Role of foods in the pathogenesis of chronic paronychia. J Am Acad Dermatol 1992; 27:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/12\">",
"      Daniel CR 3rd, Daniel MP, Daniel CM, et al. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis 1996; 58:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/13\">",
"      Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol 2002; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/14\">",
"      Hengge UR, Bardeli V. Images in clinical medicine. Green nails. N Engl J Med 2009; 360:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/15\">",
"      Clark DC. Common acute hand infections. Am Fam Physician 2003; 68:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/16\">",
"      Wollina U. Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid. J Eur Acad Dermatol Venereol 2001; 15:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/17\">",
"      Rigopoulos D, Gregoriou S, Belyayeva E, et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol 2009; 160:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/18\">",
"      Rigopoulos D, Gregoriou S, Belyayeva H, et al. Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study: reply from authors. Br J Dermatol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/19\">",
"      Connolly B, Fitzgerald RJ. Pledgets in ingrowing toenails. Arch Dis Child 1988; 63:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/20\">",
"      Senapati A. Conservative outpatient management of ingrowing toenails. J R Soc Med 1986; 79:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/21\">",
"      Heidelbaugh JJ, Lee H. Management of the ingrown toenail. Am Fam Physician 2009; 79:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/22\">",
"      Daniel CR 3rd, Iorizzo M, Tosti A, Piraccini BM. Ingrown toenails. Cutis 2006; 78:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/23\">",
"      Reyzelman AM, Trombello KA, Vayser DJ, et al. Are antibiotics necessary in the treatment of locally infected ingrown toenails? Arch Fam Med 2000; 9:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/24\">",
"      Grieg JD, Anderson JH, Ireland AJ, Anderson JR. The surgical treatment of ingrowing toenails. J Bone Joint Surg Br 1991; 73:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/25\">",
"      Eekhof JA, Van Wijk B, Knuistingh Neven A, van der Wouden JC. Interventions for ingrowing toenails. Cochrane Database Syst Rev 2012; 4:CD001541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37846/abstract/26\">",
"      Bostanci S, Kocyigit P, G&uuml;rgey E. Comparison of phenol and sodium hydroxide chemical matricectomies for the treatment of ingrowing toenails. Dermatol Surg 2007; 33:680.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5574 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37846=[""].join("\n");
var outline_f36_61_37846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H478700\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PARONYCHIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acute paronychia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chronic paronychia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INGROWN TOENAIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mild to moderate lesion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Moderate to severe lesion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Recurrent ingrown toenail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478700\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5574|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/36/26191\" title=\"figure 1\">",
"      Felon cross section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5574|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/42/673\" title=\"picture 1A\">",
"      Acute paronychia 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/10/42159\" title=\"picture 1B\">",
"      Acute paronychia finger 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/1/13329\" title=\"picture 1C\">",
"      Acute paronychia toe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/13/42195\" title=\"picture 2A\">",
"      Chronic paronychia 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/55/9073\" title=\"picture 2B\">",
"      Chronic paronychia 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/1/3089\" title=\"picture 3\">",
"      Proximal subungual onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31231\" title=\"picture 4A\">",
"      Herpetic whitlow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9696\" title=\"picture 4B\">",
"      Herpetic whitlow finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/42/43694\" title=\"picture 5\">",
"      Acrodermatitis continua of Hallopeau",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/7/40049\" title=\"picture 6\">",
"      Pseudomonal nail infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/22/9581\" title=\"picture 7\">",
"      Felon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/25/19857\" title=\"picture 8\">",
"      Ingrown toenail 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/21/14676\" title=\"picture 9\">",
"      Pincer nails 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/28/22990\" title=\"picture 10\">",
"      Inflamed ingrown toenail",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5574|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/59/4028\" title=\"table 1\">",
"      Oral abx paronychia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12758?source=related_link\">",
"      Nail surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5258?source=related_link\">",
"      Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/3/19505?source=related_link\">",
"      Patient information: Ingrown toenail (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/25/23953?source=related_link\">",
"      Patient information: Paronychia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37847="Escape atrial beats tutorial";
var content_f36_61_37847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1112px;\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Escape atrial beats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 101px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 4th and 5th beats are escape atrial beats. The rate of the atrial escape rhythm is slower than that of the sinus node (first 3 beats) and the P wave morphology differs from that of the sinus P wave, depending upon the location of the ectopic atrial focus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37847=[""].join("\n");
var outline_f36_61_37847=null;
var title_f36_61_37848="Homonymous hemianopia";
var content_f36_61_37848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Homonymous hemianopia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Val&eacute;rie Biousse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Sachin Kedar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Nancy J Newman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37848/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/61/37848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homonymous hemianopia is a visual field defect involving either the two right or the two left halves of the visual fields of both eyes. It is caused by lesions of the retrochiasmal visual pathways, ie, lesions of the optic tract, the lateral geniculate nucleus, the optic radiations, and the cerebral visual (occipital) cortex (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Characteristics of the visual field abnormalities (type, form, size, and congruity), along with associated neurologic signs and symptoms, have been traditionally used for localizing pathologic lesions in the brain (",
"    <a class=\"graphic graphic_table graphicRef63087 \" href=\"mobipreview.htm?38/46/39659\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homonymous hemianopia is often disabling, causing difficulties with reading and visual scanning. Patients may fail to notice relevant objects or avoid obstacles on the affected side, causing collisions with approaching people or cars. They are not legally allowed to drive in most states. This has dramatic consequences on their vocational and private lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss homonymous hemianopia as a fixed deficit; it may be a transient phenomenon resulting from migraine, transient cerebral ischemia, or seizure. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10666?source=see_link&amp;anchor=H24#H24\">",
"     \"Amaurosis fugax (transient monocular or binocular visual loss)\", section on 'Causes of transient binocular visual loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any type of intracranial lesion in the appropriate location can cause a homonymous hemianopia; however, vascular causes (cerebral infarction and intracranial hemorrhage) are the most frequent in adults, ranging from 42 to 89 percent, followed by brain tumors, trauma, surgical interventions, and other central nervous system diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1,8-13\">",
"     1,8-13",
"    </a>",
"    ]. In children, neoplasms are the most common cause of homonymous hemianopia (39 percent), followed by cerebrovascular disease (25 percent) and trauma (19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/14\">",
"     14",
"    </a>",
"    ]. Homonymous hemianopia after head trauma may be under recognized; multifocal brain injury is more common in this setting, contributing to other neurologic deficits that may overshadow the visual field defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncommon causes of homonymous hemianopia include multiple sclerosis, infections (encephalitis, abscess), degenerative dementia (posterior cortical atrophy), Creutzfeldt Jakob disease, adrenoleukodystrophy, seizures, and severe hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12,15-20\">",
"     12,15-20",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27162?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Posterior cortical atrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEUROANATOMY OF THE VISUAL PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a retinotopic arrangement of the nerve fibers in the visual pathways, which is responsible for the specific patterns of visual field defects. A homonymous hemianopia points to unilateral lesions of the visual sensory pathways posterior to the optic chiasm (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Optic chiasm and tracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the optic chiasm, the nerve fibers from the temporal retina (nasal visual field) maintain their relative position in the lateral chiasm before passing into the ipsilateral optic tract, while the nerve fibers from the nasal retina (temporal visual field) decussate in the chiasm and pass into the contralateral optic tract.",
"   </p>",
"   <p>",
"    Each optic tract contains crossed and uncrossed nerve fibers subserving the contralateral visual field; the fibers in the left optic tract contain fibers carrying information for the right half of the visual field from both the right and left eyes. Lesions of the optic tract affect the temporal fibers and nasal visual field of the ipsilateral eye and the nasal fibers and temporal visual field of the contralateral eye, giving rise to homonymous visual field defect of the contralateral visual field (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    ). The optic tract lies in close proximity to the internal capsule, cerebral peduncle and basal ganglia.",
"   </p>",
"   <p>",
"    The separation of the two hemifields occurs at the vertical raphe of the retina (through the fovea centralis retinae), implying that the visual field is split at the point of fixation into the right and the left halves. Thus, macular fibers are also both crossed and uncrossed in the optic chiasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lateral geniculate nucleus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most (80 percent) of the nerve fibers in the optic tract project into the ipsilateral lateral geniculate nucleus in the midbrain. Other optic tract fibers innervate the Edinger-Westphal nuclei in the pretectum, providing the afferent limb for the pupillary light reflex. The axons from the ipsilateral eye terminate in the second, third, and fifth laminae of the lateral geniculate nucleus, while the axons from the contralateral eye terminate in the first, fourth, and sixth laminae. The nerve fibers are believed to form a precise retinotopic map in the lateral geniculate nucleus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Optic radiations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurons originating from the lateral geniculate nucleus form the optic radiations or the geniculocalcarine tract and end in the primary visual cortex in the occipital lobe.",
"   </p>",
"   <p>",
"    The superior fibers of the optic radiations subserve the inferior visual field and pass posteriorly through the parietal lobe. The inferior fibers, which subserve the superior visual field, initially course anteriorly, superior to, and around the temporal horn of the lateral ventricle. They then pass laterally and posteriorly to the striate cortex, forming Meyer's loop (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    ). It is believed that as these fibers approach the occipital cortex, their retinotopic order increases, and the left and right eye fibers representing common visual loci fall into closer register and ultimately into ocular dominance columns in the striate cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Visual cortex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary visual cortex (also called the calcarine cortex, striate cortex, Brodman area 17) is believed to be retinotopically organized based on visual information from the corresponding retinal loci from the two eyes. The upper lip of the calcarine cortex receives projections from the inferior visual field, while the lower lip of the calcarine cortex receives information from the superior visual field. The posterior pole of the occipital lobe is concerned with the central visual field, while the peripheral visual field is represented in the most anterior part of the striate cortex.",
"   </p>",
"   <p>",
"    The striate cortex is surrounded by the visual association areas (Brodman areas 18 and 19). These areas are also believed to be retinotopically arranged with significant representation for the central visual field, as in the primary visual cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMMON VISUAL FIELD DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual cortex receives a point-to-point projection that corresponds to the retinal image of the visual fields. The fields are divided into temporal and nasal halves that respect the vertical meridian; the temporal field is somewhat larger than the nasal field. The point of visual fixation is represented centrally. The blind spot represents the optic disc and is located 15 degrees temporal to fixation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A homonymous hemianopia is",
"    <strong>",
"     complete",
"    </strong>",
"    when the visual field defect respects the vertical meridian, has macular splitting, and involves the entire hemifield on the affected side (",
"    <a class=\"graphic graphic_figure graphicRef68768 \" href=\"mobipreview.htm?7/36/7754\">",
"     figure 2",
"    </a>",
"    ). All other visual field defects are defined as",
"    <strong>",
"     partial",
"    </strong>",
"    or",
"    <strong>",
"     incomplete",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63087 \" href=\"mobipreview.htm?38/46/39659\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Incomplete homonymous hemianopias are defined as",
"    <strong>",
"     congruous",
"    </strong>",
"    if the homonymous defects in fields of the two eyes are identical in shape, depth, and size (",
"    <a class=\"graphic graphic_figure graphicRef77489 \" href=\"mobipreview.htm?3/55/3955\">",
"     figure 3",
"    </a>",
"    ). Other incomplete homonymous hemianopias are called",
"    <strong>",
"     incongruous",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef79091 \" href=\"mobipreview.htm?12/15/12537\">",
"     figure 4",
"    </a>",
"    ). It is important to emphasize that the concept of congruency applies only to incomplete homonymous hemianopias. Because of the anatomical organization of the visual pathways, congruous homonymous hemianopias are usually related to lesions involving the most posterior part of the visual pathways (ie, the occipital lobe). Lesions of the anterior radiations and optic tract are usually incongruous (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79091 \" href=\"mobipreview.htm?12/15/12537\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Congruency is a helpful but not always reliable feature for localizing lesions to the anterior versus posterior portions of the visual pathways. In one case series, congruency of incomplete hemianopias was seen in 83 percent of lesions attributed to occipital lobe lesions and 50 percent of those with optic tract pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incomplete homonymous hemianopias include: homonymous quadrantanopia; homonymous hemianopia with macular sparing; homonymous scotomatous defect; homonymous sectoranopia; unilateral loss of temporal crescent; and temporal crescent-sparing homonymous hemianopia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complete homonymous hemianopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete left or right visual field defect can occur with complete lesions anywhere along the retrochiasmal visual pathway (",
"    <a class=\"graphic graphic_figure graphicRef68768 \" href=\"mobipreview.htm?7/36/7754\">",
"     figure 2",
"    </a>",
"    ). In one study of 852 patients with homonymous hemianopia, 38 percent were complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Homonymous quadrantanopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superior and inferior homonymous visual field defects respecting the vertical and sometimes the horizontal meridians (",
"    <a class=\"graphic graphic_figure graphicRef69526 \" href=\"mobipreview.htm?31/23/32121\">",
"     figure 5",
"    </a>",
"    ) were the most common incomplete homonymous hemianopias in one large case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"     12",
"    </a>",
"    ]. These defects occur when lesions (especially infarcts) selectively damage either the inferior or superior banks of the occipital cortex (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63481 \" href=\"mobipreview.htm?29/54/30560\">",
"     image 1",
"    </a>",
"    ). Less commonly, a quadrantanopia represents a lesion in the optic radiations in the temporal or parietal lobe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Homonymous hemianopia with macular sparing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homonymous visual field defects sparing the central 5 to 25 degrees of visual field on the affected side (",
"    <a class=\"graphic graphic_figure graphicRef68020 \" href=\"mobipreview.htm?39/57/40857\">",
"     figure 6",
"    </a>",
"    ) are common when the posterior half of the occipital region has been at least partially spared by the lesion. Because of the dual vascular supply of the occipital pole in many individuals (by branches of both the middle and posterior cerebral arteries), macular-sparing homonymous hemianopia is more likely to occur with stroke than with other occipital lesions. While classically associated with occipital lobe injury, macular sparing may also represent incomplete damage to the optic radiations, and less commonly, to the optic tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to emphasize that macular sparing of 3 degrees or less is not clinically meaningful, as it may be the result of wandering fixation. Also, macular sparing should be diagnosed only when there is good fixation on visual field testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Homonymous scotomatous defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homonymous visual field defects respecting the vertical meridian and limited to the central 30 degrees are usually enclosed within an area of normal peripheral visual field (",
"    <a class=\"graphic graphic_figure graphicRef55517 \" href=\"mobipreview.htm?8/51/9017\">",
"     figure 7",
"    </a>",
"    ). These defects are the converse of macular-sparing homonymous hemianopia. The cause is most commonly occipital tip injury, most frequently due to stroke or trauma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73868 \" href=\"mobipreview.htm?32/2/32801\">",
"     image 2",
"    </a>",
"    ). However, larger lesions involving the occipital cortex and lesions in the occipital radiations and optic tract have also been associated with this defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12,23\">",
"     12,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Homonymous sectoranopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wedge-shaped defects located near the horizontal meridian, either pointed at fixation or sparing fixation (",
"    <a class=\"graphic graphic_figure graphicRef58764 \" href=\"mobipreview.htm?38/32/39426\">",
"     figure 8",
"    </a>",
"    ), are characteristic of lesions involving the lateral geniculate body (usually infarctions). These are relatively unusual visual field defects. The visual field patterns are based on the lateral geniculate body's dual blood supply from the anterior and posterior choroidal arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Unilateral loss of temporal crescent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most peripheral 30 degrees of the temporal field viewed by each eye is not overlapped by a corresponding nasal field in the other eye. This portion of the field is called the temporal crescent and has monocular representation in the anterior part of the contralateral visual cortex.",
"   </p>",
"   <p>",
"    These rare visual field defects are secondary to lesions involving the anterior 10 percent of the primary visual cortex (",
"    <a class=\"graphic graphic_figure graphicRef79367 \" href=\"mobipreview.htm?11/30/11751\">",
"     figure 9",
"    </a>",
"    ). The lesion is usually an infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/24\">",
"     24",
"    </a>",
"    ]. Unilateral loss of temporal crescent is the only example of a monocular visual field defect caused by a retrochiasmal lesion (all other defects are bilateral and homonymous).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Temporal crescent-sparing homonymous hemianopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the anterior portion of the primary visual cortex is spared by an occipital lesion producing a homonymous hemianopia, there is sparing of the temporal crescent on the contralateral eye visual field (",
"    <a class=\"graphic graphic_figure graphicRef60242 \" href=\"mobipreview.htm?33/25/34195\">",
"     figure 10",
"    </a>",
"    ). A small percentage (&lt;20 percent) of individuals with this pattern of vision loss will have lesions of the optic radiations instead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/25\">",
"     25",
"    </a>",
"    ]. The temporal crescent is particularly sensitive to moving stimuli, making this lesion somewhat less disabling.",
"   </p>",
"   <p>",
"    The unilateral loss of, or preservation of, the temporal crescent is more likely to be detected with Goldmann perimetry rather than automated perimetry (eg, Humphrey visual fields or the Octopus), which concentrates on the central 30 percent of the visual field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with homonymous hemianopia may not complain specifically of visual field loss. They may complain instead of monocular vision loss or of an ill-described difficulty with seeing or reading (dyslexia). Unilateral retrochiasmal lesions producing homonymous hemianopia do NOT affect visual acuity. Complaints of visual impairments, therefore, should prompt an examination of the visual fields as well as of visual acuity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link&amp;anchor=H19#H19\">",
"     \"The detailed neurologic examination in adults\", section on 'Visual fields'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristics of the visual field defect as described above, along with accompanying neurologic signs, help to localize the lesion within the brain; occipital lobe lesions are most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lesions of the optic tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of the optic tract account for 3 to 11 percent of all homonymous hemianopias. Optic tract lesions produce characteristic clinical features, which are exquisitely localizing (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1,26,27\">",
"     1,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions of the optic tract produce either complete or incomplete homonymous hemianopia. When incomplete, the visual field defect is often (but not always) incongruous [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/21\">",
"       21",
"      </a>",
"      ]. Rarely, small lesions of the optic tract may produce congruent homonymous scotomatous defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isolated lesions of the optic tract produce a relative afferent pupillary defect in the eye contralateral to the side of the lesion (eye with the temporal field loss). Another pupillary phenomenon commonly ascribed to lesions of the optic tract is pupillary hemiakinesia (hemianopic pupillary reaction or Wernicke's pupil). When a sharp focused beam of light is projected onto the retina from the intact hemifield, the pupil is found to constrict normally. However, when light is shone from the blind hemifield, the pupillary reaction is either decreased or absent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1\">",
"       1",
"      </a>",
"      ]. In practice, it may be difficult to demonstrate the hemianopic pupillary reaction; light often scatters across the iris, stimulating the intact field and producing pupillary constriction.",
"     </li>",
"     <li>",
"      Lesions of the optic tract cause a characteristic pattern of optic atrophy. While the eye ipsilateral to the side of injury develops diffuse pallor, the contralateral optic disc develops a horizontal band of pallor in a \"bow-tie\" configuration within four to six weeks after the injury (",
"      <a class=\"graphic graphic_figure graphicRef58927 \" href=\"mobipreview.htm?39/4/40010\">",
"       figure 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef64106 \" href=\"mobipreview.htm?31/14/31982\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with optic tract lesions may also show neurologic deficits related to hypothalamic signs and symptoms and contralateral hemiparesis from contiguous internal capsular damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lesions of the lateral geniculate nucleus",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual field defects resulting from lesions of the lateral geniculate nucleus are of variable nature because of the intricate retinotopic organization of the lateral geniculate nucleus. The nature of the visual field defect is also influenced by the underlying cause. Vascular lesions of the lateral geniculate nucleus usually produce congruous and characteristic visual field defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4,29,30\">",
"       1-4,29,30",
"      </a>",
"      ]. Occlusion of the posterior choroidal artery causes a wedge defect that straddles the horizontal meridian region (sectoranopia), while occlusion of the anterior choroidal artery spares that sector of visual field (sector-sparing) (",
"      <a class=\"graphic graphic_figure graphicRef58764 \" href=\"mobipreview.htm?38/32/39426\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4,29,30\">",
"       1-4,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The pupillary reactions in patients with lesions of the lateral geniculate nucleus are normal, unless there is involvement of the optic tract or the brachium of the superior colliculus, which produces a contralateral relative afferent papillary defect.",
"     </li>",
"     <li>",
"      Patients with lesions of the lateral geniculate nucleus may also show signs and symptoms suggestive of damage to the ipsilateral thalamus (contralateral hemihypoesthesia, abnormal referred pain on the contralateral side)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pyramidal tract (contralateral motor weakness).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lesions of the optic radiations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optic radiations project from the lateral geniculate nucleus to the striate cortex (",
"    <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first part of the optic radiations makes up the most posterior limb of the internal capsule. Here, the optic radiations lie in close proximity to the corticospinal and corticobulbar tracts, as well as the thalamocortical fibers. Lesions of the optic radiation in this location typically produce a contralateral, usually complete, homonymous hemianopia, associated with contralateral hemianesthesia and hemiplegia. A relative afferent pupillary defect may also be observed in lesions that are proximate to the lateral geniculate body [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involvement of the optic radiations in the temporal lobe produce a homonymous defect, which is usually incomplete, incongruous, either confined to the superior quadrants or more dense superiorly than inferiorly and often called \"pie-in-the sky\" defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. Temporal lobe lesions also produce other neurologic manifestations, including aphasia, memory deficits (dominant hemisphere lesions), complex seizures, and auditory and visual hallucinations. Evaluations of visual field defects after temporal lobectomy in patients with epilepsy demonstrate 15 percent greater loss in the nasal than the temporal field, and considerable interindividual variance, especially as regards the anterior extent of Meyer's loop [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involvement of the optic radiations in the parietal lobe usually produce incomplete, mildly incongruous homonymous hemianopia, which is either limited to the inferior visual fields or is more dense inferiorly than superiorly. However, large lesions may produce a complete homonymous hemianopia. Contralateral hemifield neglect is also seen in lesions of the nondominant hemisphere and can be difficult to distinguish from a visual field defect. Since the parietal lobe is the principal sensory area of the cerebral cortex, lesions often produce sensory deficits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. Lesions extending to the dominant angular gyrus lobe may also produce Gerstmann's syndrome (finger agnosia, agraphia, acalculia, and right-left disorientation), while lesions of the nondominant parietal lobe may cause inattention or neglect and impaired constructional ability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lesions of the occipital lobe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occipital lobe lesions are the most common cause of homonymous hemianopia and are most often vascular in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Lesions of the occipital lobe tend to produce an isolated homonymous hemianopia (ie, not associated with other neurologic deficits). Depending on the location of the lesion, various visual field patterns are seen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions of the occipital pole (most posterior aspect of the striate cortex) typically cause congruous homonymous scotomas (",
"      <a class=\"graphic graphic_figure graphicRef74068 \" href=\"mobipreview.htm?24/19/24887\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55517 \" href=\"mobipreview.htm?8/51/9017\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/34\">",
"       34",
"      </a>",
"      ]. Lesions extending to the dominant angular gyrus lobe may also produce Gerstmann's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lesions of the most anterior part of the striate cortex produce homonymous defects involving the peripheral visual field (temporal crescent) (",
"      <a class=\"graphic graphic_figure graphicRef79367 \" href=\"mobipreview.htm?11/30/11751\">",
"       figure 9",
"      </a>",
"      ). Conversely, large lesions of the posterior occipital lobe may produce a homonymous hemianopia with sparing of the contralateral crescentic temporal visual field (",
"      <a class=\"graphic graphic_figure graphicRef60242 \" href=\"mobipreview.htm?33/25/34195\">",
"       figure 10",
"      </a>",
"      ). Unilateral temporal crescent may be missed if only the central visual field is tested, as is common with automated perimetry. In cases with unilateral temporal visual field defects, the nasal retinal periphery should be carefully examined, as lesions in this location may also produce unilateral temporal visual field defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Homonymous hemianopia due to occipital lesions often have macular sparing (sparing of the central visual field) (",
"      <a class=\"graphic graphic_figure graphicRef68020 \" href=\"mobipreview.htm?39/57/40857\">",
"       figure 6",
"      </a>",
"      ). Explanations for this phenomenon include bilateral representation of the macula in the occipital cortex, incomplete damage to the striate cortex on the affected side, and, more commonly, dual blood supply of the occipital pole by middle and posterior cerebral arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A right homonymous hemianopia may be accompanied by alexia if the lesion involving the left occipital lobe extends anteriorly to involve the splenium of the corpus callosum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/35\">",
"       35",
"      </a>",
"      ]. Because patients often retain the ability to write (if the angular gyrus is spared), this classic syndrome is generally referred to as \"alexia without agraphia\".",
"     </li>",
"     <li>",
"      Bilateral homonymous hemianopias are produced by bilateral lesions of the occipital lobe, either simultaneously or consecutively. The extent of the visual field defect depends on the extent of involvement of the striate cortex and can include a combination of visual field defects such as bilateral complete hemianopias (cortical blindness), \"checkerboard\" field defects, and combinations of complete homonymous hemianopia, scotomatous, and altitudinal defects (",
"      <a class=\"graphic graphic_figure graphicRef58028 \" href=\"mobipreview.htm?13/29/13779\">",
"       figure 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77953 \" href=\"mobipreview.htm?36/30/37346\">",
"       figure 13",
"      </a>",
"      ). In cases with bilateral homonymous hemianopia, visual acuity may be reduced. It is important to emphasize that the amount of visual loss should be symmetric in both eyes, unless the patient has another anterior visual pathway cause for his decreased visual acuity. Cortical blindness may be accompanied by a striking anosognosia, in which the patient is unaware of his deficit; this is called Anton's syndrome.",
"     </li>",
"     <li>",
"      A lesion involving the extrastriate cortex produces congruous quadrantic visual field defects (",
"      <a class=\"graphic graphic_figure graphicRef69526 \" href=\"mobipreview.htm?31/23/32121\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confrontation testing of the visual fields is the usual screening test for visual field defects. Techniques are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link&amp;anchor=H19#H19\">",
"     \"The detailed neurologic examination in adults\", section on 'Visual fields'",
"    </a>",
"    .) Comparison of these techniques found that they had poor sensitivity (35 to 74 percent) for the detection of visual field abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Use of a small, red target gave the most sensitive results. Combining two confrontation tests can improve sensitivity.",
"   </p>",
"   <p>",
"    In addition to increased sensitivity, visual field perimetry gives more information regarding the type, size, and form of the visual field loss. These tests include automated static perimetry as well as manual kinetic perimetry (eg, Goldmann, tangent screen). These are similarly reliable in their ability to detect the presence of a homonymous hemianopia. However, the manual kinetic techniques are more precise in providing information regarding the type, size, and form of the visual field defect and in one study, were more predictive of the lesion location on magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perimetry should be performed in all patients with neurological lesions that may produce a visual field defect. Confrontation perimetry at bedside is insufficient to identify and follow visual field changes. Formal visual fields are important from a medicolegal point and are also useful prior to allowing a stroke patient to drive or return to work (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Driving'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    All patients with homonymous hemianopia require neuroimaging, usually MRI study, to define the underlying etiology (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above). In cases in which there is no underlying MRI abnormality, neurodegenerative disease is often the underlying cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of spontaneous improvement of homonymous hemianopia varies greatly, between 18 to 67 percent, and depends to a large extent on the time period after the brain injury when the visual fields were tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1-4,9,13,39-41\">",
"     1-4,9,13,39-41",
"    </a>",
"    ]. One study reported 46 percent spontaneous improvement of homonymous hemianopia within three weeks from onset of ischemic stroke event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/41\">",
"     41",
"    </a>",
"    ]. Another study reported 67 percent spontaneous recovery of homonymous hemianopia (by confrontation method) within one month of a stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/40\">",
"     40",
"    </a>",
"    ]. Spontaneous improvement of the visual field defect is unlikely after six months from the injury unless there is an improvement of the underlying disease, such as can occur in multiple sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/1,13,42\">",
"     1,13,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While it seems likely that lesion size and location and underlying cause play an important role in the recovery of visual field deficits, the evidence is somewhat conflicting. In one study of 113 patients with homonymous hemianopia from a variety of causes, no patient, lesion, or visual field characteristic was found to correlate with the final visual outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, a study in a more restricted population of 31 individuals after occipital lobe stroke, a better recovery of visual fields was noted in patients with a smaller lesion size and in whom the striate cortex was spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with homonymous hemianopia secondary to a stroke are unaware of their visual field defect and may continue to drive, if not otherwise disabled from doing so [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients should be aware that driving abilities are compromised by a homonymous hemianopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/44\">",
"     44",
"    </a>",
"    ]. In most states of the United States, patients with a complete homonymous hemianopia are not legally allowed to drive.",
"   </p>",
"   <p>",
"    Medically, it is intuitive that if a person misses large parts of his visual field especially an entire half, then he would not be safe on the road. Decisions regarding the legality to drive are solely based on prescribed visual criteria, which differ for each state in the USA. It is the responsibility of the treating physician to counsel the patient regarding driving once it is determined that the patient no longer meets the minimum required vision criteria. However, it is not incumbent upon the treating physician to notify the Department of Motor Vehicles.",
"   </p>",
"   <p>",
"    The International Council of Ophthalmology summarizes the vision criteria for driving licenses in different countries and states in the USA. It is available at",
"    <a class=\"external\" href=\"file://www.icoph.org/downloads/visionfordriving.pdf\">",
"     file://www.icoph.org/downloads/visionfordriving.pdf",
"    </a>",
"    , Appendix 1 and 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT AND REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with homonymous hemianopia, no or few treatments are usually offered. Some rehabilitation techniques have been suggested over the past decade, but remain controversial with limited evidence supporting their efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. They are based upon three principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compensation (use of intact function)",
"     </li>",
"     <li>",
"      Substitution (adapt the patient's environment to the patient's functional impairment)",
"     </li>",
"     <li>",
"      Restitution (retraining the impaired function; ie, expanding the visual field)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One approach includes the use of hemianopic mirrors or prisms. The principle is to project the images from the blind hemifield onto the intact hemifield. However, these techniques may cause significant spatial disorientation and confusion for some patients and there are no controlled data that support their efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/7,46,47\">",
"     7,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with homonymous hemianopia experience considerable difficulty reading, especially when the visual field defect is complete or involves fixation. Patients with right-sided defects cannot see the letters immediately following the ones that they have read, while patients with left-sided defects have problems returning to the next line, as it falls in the blind hemifield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. These patients notice benefit in reading if they use their finger or a ruler positioned under each line of text, so that they do not lose the position while reading the text, or if they train themselves to read vertically. Computerized saccadic training programs may improve patients' visual function by training patients with homonymous hemianopia to make saccades into their blind hemifield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Systematic reviews have reported that small studies suggest modest benefits in increased reading times and decreased reading and scanning errors using this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/46,53\">",
"     46,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Restorative methods are based upon the stimulation of a transition zone adjacent to the blind hemifield, resulting in visual field expansion, presumably due to cortical plasticity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/47,54\">",
"     47,54",
"    </a>",
"    ]. Although this concept remains debated with little objective evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/46,55,56\">",
"     46,55,56",
"    </a>",
"    ], visual restoration therapy has been approved United States Food and Drug Administration (FDA) and is used at some centers in the United States and in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another investigational approach uses repetitive transcranial magnetic stimulation (rTMS) applied over the posterior parietal cortex. In one randomized study of 20 patient with left hemispatial neglect following a right hemisphere stroke, patients who received two weeks of rTMS had improved composite scores on a battery of tests of spatial function compared to those who received sham treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/57\">",
"     57",
"    </a>",
"    ]. The effects persisted for at least two weeks after treatment ended. Other small studies have shown similar benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37848/abstract/58\">",
"     58",
"    </a>",
"    ]. The duration and clinical significance of the observed benefit needs to be defined in further trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homonymous hemianopia represents a visual field defect relating to loss of vision in all or part of the left or right visual field in both eyes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stroke is the most common etiology in one-half to two-thirds of patients, followed by traumatic brain injury, brain tumors, and other structural brain lesions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Homonymous hemianopia occurs with lesions in the retrochiasmal visual pathways: the optic tracts, lateral geniculate body, the optic radiations, and the occipital cortex. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Neuroanatomy of the visual pathways'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific features of the visual field defect (type, form, congruity, and size), along with other neurologic symptoms and signs, help to localize the underlying lesion (",
"      <a class=\"graphic graphic_table graphicRef63087 \" href=\"mobipreview.htm?38/46/39659\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Common visual field defects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While homonymous hemianopia may frequently go unrecognized by patients and clinicians, it is nonetheless disabling, impairing visual scanning and reading, and restricting driving. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment and rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients will recover spontaneously, over half within the first month. Recovery after six months is unlikely. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options are limited and include rehabilitation techniques aimed primarily at compensation and accommodation. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment and rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87736698\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Xiaojun Zhang, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Levin LA. Topical diagnosis of chiasmal and retrochiasmal disorders. In: Walsh and Hoyt Clinical Neuro-ophthalmology, 6th, Miller NR, Newman NJ, Biousse V, Kerrison JB.  (Eds), Williams &amp; Wilkins, Baltimore 2005. p.503.",
"    </li>",
"    <li>",
"     Liu GT, Volpe NJ, Galetta SL. Retrochiasmal disorders. In: Neuro-ophthalmology: Diagnosis and Management, Liu GT, Volpe NJ, Galetta SL.  (Eds), W.B. Saunders, Philadelphia 2001. p.296.",
"    </li>",
"    <li>",
"     Trobe JD. Visual fields. In: The Neurology of Vision, Trobe JD.  (Ed), Oxford, Oxford 2001. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/4\">",
"      Newman, NJ, Galetta, SL, Biousse, V, et al. Disorder of vision. Continuum: Lifelong learning in Neurology. Neuroophthalmology 2003; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/5\">",
"      Harrington, DO. Localizing value of incongruity in defects in the visual fields. Arch Ophthalmol 1939; 21:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/6\">",
"      HARRINGTON DO. Visual field character in temporal and occipital lobe lesions. Localizing values of congruity and incogruity in incomplete homonymous hemianopsia. Arch Ophthalmol 1961; 66:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/7\">",
"      Pambakian AL, Kennard C. Can visual function be restored in patients with homonymous hemianopia? Br J Ophthalmol 1997; 81:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/8\">",
"      Fujino, T, Kigazawa, K, Yamada, R. Homonymous hemianopia: a retrospective study of 140 cases. Neuroophthalmology 1986; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/9\">",
"      SMITH JL. Homonymous hemianopia. A review of one hundred cases. Am J Ophthalmol 1962; 54:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/10\">",
"      Trobe JD, Lorber ML, Schlezinger NS. Isolated homonymous hemianopia. A review of 104 cases. Arch Ophthalmol 1973; 89:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/11\">",
"      Huber, A. Homonymous hemianopia. Neuroophthalmology 1992; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/12\">",
"      Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/13\">",
"      Bruce BB, Zhang X, Kedar S, et al. Traumatic homonymous hemianopia. J Neurol Neurosurg Psychiatry 2006; 77:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/14\">",
"      Liu GT, Galetta SL. Homonymous hemifield loss in childhood. Neurology 1997; 49:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/15\">",
"      Lee AG, Martin CO. Neuro-ophthalmic findings in the visual variant of Alzheimer's disease. Ophthalmology 2004; 111:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/16\">",
"      Horton JC, Hoyt WF. Quadrantic visual field defects. A hallmark of lesions in extrastriate (V2/V3) cortex. Brain 1991; 114 ( Pt 4):1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/17\">",
"      Rosenberg YJ, Parish CR. Ontogeny of the antibody-forming cell line in mice. IV. Appearance of cells bearing Fc receptors, complement receptors, and surface immunoglobulin. J Immunol 1977; 118:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/18\">",
"      Schrauzer GN, Kiefer GW, Tano K, Robinson PR. Chemical evolution of a nitrogenase model. IX. Concerning the effects of adenosine 5'-triphosphate and of acids in the model system and the adenosine 5'-triphosphate requirement of nitrogenase. J Am Chem Soc 1975; 97:6088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/19\">",
"      Hughes S, Field CA, Kennedy MR, Dash CH. Cephalosporins in bone cement: studies in vitro and in vivo. J Bone Joint Surg Br 1979; 61:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/20\">",
"      Shaw S, Kim P, Millett D. Status epilepticus amauroticus revisited: ictal and peri-ictal homonymous hemianopsia. Arch Neurol 2012; 69:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/21\">",
"      Kedar S, Zhang X, Lynn MJ, et al. Congruency in homonymous hemianopia. Am J Ophthalmol 2007; 143:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/22\">",
"      Jacobson DM. The localizing value of a quadrantanopia. Arch Neurol 1997; 54:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/23\">",
"      Isa K, Miyashita K, Yanagimoto S, et al. Homonymous defect of macular vision in ischemic stroke. Eur Neurol 2001; 46:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/24\">",
"      Landau K, Wichmann W, Valavanis A. The missing temporal crescent. Am J Ophthalmol 1995; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/25\">",
"      Lepore FE. The preserved temporal crescent: the clinical implications of an \"endangered\" finding. Neurology 2001; 57:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/26\">",
"      Savino PJ, Paris M, Schatz NJ, et al. Optic tract syndrome. A review of 21 patients. Arch Ophthalmol 1978; 96:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/27\">",
"      Newman SA, Miller NR. Optic tract syndrome. Neuro-ophthalmologic considerations. Arch Ophthalmol 1983; 101:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/28\">",
"      Biousse V, Newman NJ, Carroll C, et al. Visual fields in patients with posterior GPi pallidotomy. Neurology 1998; 50:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/29\">",
"      Fris&eacute;n L, Holmegaard L, Rosencrantz M. Sectorial optic atrophy and homonymous, horizontal sectoranopia: a lateral choroidal artery syndrome? J Neurol Neurosurg Psychiatry 1978; 41:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/30\">",
"      Fris&eacute;n L. Quadruple sectoranopia and sectorial optic atrophy: a syndrome of the distal anterior choroidal artery. J Neurol Neurosurg Psychiatry 1979; 42:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/31\">",
"      Papageorgiou E, Ticini LF, Hardiess G, et al. The pupillary light reflex pathway: cytoarchitectonic probabilistic maps in hemianopic patients. Neurology 2008; 70:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/32\">",
"      Barton JJ, Hefter R, Chang B, et al. The field defects of anterior temporal lobectomy: a quantitative reassessment of Meyer's loop. Brain 2005; 128:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/33\">",
"      Yogarajah M, Focke NK, Bonelli S, et al. Defining Meyer's loop-temporal lobe resections, visual field deficits and diffusion tensor tractography. Brain 2009; 132:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/34\">",
"      &Ccedil;elebisoy M, &Ccedil;elebisoy N, Bayam E, K&ouml;se T. Recovery of visual-field defects after occipital lobe infarction: a perimetric study. J Neurol Neurosurg Psychiatry 2011; 82:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/35\">",
"      Weisberg LA, Wall M. Alexia without agraphia: clinical-computed tomographic correlations. Neuroradiology 1987; 29:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/36\">",
"      Pandit RJ, Gales K, Griffiths PG. Effectiveness of testing visual fields by confrontation. Lancet 2001; 358:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/37\">",
"      Kerr NM, Chew SS, Eady EK, et al. Diagnostic accuracy of confrontation visual field tests. Neurology 2010; 74:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/38\">",
"      Wong AM, Sharpe JA. A comparison of tangent screen, goldmann, and humphrey perimetry in the detection and localization of occipital lesions. Ophthalmology 2000; 107:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/39\">",
"      Parisi JL, Bell RA, Yassein H. Homonymous hemianopic field defects and driving in Canada. Can J Ophthalmol 1991; 26:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/40\">",
"      Gray CS, French JM, Bates D, et al. Recovery of visual fields in acute stroke: homonymous hemianopia associated with adverse prognosis. Age Ageing 1989; 18:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/41\">",
"      Tiel, K, Kolmel, HW. Patterns of recovery from homonymous hemianopia subsequent to infarction in the distribution of posterior cerebral artery. Neuroophthalmology 1991; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/42\">",
"      Zhang X, Kedar S, Lynn MJ, et al. Natural history of homonymous hemianopia. Neurology 2006; 66:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/43\">",
"      Gilhotra JS, Mitchell P, Healey PR, et al. Homonymous visual field defects and stroke in an older population. Stroke 2002; 33:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/44\">",
"      Racette L, Casson EJ. The impact of visual field loss on driving performance: evidence from on-road driving assessments. Optom Vis Sci 2005; 82:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/45\">",
"      Pambakian A, Currie J, Kennard C. Rehabilitation strategies for patients with homonymous visual field defects. J Neuroophthalmol 2005; 25:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/46\">",
"      Pollock A, Hazelton C, Henderson CA, et al. Interventions for visual field defects in patients with stroke. Cochrane Database Syst Rev 2011; :CD008388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/47\">",
"      Bowers AR, Keeney K, Peli E. Community-based trial of a peripheral prism visual field expansion device for hemianopia. Arch Ophthalmol 2008; 126:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/48\">",
"      Pameijer JK. Reading problems in hemianopia. Ophthalmologica 1970; 160:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/49\">",
"      Schuett S, Heywood CA, Kentridge RW, Zihl J. Rehabilitation of hemianopic dyslexia: are words necessary for re-learning oculomotor control? Brain 2008; 131:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/50\">",
"      Pambakian AL, Mannan SK, Hodgson TL, Kennard C. Saccadic visual search training: a treatment for patients with homonymous hemianopia. J Neurol Neurosurg Psychiatry 2004; 75:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/51\">",
"      Spitzyna GA, Wise RJ, McDonald SA, et al. Optokinetic therapy improves text reading in patients with hemianopic alexia: a controlled trial. Neurology 2007; 68:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/52\">",
"      Roth T, Sokolov AN, Messias A, et al. Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. Neurology 2009; 72:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/53\">",
"      Bouwmeester L, Heutink J, Lucas C. The effect of visual training for patients with visual field defects due to brain damage: a systematic review. J Neurol Neurosurg Psychiatry 2007; 78:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/54\">",
"      Sabel BA, Kasten E. Restoration of vision by training of residual functions. Curr Opin Ophthalmol 2000; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/55\">",
"      Sabel BA, Trauzettel-Klosinksi S. Improving vision in a patient with homonymous hemianopia. J Neuroophthalmol 2005; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/56\">",
"      Schreiber A, Vonthein R, Reinhard J, et al. Effect of visual restitution training on absolute homonymous scotomas. Neurology 2006; 67:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/57\">",
"      Koch G, Bonn&igrave; S, Giacobbe V, et al. &theta;-burst stimulation of the left hemisphere accelerates recovery of hemispatial neglect. Neurology 2012; 78:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37848/abstract/58\">",
"      Cazzoli D, M&uuml;ri RM, Hess CW, Nyffeler T. Treatment of hemispatial neglect by means of rTMS--a review. Restor Neurol Neurosci 2010; 28:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5247 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37848=[""].join("\n");
var outline_f36_61_37848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEUROANATOMY OF THE VISUAL PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Optic chiasm and tracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lateral geniculate nucleus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Optic radiations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Visual cortex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMMON VISUAL FIELD DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complete homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Homonymous quadrantanopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Homonymous hemianopia with macular sparing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Homonymous scotomatous defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Homonymous sectoranopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Unilateral loss of temporal crescent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Temporal crescent-sparing homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lesions of the optic tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lesions of the lateral geniculate nucleus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lesions of the optic radiations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lesions of the occipital lobe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DRIVING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT AND REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87736698\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5247|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/54/30560\" title=\"diagnostic image 1\">",
"      MRI left occipit lobe infar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/2/32801\" title=\"diagnostic image 2\">",
"      MRI right occipital infarct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5247|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/19/24887\" title=\"figure 1\">",
"      Localization VFD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/36/7754\" title=\"figure 2\">",
"      VF complete HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/55/3955\" title=\"figure 3\">",
"      VF congr incompl HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/15/12537\" title=\"figure 4\">",
"      VF incongr incompl HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/23/32121\" title=\"figure 5\">",
"      VF sup quadrantanopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/57/40857\" title=\"figure 6\">",
"      VF HH with mac sparing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/51/9017\" title=\"figure 7\">",
"      VF congr inf quadrantanopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/32/39426\" title=\"figure 8\">",
"      VF sectoral defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/30/11751\" title=\"figure 9\">",
"      VF temporal crescent defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/25/34195\" title=\"figure 10\">",
"      VF temp crescent sparing HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/4/40010\" title=\"figure 11\">",
"      Mechanism Bowtie atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/29/13779\" title=\"figure 12\">",
"      VF bilat quadrantanopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/30/37346\" title=\"figure 13\">",
"      VF bilateral HH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5247|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/14/31982\" title=\"picture 1\">",
"      Fundus bowtie atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/46/39659\" title=\"table 1\">",
"      VFD localization asso sx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10666?source=related_link\">",
"      Amaurosis fugax (transient monocular or binocular visual loss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37849="Non-access related infections in chronic dialysis patients";
var content_f36_61_37849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Non-access related infections in chronic dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Rebecca J Schmidt, DO, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/61/37849/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/61/37849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to infections associated with dialysis access devices, patients with end stage renal disease (ESRD) who require renal replacement therapy may be susceptible to non-access related infections. Diagnostic strategies for these infections are similar to those used for patients without renal failure. However, a higher index of suspicion and a lower threshold for the initiation of a search is appropriate, since patients with ESRD are frequently diabetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppressed because of the retention of uremic toxins. Careful attention to appropriate dosing of antibiotics and the avoidance (if possible) of nephrotoxic drugs in the patient with residual renal function are also significant issues.",
"   </p>",
"   <p>",
"    Many of the infections reviewed in this topic are not unique to the dialysis patient. As a result, although the likelihood of their occurrence may be increased, special considerations and guidelines for the dialysis patient are not available. Diagnostic and treatment strategies must be tailored to the individual patient, including the consequences of kidney failure and other comorbid conditions, the geographic location, and specific environmental exposures.",
"   </p>",
"   <p>",
"    A review of the clinical characteristics of infections not related to the dialysis access is presented here. Reviews of access related infections and the clinical manifestations and treatment of sepsis in dialysis patients, a complication most commonly due to infection of dialysis access devices, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link\">",
"     \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the United States Renal Data System (USRDS) indicates that infections are a leading cause of death among patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/1\">",
"     1",
"    </a>",
"    ], accounting for approximately 15 percent of all fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/2\">",
"     2",
"    </a>",
"    ]. The vast majority result from",
"    <span class=\"nowrap\">",
"     bacteremia/sepsis,",
"    </span>",
"    followed by pulmonary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with the population with normal kidney function, patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) are at higher risk of contracting bacterial infections, particularly urinary tract infections, pneumonia, and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of their propensity for causing sepsis, infections related to dialysis access devices are potentially catastrophic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The annual mortality secondary to sepsis is 100- to 300-fold higher in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    .) In addition, a prospective study evaluating the outcome of 65 episodes of Staphylococcus aureus bacteremia in hemodialysis patients (89 percent of which were due to an access) found that metastatic complications and death occurred in 44 and 14 percent of patients, respectively. In contrast, other studies suggest that non-access related infections are less common and not as devastating, accounting for an overall mortality rate of less than three percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older dialysis patients may be at higher risk for acquiring infection caused by drug-resistant organisms and for death resulting from infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/8\">",
"     8",
"    </a>",
"    ]. As reported by the USRDS, death due to infection in patients over the age of 65 is approximately twice that of younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/2\">",
"     2",
"    </a>",
"    ]. Smoking has been shown to be an important risk factor for infection-related morbidity and mortality among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients undergoing chronic renal replacement therapy, the most important infections not related to the dialysis access include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections of the upper and lower respiratory tract",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Infections of the central nervous system, including mucormycosis",
"     </li>",
"     <li>",
"      Gastrointestinal infections, such as hepatitis and Clostridium difficile colitis",
"     </li>",
"     <li>",
"      Genitourinary tract infections, including pyocystis",
"     </li>",
"     <li>",
"      Cellulitis and osteomyelitis",
"     </li>",
"     <li>",
"      Infections due to highly drug-resistant organisms",
"     </li>",
"     <li>",
"      Tuberculosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESPIRATORY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory tract infections in dialysis patients may be community- or hospital-acquired. As previously mentioned, respiratory infections are the second leading cause of infection-related deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Upper respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with the general population, patients with ESRD are not overly susceptible to sinusitis, rhinitis, or pharyngitis. Diagnoses and treatments are therefore similar to those for the general population. However, special attention must be given to accurate drug dosing and the loss of antibiotics across the dialysis membrane among those undergoing hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lower respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchitis and pneumonia are common in dialysis patients. In one retrospective observational study of dialysis patients, the probability of being hospitalized from pneumonia was 9 and 36 percent at one and five years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumonia is an important cause of death and hospitalization in patients, carrying significant risk for those with advanced CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared with the population with normal kidney function, the rate of pneumonia is three times greater in those with CKD and five times greater in those with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/3\">",
"     3",
"    </a>",
"    ]. One in five ESRD patients developed pneumonia during their first year on dialysis, and 42 percent of these required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/12\">",
"     12",
"    </a>",
"    ]. The lengths of hospitalization in CKD and ESRD patients with pneumonia are similar and are four to six times longer than the population with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of the bacteriology and outcomes of empyema in 84 stage 4 CKD and 40 ESRD patients found that most empyemas were secondary to pneumonia. Gram negative organisms were cultured in 67 percent of stage 4 CKD patients (34 percent were Klebsiella pneumoniae), but aerobic Gram positive organisms predominated in the ESRD patients (54 percent, with 67 percent of those Staphylococcus aureus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with the stage 4 CKD patients, ESRD patients had a higher catheter-associated infection and infection-associated mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with patients without renal failure, bronchitis and pneumonia may be more difficult to diagnose since pulmonary fluid fluctuates markedly with dialysis treatments. Nevertheless, the presence of a productive cough, fever, chills, pleuritic pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dyspnea suggest an infectious pulmonary process. The diagnosis may be confirmed by sputum evaluation and chest radiograph. Treatment should not be withheld if a high index of suspicion remains, despite the absence of diagnostic test results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link\">",
"     \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early studies, survival on dialysis was short in most patients with AIDS (only a few months), although some asymptomatic patients or those with early AIDS survived for one to two years. Subsequent studies, however, have noted prolonged survival in infected patients requiring renal replacement therapy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34344?source=see_link\">",
"     \"Human immunodeficiency virus and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NERVOUS SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis and infections of the brain parenchyma should be considered in dialysis patients with fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system symptoms or findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of literature exists concerning the incidence of meningitis in dialysis patients. Streptococcus meningitis, an uncommon infection in all adults, was reported as a complication of peritonitis in one peritoneal dialysis patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal meningitis has also been reported in patients with ESRD. Cryptococcal meningoencephalitis, the most frequent manifestation of cryptococcal infection, has been noted with increased frequency among the general patient population because of HIV infection. Involvement of the meninges with Cryptococcus in peritoneal dialysis patients most commonly results from systemic disease initially arising from infection of the peritoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163926816\">",
"    <span class=\"h2\">",
"     Herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Risk factors'",
"    </a>",
"    .) Chronic kidney disease is risk factor for the development of zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In one study, among 843 hemodialysis patients, the risk of developing a zoster infection by 4.7 years of follow-up was approximately twice that of non-dialysis control patients (adjusted hazard ratio of 1.98, 95% CI 1.72-2.27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with antiviral agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    requires adjustment in dosage for dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucormycosis, a life-threatening fungal disease, is characterized by fungal sinusitis with invasion of adjacent structures, including the brain. It most commonly occurs in immunocompromised and diabetic patients, and dialysis patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO). The fungal infection may be contracted from the environment and then disseminate, frequently affecting the central nervous system and sinuses (rhinocerebral mucor). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis patients in whom aluminum chelation therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    has been administered at relatively high doses appear to be at significant risk for mucormycosis. Presenting forms of the infection most commonly include rhinocerebral and disseminated disease (31 and 44 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucormycosis infecting the peritoneum has also been reported in peritoneal dialysis patients. In one case report, Rhizopus species grew from cultures obtained from a patient with clinical signs of peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/21\">",
"     21",
"    </a>",
"    ]. The patient had no known risk factor for the infection.",
"   </p>",
"   <p>",
"    The management of these fungal infections is discussed in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gallbladder and biliary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of literature exists concerning the prevalence of cholecystitis and cholecystolithiasis in patients with ESRD. In one ultrasonographic study, no significant difference was observed in the prevalence of cholecystolithiasis in 73 hemodialysis patients and a control group (16 and 23 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/22\">",
"     22",
"    </a>",
"    ]; in addition, gender or duration of hemodialysis treatment did not correlate with the presence or absence of gallstones. A case report of emphysematous cholecystitis in a peritoneal dialysis patient suggests that ischemia may play a role in the development of this entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common bile duct dilatation may occur more commonly among patients with renal failure due to polycystic kidney disease compared to those without the disorder. In one study, for example, 22 of 55 patients (40 percent) with polycystic kidney disease and varying levels of renal function were found to have biliary dilatation measuring at least seven millimeters, compared to 5 of 55 controls (9.1 percent) matched for age, gender, renal function, and duration of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/24\">",
"     24",
"    </a>",
"    ]. Whether this is associated with an enhanced risk of biliary infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathology is unknown.",
"   </p>",
"   <p>",
"    The clinical presentation and overall management of dialysis patients with cholecystitis is similar to those without renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Visceral leakage causing peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis is a common complication in patients undergoing peritoneal dialysis. Although associated with significant morbidity, it is usually easily treatable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .) However, peritonitis resulting from enteric bacteria is frequently caused by injury to gastrointestinal viscera and may have devastating consequences. Peritonitis acquired by virtue of microscopic perforation may be insidious, with subtle or no radiographic abnormalities despite evolving clinical symptoms. In a review of 230 peritoneal dialysis patients followed over eight years, approximately 30 percent of peritonitis episodes resulting from enteric organisms were due to documented visceral leakage, including cholecystitis, ischemic bowel disease, viscus perforation, or diverticulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/25\">",
"     25",
"    </a>",
"    ]. Among these 26 patients with visceral disease, 50 percent died and 30 percent switched to hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Helicobacter pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature is variable with regard to the prevalence of gastroduodenal Helicobacter pylori infection in dialysis patients. The prevalence, diagnosis, and management of Helicobacter pylori infection in dialysis patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious hepatitis, particularly with hepatitis B and C, is a significant cause of morbidity and mortality in hemodialysis patients, with hepatitis C being a leading cause of liver disease. Fortunately, the incidence of both hepatitis B and C infections is declining in this patient population.",
"   </p>",
"   <p>",
"    Discussions concerning the epidemiology, diagnosis, and treatment of hepatitis B and C infections in patients with and without renal failure are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1048?source=see_link\">",
"     \"Diagnosis of hepatitis C virus infection in patients on dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"     \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ESRD are susceptible to the same viral gastroenteritides as the general population, although their ability to combat such illnesses may be suppressed. An important issue in the dialysis patient with significant gastrointestinal fluid loss (by vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea) is the accurate assessment of intravascular volume to avoid a substantial decrease in the effective circulating volume with dialysis therapy. Careful attention must therefore be given to variations in blood pressure during the procedure and the accurate determination of dry weight. Acute symptomatic relief may be obtained with the administration of an anti-diarrheal agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    given at a dose of 2 to 4 mg PO initially then 2 mg after each unformed stool up to 10 to 12 mg Q day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diverticulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients develop diverticulitis at least as frequently as non-dialysis patients. An enhanced incidence is observed in patients with polycystic kidney disease since a majority of such individuals who require dialysis have diverticula. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presentation of diverticulitis in the chronically ill dialysis patient may be more insidious than that of the patient without renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .) Management must be individualized, but is essentially similar to that for non-dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13450?source=see_link\">",
"     \"Treatment of acute diverticulitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clostridium difficile colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients are particularly susceptible to Clostridium difficile colitis, since they are commonly administered antibiotics. In one study of 62 dialysis patients and eight individuals with acute renal failure, 110 episodes of Clostridium difficile colitis reportedly occurred over a two-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/26\">",
"     26",
"    </a>",
"    ]. In this cohort, infection was associated with a dismal long-term prognosis: 60 of 70 patients died over a follow-up period of five years.",
"   </p>",
"   <p>",
"    Another study found that the incidence of Clostridium difficile associated infection was 10.7 per 1000 admissions for patients with chronic kidney disease compared with 2.7 per 1000 among other patients (p&lt;0.0001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/27\">",
"     27",
"    </a>",
"    ]. In this study, symptoms included diarrhea, fever, and ileus or abdominal pain in 89, 53, and 44 percent of renal patients, respectively. ESRD and being on dialysis, as opposed to CKD stages 3 to 5 appears to be a risk factor for clostridium difficile colitis for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of C. difficile colitis in dialysis patients is similar to the regimen used in non-dialysis patients, but with minor dosing adjustments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/29\">",
"     29",
"    </a>",
"    ]. It is recommended that dialysis patients with estimated glomerular filtration rates of less than 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    receive a 50 percent dose reduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/30\">",
"     30",
"    </a>",
"    ]; the drug should also be administered after hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GENITOURINARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of urinary tract infection in a dialysis patient with residual urine production is similar to that of an individual without renal failure. By comparison, anuric patients may present with only bladder discomfort",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever.",
"   </p>",
"   <p>",
"    The presence of pyuria, including white blood cell casts, without bacterial infection is common in dialysis patients. Some investigators have suggested that pyuria is a marker for urinary tract infection, even in asymptomatic dialysis-dependent patients. The literature is sparse and conflicting concerning this issue. One study of 25 chronic hemodialysis patients reported no correlation between a predominance of white blood cells and white blood cell casts in the urinalysis, and the presence of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/31\">",
"     31",
"    </a>",
"    ]. By comparison, another report of asymptomatic dialysis patients suggested that pyuria (defined by greater than 10 white blood cells per high power field) was associated with a propensity for urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/32\">",
"     32",
"    </a>",
"    ]. In this report, urine cultures of 7 of 10 asymptomatic dialysis patients with significant pyuria grew possible urinary pathogens compared to only 4 of 18 with insignificant pyuria.",
"   </p>",
"   <p>",
"    A subsequent study of asymptomatic patients (11 hemodialysis and 11 peritoneal dialysis) found a poor correlation between significant pyuria (defined as above) and positive urine cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/33\">",
"     33",
"    </a>",
"    ]. Eight of nine patients with significant pyuria and 10 of 11 patients without significant pyuria grew one or more pathogens considered clinically significant. The urine cultures of only two patients, one from each group, grew a significant pathogen, thereby suggesting that even significant pyuria does not strongly correlate with the presence of infection.",
"   </p>",
"   <p>",
"    Similar findings were found in a study of 43 asymptomatic peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/34\">",
"     34",
"    </a>",
"    ]. Of the 12 patients found on culture to be infected, 67 percent had pyuria. By contrast, among non-infected patients,13 percent had pyuria.",
"   </p>",
"   <p>",
"    In a review of the small body of literature dealing with this issue, it was concluded that asymptomatic pyuria is common in dialysis patients (30 to 40 percent). However, its presence does not necessarily indicate a true infection, with the correlation being quite variable (11 to 70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, asymptomatic pyuria is of unclear significance in dialysis patients. Establishing the diagnosis of a urinary tract infection in this setting requires a positive urine culture.",
"   </p>",
"   <p>",
"    Urinary tract infections are the most common nosocomial infections among hospitalized chronic dialysis patients who have undergone urinary catheterization. They appear to be responsible for nearly one-half of such infections, with Candida being the most frequently observed pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of symptomatic urinary tract infection must be tailored to the individual dialysis patient and the cultured organism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pyocystis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyocystis, defined as a large collection of pus in a nonfunctioning bladder, may occur in anuric dialysis patients; it is an overlooked cause of fever in this patient population. In this setting, culture most commonly yields multiple organisms. Treatment usually consists of bladder irrigation with antimicrobial solutions, and possibly antimicrobial therapy depending upon the virulence of the pathogen and the clinical state of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pyelonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of pyelonephritis in the patient with and without renal failure is similar; symptoms or signs may include fever, abdominal pain, dysuria (if not anuric), and flank pain. Patients with end-stage renal disease due to polycystic kidneys",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    older dialysis patients may be at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with a urinary tract infection, treatment of the patient with pyelonephritis is based upon the clinical characteristics of the patient and microbiologic results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .) The treatment of renal infection in the patient with polycystic kidneys is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SKIN AND BONE INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis and osteomyelitis are significant causes of morbidity in dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis frequently occurs in the diabetic dialysis patient with neurologic and peripheral vascular disease. It must be aggressively sought out and treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .) The duration of treatment among these patients is often longer than for immunocompetent non-dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis may result from direct extension of cellulitis, which, as mentioned, is a common occurrence in diabetics, and via hematogenous spread caused by the failure to recognize and remove infected central venous hemodialysis catheters",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic access. A high index of suspicion is therefore appropriate in dialysis patients, particularly diabetics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .) As with nondialysis patients, treatment is based upon cultured pathogens (when available)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    empiric regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection and calciphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calciphylaxis, a rare complication of the skin microvasculature, affects an estimated one percent of patients with ESRD per year. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .) This disorder is associated with extensive microvascular calcification and occlusion with thrombosis of the skin, thereby resulting in characteristic violaceous skin lesions. Progression to nonhealing ulcers and sepsis is confounded by secondary infection, which also leads to blood-borne infection and often death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus bacteremia is common in hemodialysis patients; it is usually related to the presence of an indwelling dialysis catheter or arteriovenous graft,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritonitis. The widespread use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in dialysis patients has resulted from the convenience of infrequent dosing related to hemodialysis treatments, and the recognition that staphylococcus species cultured from these populations were often resistant to methicillin, thereby leaving vancomycin as the only drug known to cure methicillin-resistant Staphylococcus aureus (MRSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/38\">",
"     38",
"    </a>",
"    ]. In 2005, the incidence of invasive MRSA infection was 45.2 cases per 1000 dialysis patients compared with a rate of 0.2 to 0.4 cases per 1000 in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, relatively low rates of MRSA are generally seen in hemodialysis outpatients. In one study of 198 such patients, the rate of MRSA colonization was 5.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/40\">",
"     40",
"    </a>",
"    ]. MRSA colonization was increased in those with prior MRSA exposure.",
"   </p>",
"   <p>",
"    Many staphylococcus infections in peritoneal dialysis patients are actually Staphylococcus epidermidis; this is a less virulent pathogen, but one that is also often resistant to methicillin (MRSE). Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    has been widely used as empiric therapy for the past decade, there is concern about the enhanced incidence of infection resulting from vancomycin-resistant enterococcus (see next section) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     VANCOMYCIN-RESISTANT ENTEROCOCCUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcus (VRE) and the rising incidence of VRE",
"    <span class=\"nowrap\">",
"     infection/colonization",
"    </span>",
"    pose significant health care risks:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Colonization of this organism can evolve into serious infection.",
"     </li>",
"     <li>",
"      Resistance may be passed to more virulent organisms such as Staphylococcus aureus.",
"     </li>",
"     <li>",
"      The carriage of VRE may render the dialysis patient unacceptable for kidney transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VRE bacteremia predominantly affects severely ill patients who have previously received extensive antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/42\">",
"     42",
"    </a>",
"    ]. Dialysis patients, with their propensity for access infection and comorbid conditions requiring prolonged hospitalization, are at particular risk; however, the duration of hemodialysis has not been found to correlate with the presence of VRE nor has an increased risk of death been observed in VRE-positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergence of VRE has prompted national concern that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    no longer be used as empiric therapy in peritonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .) However, the concern may be excessive since controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/44\">",
"     44",
"    </a>",
"    ] and retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/45\">",
"     45",
"    </a>",
"    ] studies of patients with ESRD published in 1998 and 1999 found that the incidence of VRE was less than in previous reports. The range of centers with one or more VRE-positive patient appears to vary markedly by ESRD network. In a survey performed in 2001, for example, the percentage of centers in each network with one or more patients with VRE varied from 16 to 64 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, relatively low rates of VRE colonization are generally seen in hemodialysis outpatients. In one study of 198 patients, the rate of VRE colonization was 3.14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/40\">",
"     40",
"    </a>",
"    ]. VRE colonization was more likely to be found in those with an increased number of hospitalizations and prior VRE exposure.",
"   </p>",
"   <p>",
"    Centers for Disease Control and Prevention (CDC) guidelines mandate that VRE-positive hemodialysis patients must be isolated during treatment and hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The acquisition of VRE is also of particular concern among peritoneal dialysis patients. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    , an antimicrobial used in the treatment of VRE infections, is not well suited as long-term therapy because myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) can develop in patients receiving linezolid for more than two weeks. Such adverse hematologic effects may be more common in dialysis patients. As an example, in a retrospective case-control study, patients with ESRD, compared to those without renal disease, had a significantly higher rate of linezolid-associated thrombocytopenia (79 versus 43 percent) and anemia (72 versus 37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of VRE is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although very few early reports were published, the incidence of tuberculosis in patients undergoing dialysis was considered to be relatively low. However, it appears that dialysis patients have an enhanced risk for developing tuberculosis. As an example, a 12-year study of 110 hemodialysis patients found an incidence of 24 percent, with the majority of patients having pulmonary involvement (70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/50\">",
"     50",
"    </a>",
"    ]. With early therapy, all patients survived and developed no recurrence within five years of follow-up. Similar findings have been noted in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Other than attention to appropriate dosing regimens for those with ESRD, the treatment of tuberculosis in dialysis patients is the same as for non-dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a heightened awareness of the propensity for immunosuppressed patients, including those on dialysis, to reactivate old or acquire new tuberculosis infections. In a single dialysis center, for example, one infected health care worker apparently transmitted tuberculosis to 29 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients frequently present with fever, anorexia, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/54\">",
"     54",
"    </a>",
"    ]. Involvement of extrapulmonary organs is also common, particularly the lymphatic system and peritoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/55-57\">",
"     55-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since approximately 30 to 40 percent or more of hemodialysis patients are anergic, additional clinical testing for the presence of tuberculosis may be appropriate in patients for whom the index of suspicion is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/58-63\">",
"     58-63",
"    </a>",
"    ]. The interferon (IFN)-gamma release assay (IGRA) has been useful for the diagnosis of tuberculosis in non-dialysis patients. A number of studies have also been published suggesting that the IGRA is also useful in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. IGRA tests for latent tuberculosis may be advisable in areas where there is a moderate to high burden of TB, as these tests correlate better than skin testing with the risk of TB infection and past TB disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/66\">",
"     66",
"    </a>",
"    ]. Although some advocate IGRA for TB screening in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/65\">",
"     65",
"    </a>",
"    ], the practice has not yet gained widespread acceptance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/61/37849/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2614690\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections are a leading cause of death among patients with ESRD, accounting for approximately 15 percent of all fatalities. Access-related infections are the most common and respiratory tract infections are the second most common causes of infection-related deaths. Others include HIV infection, infections of the central nervous system, gastrointestinal tract, genitourinary tract, skin (cellulitis) and bone (osteomyelitis). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      (DFO) are at increased risk of mucormycosis, a life-threatening fungal disease that most commonly occurs in immunocompromised and diabetic patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mucormycosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peritonitis is common in patients undergoing peritoneal dialysis but is usually easily treatable. Peritonitis caused by enteric bacteria is frequently caused by injury to gastrointestinal viscera and may have devastating consequences. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Visceral leakage causing peritonitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"       \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infectious hepatitis, particularly with hepatitis B and C, is a significant cause of morbidity and mortality in hemodialysis patients, with hepatitis C being a leading cause of liver disease. The incidence of both hepatitis B and C infections is declining in this patient population. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hepatitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1048?source=see_link\">",
"       \"Diagnosis of hepatitis C virus infection in patients on dialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=see_link\">",
"       \"Hepatitis C virus infection in patients on maintenance dialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40024?source=see_link\">",
"       \"Hepatitis B virus and dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis patients are particularly susceptible to Clostridium difficile colitis, since they are commonly administered antibiotics. Management of Clostridium difficile colitis in dialysis patients is similar to the regimen used in non-dialysis patients, but with minor dosing adjustments. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clostridium difficile colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary tract infections are the most common nosocomial infections among hospitalized chronic dialysis patients who have undergone urinary catheterization. Candida is the most frequently observed pathogen. The management of symptomatic urinary tract infection must be tailored to the individual dialysis patient and the cultured organism. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Genitourinary infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"       \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cellulitis is common in the diabetic dialysis patient with neurologic and peripheral vascular disease. Osteomyelitis may result from direct extension of cellulitis or via hematogenous spread from an infected central venous hemodialysis catheters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic access. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Skin and bone infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"       \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staphylococcus aureus bacteremia is common in hemodialysis patients and is usually related to the presence of an indwelling dialysis catheter or arteriovenous graft,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritonitis. Invasive methicillin-resistant Staphylococcus aureus (MRSA) infection is more common in the hemodialysis population compared to the general population but relatively low rates of MRSA are generally seen in hemodialysis outpatients. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Methicillin-resistant staphylococcus aureus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      resistant enterococcus (VRE) colonization is not common among hemodialysis outpatients. Centers for Disease Control and Prevention (CDC) guidelines mandate that VRE-positive hemodialysis patients must be isolated during treatment and hospitalizations. The carriage of VRE may render the dialysis patient unacceptable for kidney transplantation. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Vancomycin-resistant enterococcus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=see_link\">",
"       \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis patients have an enhanced risk for developing tuberculosis. Other than attention to appropriate dosing regimens for those with ESRD, the treatment of tuberculosis in dialysis patients is the same as for non-dialysis patients. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Tuberculosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Herpes zoster is more common in hemodialysis patients than in the general population, and treatment with antiviral agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      requires adjustment in dosage for dialysis patients. (See",
"      <a class=\"local\" href=\"#H163926816\">",
"       'Herpes zoster'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/1\">",
"      United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/2\">",
"      Survival, mortality, &amp; causes of death. USRDS. United States Renal Data System. Am J Kidney Dis 2001; 38:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/3\">",
"      Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006; 13:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/4\">",
"      Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/5\">",
"      Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/6\">",
"      Foley RN, Guo H, Snyder JJ, et al. Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/7\">",
"      Khan IH, Catto GR. Long-term complications of dialysis: infection. Kidney Int Suppl 1993; 41:S143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/8\">",
"      Alexander D, Peacock E. Drug resistant organisms and their implications for the outpatient dialysis setting. Nephrol News Issues 1997; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/9\">",
"      Mc Causland FR, Brunelli SM, Waikar SS. Association of smoking with cardiovascular and infection-related morbidity and mortality in chronic hemodialysis. Clin J Am Soc Nephrol 2012; 7:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/10\">",
"      Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int 2006; 70:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/11\">",
"      James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/12\">",
"      Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrol Dial Transplant 2008; 23:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/13\">",
"      Chen CH, Hsu WH, Chen HJ, et al. Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease. Chest 2007; 132:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/14\">",
"      Lerner PI. Meningitis caused by Streptococcus in adults. J Infect Dis 1975; 131 Suppl:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/15\">",
"      Mansoor GA, Ornt DB. Cryptococcal peritonitis in peritoneal dialysis patients: a case report. Clin Nephrol 1994; 41:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/16\">",
"      Smith JW, Arnold WC. Cryptococcal peritonitis in patients on peritoneal dialysis. Am J Kidney Dis 1988; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/17\">",
"      Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993; 17:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/18\">",
"      McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/19\">",
"      Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/20\">",
"      Wu MY, Hsu YH, Su CL, et al. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 2012; 60:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/21\">",
"      Polo JR, Lu&ntilde;o J, Menarguez C, et al. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1989; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/22\">",
"      Hojs R. Cholecystolithiasis in patients with end-stage renal disease treated with haemodialysis: a study of prevalence. Am J Nephrol 1995; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/23\">",
"      Mirza MM, Wall BM. Emphysematous cholecystitis in a CAPD patient. Perit Dial Int 1997; 17:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/24\">",
"      Ishikawa I, Chikamoto E, Nakamura M, et al. High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. Am J Kidney Dis 1996; 27:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/25\">",
"      Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/26\">",
"      B&aacute;r&aacute;ny P, Stenvinkel P, Nord CE, Bergstr&ouml;m J. Clostridium difficile infection--a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/27\">",
"      Cunney RJ, Magee C, McNamara E, et al. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998; 13:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/28\">",
"      Eddi R, Malik MN, Shakov R, et al. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010; 15:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/29\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     Gilbert, DN, Moellering, RC, Sande, MA. Table 17. In: The Sanford guide to antimicrobial therapy. 28th ed, Sanford 1998. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/31\">",
"      Cabaluna CC, Gary NE, Eisinger RP. Urinalysis in patients on chronic hemodialysis. Urology 1977; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/32\">",
"      Chaudhry A, Stone WJ, Breyer JA. Occurrence of pyuria and bacteriuria in asymptomatic hemodialysis patients. Am J Kidney Dis 1993; 21:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/33\">",
"      Eisinger RP, Asghar F, Kolasa C, Weinstein MP. Does pyuria indicate infection in asymptomatic dialysis patients? Clin Nephrol 1997; 47:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/34\">",
"      Orowska A, Majdan M, Kozio-Montewka M, et al. Asymptomatic bacteriuria in patients on continuous ambulatory peritoneal dialysis. Ann Univ Mariae Curie Sklodowska Med 2002; 57:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/35\">",
"      Fasolo LR, Rocha LM, Campbell S, Peixoto AJ. Diagnostic relevance of pyuria in dialysis patients. Kidney Int 2006; 70:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/36\">",
"      D'Agata EM, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000; 35:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/37\">",
"      Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/38\">",
"      Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/39\">",
"      MMWR. Morbidity and Mortality Weekly Report 2007; 56:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/40\">",
"      Hadley AC, Karchmer TB, Russell GB, et al. The prevalence of resistant bacterial colonization in chronic hemodialysis patients. Am J Nephrol 2007; 27:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/41\">",
"      Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. Am J Kidney Dis 1990; 16:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/42\">",
"      Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/43\">",
"      Roghmann MC, Fink JC, Polish L, et al. Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis 1998; 32:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/44\">",
"      Brady JP, Snyder JW, Hasbargen JA. Vancomycin-resistant enterococcus in end-stage renal disease. Am J Kidney Dis 1998; 32:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/45\">",
"      Ng R, Zabetakis PM, Callahan C, et al. Vancomycin-resistant enterococcus infection is a rare complication in patients receiving PD on an outpatient basis. Perit Dial Int 1999; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/46\">",
"      Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/47\">",
"      Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycin resistance. Infect Cont Hosp Epid 1995; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Review Board Workgroup on VRE. Reducing the spread of vancomycin-resistant enterococcus in the dialysis setting. Mid-Atlantic Renal Coalition, 1996 Report.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/49\">",
"      Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/50\">",
"      Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 1996; 73:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/51\">",
"      Taskapan H, Utas C, Oymak FS, et al. The outcome of tuberculosis in patients on chronic hemodialysis. Clin Nephrol 2000; 54:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/52\">",
"      Lui SL, Tang S, Li FK, et al. Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2001; 38:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Tuberculosis transmission in a renal dialysis center--Nevada, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/54\">",
"      Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the kidney. J Am Soc Nephrol 2001; 12:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/55\">",
"      Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/56\">",
"      Hung KH, Lee CT, Chen JB, Hsu KT. Tuberculous peritonitis in uremic patients. Clin Nephrol 2003; 60:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/57\">",
"      Kriki P, Thodis E, Deftereos S, et al. A tumor-like manifestation of extrapulmonary tuberculosis in a hemodialysis patient. Clin Nephrol 2009; 71:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/58\">",
"      Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/59\">",
"      Woeltje KF, Mathew A, Rothstein M, et al. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/60\">",
"      Korzets A, Gafter U. Tuberculosis prophylaxis for the chronically dialysed patient--yes or no? Nephrol Dial Transplant 1999; 14:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/61\">",
"      Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients--is the tuberculin test effective? Clin Nephrol 2003; 59:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/62\">",
"      Wauters A, Peetermans WE, Van den Brande P, et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/63\">",
"      Eleftheriadis T, Tsiaga P, Antoniadi G, et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. Am J Kidney Dis 2005; 46:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/64\">",
"      Winthrop KL, Nyendak M, Calvet H, et al. Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008; 3:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/65\">",
"      Segall L, Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010; 5:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/61/37849/abstract/66\">",
"      Lee SS, Chou KJ, Dou HY, et al. High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test. Clin J Am Soc Nephrol 2010; 5:1451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1893 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37849=[""].join("\n");
var outline_f36_61_37849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2614690\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESPIRATORY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Upper respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lower respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NERVOUS SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H163926816\">",
"      Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GASTROINTESTINAL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gallbladder and biliary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Visceral leakage causing peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clostridium difficile colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GENITOURINARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pyocystis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SKIN AND BONE INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection and calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      VANCOMYCIN-RESISTANT ENTEROCOCCUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2614690\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1048?source=related_link\">",
"      Diagnosis of hepatitis C virus infection in patients on dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40024?source=related_link\">",
"      Hepatitis B virus and dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31114?source=related_link\">",
"      Hepatitis C virus infection in patients on maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34344?source=related_link\">",
"      Human immunodeficiency virus and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=related_link\">",
"      Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13450?source=related_link\">",
"      Treatment of acute diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=related_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_61_37850="Seborrheic dermatitis face 2";
var content_f36_61_37850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59104%7EDERM%2F82073%7EDERM%2F54173%7EDERM%2F52803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59104%7EDERM%2F82073%7EDERM%2F54173%7EDERM%2F52803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Facial seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has involvement of the retroauricular area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, fine scaliness of the scalp without underlying erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis involving multiple skin folds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37850=[""].join("\n");
var outline_f36_61_37850=null;
var title_f36_61_37851="Cetuximab dose modify derm tox";
var content_f36_61_37851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose modification guidelines for cetuximab (Erbitux) based upon cutaneous adverse reaction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Severe acneiform rash",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial management",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose modification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        First occurrence",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Delay infusion 1 to 2 weeks",
"       </td>",
"       <td>",
"        Improvement",
"       </td>",
"       <td>",
"        Continue at 250 mg/m2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No improvement",
"       </td>",
"       <td>",
"        Discontinue cetuximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Second occurrence",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Delay infusion 1 to 2 weeks",
"       </td>",
"       <td>",
"        Improvement",
"       </td>",
"       <td>",
"        Reduce dose to 200 mg/m2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No improvement",
"       </td>",
"       <td>",
"        Discontinue cetuximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Third occurrence",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Delay infusion 1 to 2 weeks",
"       </td>",
"       <td>",
"        Improvement",
"       </td>",
"       <td>",
"        Reduce dose to 150 mg/m2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No improvement",
"       </td>",
"       <td>",
"        Discontinue cetuximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fourth occurrence",
"       </td>",
"       <td>",
"        Discontinue cetuximab",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Cetuximab package insert, ImClone systems, February, 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37851=[""].join("\n");
var outline_f36_61_37851=null;
var title_f36_61_37852="Cardiac involvement in vasculitis";
var content_f36_61_37852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Principle features and cardiovascular/pericardial involvement in vasculitides",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vasculitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Principle features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated frequency of cardiac/pericardial involvement (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of cardiac/pericardial involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Takayasu arteritis",
"       </td>",
"       <td rowspan=\"2\">",
"        Chronic inflammatory and obliterative disease of the aorta and its major branches.",
"       </td>",
"       <td>",
"        Cardiac: rare",
"       </td>",
"       <td>",
"        Fibrosis, narrowing and aneurysm of the aorta, its branches, and pulmonary arteries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: rare (case reports)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Giant cell arteritis",
"       </td>",
"       <td rowspan=\"2\">",
"        Vasculitis that affects large and medium-sized blood vessels (especially cranial arteries branching from the carotid artery).",
"       </td>",
"       <td>",
"        Cardiac: &lt;10",
"       </td>",
"       <td>",
"        Aneurysm, coronary arteritis, myocardial infarction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: rare (case reports)",
"       </td>",
"       <td>",
"        Pericarditis, pericardial effusion.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Polyarteritis nodosa",
"       </td>",
"       <td rowspan=\"2\">",
"        Necrotizing arteritis involving medium-sized and small-sized arteries with inflammation and ischemia of affected organs.",
"       </td>",
"       <td>",
"        Cardiac: &lt;50",
"       </td>",
"       <td>",
"        Hypertension (renal vasculitis), aneurysm, and myocardial infarction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: rare (case reports, limited series)",
"       </td>",
"       <td>",
"        Pericarditis.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Kawasaki disease",
"       </td>",
"       <td rowspan=\"2\">",
"        Systemic necrotizing medium-sized vessel vasculitis mainly affecting blood vessels, skin, mucous membranes and lymph nodes.",
"       </td>",
"       <td>",
"        Cardiac: 30",
"       </td>",
"       <td>",
"        Coronary arteritis and aneurysm, myocardial infarction, myocarditis, heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: 30",
"       </td>",
"       <td>",
"        Pericardial effusion, pericarditis.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Churg-Strauss syndrome",
"       </td>",
"       <td rowspan=\"2\">",
"        Systemic necrotizing vasculitis affecting small-sized to medium-sized vessels, characterized by asthma, hypereosinophilia, and eosinophil-rich granulomatous inflammation of the respiratory tract.",
"       </td>",
"       <td>",
"        Cardiac: &gt;50",
"       </td>",
"       <td>",
"        Eosinophilic endomyocarditis, heart failure, heart block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: 25-50",
"       </td>",
"       <td>",
"        Pericarditis, pericardial effusion.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Granulomatosis with polyangiitis",
"       </td>",
"       <td rowspan=\"2\">",
"        Necrotizing vasculitis that mainly affects arteries in the respiratory tract and kidneys.",
"       </td>",
"       <td>",
"        Cardiac: 10-40",
"       </td>",
"       <td>",
"        Coronary arteritis, valve lesions, heart block, aortic aneurysm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial: &lt;10",
"       </td>",
"       <td>",
"        Pericarditis, pericardial effusion.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37852=[""].join("\n");
var outline_f36_61_37852=null;
var title_f36_61_37853="WHO MEC for neurologic conditions";
var content_f36_61_37853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Neurologic conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       COC",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       CIC",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       P/R",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       POP",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       <p>",
"        DMPA",
"       </p>",
"       <p>",
"        NET-EN",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       <p>",
"        LNG/ETG",
"       </p>",
"       <p>",
"        Implants",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Cu-IUD",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       LNG-IUD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"      <td class=\"subtitle2\">",
"       I",
"      </td>",
"      <td class=\"subtitle2\">",
"       C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"16\" rowspan=\"1\">",
"       Headaches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Non-migrainous (mild or severe)",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"16\" rowspan=\"1\">",
"       Migraine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\" colspan=\"16\" rowspan=\"1\">",
"       Without aura",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Age &lt;35",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Age &ge;35",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       4",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       4",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       4",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       With aura (at any age)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       <p>",
"        Epilepsy",
"       </p>",
"       <p>",
"        (these eligibility categories do NOT apply to women taking antiepileptic drugs*)",
"       </p>",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td colspan=\"2\">",
"       1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1: A condition for which there is no restriction for the use of the contraceptive method.",
"     <br>",
"      2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"      <br>",
"       3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"       <br>",
"        4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"        <br>",
"         COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization; I: Initiation of method; C: Continuation of method",
"         <br>",
"          * For women taking antiepileptic drugs, please refer to the corresponding WHO table on Drug Interactions and contraceptive choice.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37853=[""].join("\n");
var outline_f36_61_37853=null;
var title_f36_61_37854="Lateral view of minimally displaced transverse patella fracture";
var content_f36_61_37854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral view of minimally displaced transverse patella fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral plain radiograph shows a transverse patella fracture (arrow) with minimal displacement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37854=[""].join("\n");
var outline_f36_61_37854=null;
var title_f36_61_37855="Nail elevator and spatula";
var content_f36_61_37855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Nail elevator and dental spatula used in performing an avulsion of the nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDllzj1wccUoJDHJx7UAYJzgZoJ56DNegYEqnHSrEZPGTiqqHjA7VMhwTzj6UxFpTnB7+hp4IwSP59ahBIwMrUinOQSvNAEqg+mKRuAMhcn2pRkDjnj1pxwep569aAI9p9F/Kmt1GST24qbvxmomU7OmPrQAqY5OMZ5FTqSMH1HPFVgecE4J7Cno2cAmgRYBxinAfex9MimAg9cH8KegHPH6UwFGQOMjnpijB6ZNKx68ULghvp61QmNAPXknHSgbs4yetPxz9OpJzim7f8AZ4Iz1oEOGcnGfzpMEYJ3GhcHqMfzpeoz3yaYAwyOAcZ7mkI44wD9KXjHpn2oUgDg/gKAEOMZJ/MUqlQoOQD/ADpCp+gPTmg8Lxz9BQAp6DP6U/OVHemk5zj7vX604fLnkDH50CFXOTnOB1qRSM470zHzcEnjI+tOwcZHBY0wJM4OVx171Ievv7VFglmJUcc09AScnaCaBDmByMA/nRngHJx/nijvggZ60oU4AwBTEO3DIBPbtSbjjB5x05pvAHIAP0pVxxnHHB4pAPBB6gelAGMDGOxNNHJGQv1pT74oGLnB4ABppBzgHjNKThuBxzxSduAMmgBTjIpv0FOViBkEcUnUcEnJoABxgHj6UuMHp9MnNAzjII54oPTvz6UAIM4PUUq4Knjg+tIV7YPPNKvTjn0oAAeRyMewp2Dg5PbikIPH3s0vU4Uk+tIBGPA659jSHljx270mBgkkYz0NKRnn9M0ANI59B04pDnj/ADml56g8+xpG4xnp9KBjScdj1pDnGOfpQeDyRg0rZzhcZ7+1ACMckZ7U1ivJ5xQTxk+tHHOCOnagBu3nJGaa2efTHSne3brmmMPmPBP1piGDOOKUEHGSM+9KACh4+vFMzg8cfrQMC3PU4pGwMenqacWyw601toJycD86BDmPTGMmkJ6Y6e1BGV6Z780hY5wT+VIB5GSvT6UU1emR9OaKTGc5tOcAjimHOBkDnirCgk/XvSMhGcde3FZmpEoPbgD1qQMc9sGkAxjn8aQAgDqfehCJkc89M56VYVuM5BNVAcLyT9KkVsjg5FMRcVh2wOKcDhuOlQB89WOMelSbsY5OOnFAXJe+DwaTb1HfPehWJ/iPFKXOM9xQMicEg9Dz2FMGdwwfyqd8FT6VC33flHOaYiZGIyNtSxkbQMD1FVgeeCPrUqMCCM/ShCLQIwOhBGKVeRgZxjqD1qNWGOeCPapEK9eM464qgEOSc5OaUDsO/pQwAbgjP1o7gDr9e9Ag249c9qaR7/pT+pA5x6ZpCMjvQAgBxypNOwCRn+dNPHTnjPWlGMAYHtQAEeuOKByAAcc8DrSkgZ7Dp0poBOO+fwoAU5Oc596eowTgjjFIFwuWXJ+tLtwBgKOKYAAMZ5p2ORkDHc0zIHIzz7daeA3PTrQIlAwcEDb9KcNpBzt5FID8v8IH86EJBzxnGPrTESE8Dj8+1IQOm3ocnmhjyM4/GkYnafu49u9Ag3DGRj8KUEY4YD8KZuy1Kp7ZOTzwKBj9xBXB4HHSnLkdz7YFRqxyCcnntUjAnnnn3xQIM/MM8E0meeD9cUHjGR0PrShcY69aAAN25PFKfypvTPAB+tHRRzzigYqY49fanHnjGR15NM74PT60Zyc4Gf6UWEJ8p5547j0pytkY5xio+ScjP0p3QAfpQA8ZAGBx6ZoAGOOtNJHJyKTOcjvQA4jgjtS8nOA2Dx1pgPHGSfUnpQpHAPGaBisCM5B+lIzcDA6UvBJ28n6008DB796QCEZHt60hBYdxx0oPUr0pASRgke9AxMYHAz3pp64yQKeAeA3Ax3ph6DcaYA3NMzuYgdfpTmOc8ZzSEYHBOfY0ANODnHJHqajbGeD19BTwQO4z9KaR82fbtQIQHB703OM4PA9qceeTj6mmkkdOg9qQCgk87f8ACkYknAOB+WKQkg8ge9DEg4z+lAxRkd8n1opvb0FFAjIA46dOoFLggDbn0+tAPy8Acd6cAM56VibkeCQc5xTcNhuPxqfHOfagpkY7H3pksgCnkAAfWgfdwR+tTFcHocfWk2EhuOppiAE+49Keh6Hj69KZsIX7vP8AOgjgE8mgCwrYz6/Wn5+Xj0xVdfuYIB5qQD1wPxpiJSQFI2gDHHeon+8RninDjjj25poJYEcn8KAExwDxntUiEgggkYPTFRYHTB9qcvGPmx7DvQBdjJ4Aye9SKCRyTzVeNg2OD1qWMjI+8M+ppoCU8MMn9KQkbsnp9KCAeefrnigHjABI+lMBvHy9zn9KcW5xwT9KCMH198UmSDyCR1pAKeW4z7YFCKcYyc0Hp0bOOMUjAADj8zTEOJPQg/Q0hHCnj3zRkdR645NBGRnGfbFACjnIBPHtUm3IG0np6VECTjHXrUyH5een1oAaVy3QnHHWk5GSR04NP2jcAev1oYAZyBjNNCFDDjIApwYBh1x34pqnnoc0pOc8N6mgQ/04PAPbNJkbcZ68nijcRtxnBFKoO3gH2xQAmRkYbj6UAkA/48UjZzxnj3pBjJwOfrTAm5bHp7mjd7genemqAoCjH40oJHGOntQA7A9jn0perdOPamq2TnBI9qUAkYOaQDuTnGTSE575+pobBzjn+lIGypIJyBzxTEAOM4I9sUDknk/lQBzgHgfpSYA/DrmgAOQCSM96RsjnjBp3AyQQB9KCMAnrn0FAB2yCee1A6DkmkOPfpxzSMO5HPuaBjseuB+NIm3j5h+VIzA4x29aRT0GD9aAF4Odp/DFJwfbPtTix3fdJpu4Z55+lILCHP4/Wl529Rx2ppOcg9KBggE8euKBhnpzye1BwQPr60gx1GR+tDkbOvP0oAQ/MMDoPemntgAUhySB/SlGT29qAEIOT1/HtTCoHoB7044yfU80w9ec+vAoAYTtPUnPHFD8H0/GnHpk5/E9aY4wB9KAEJGQc/QgUEZ9Me5pOMDggZ9aQnA4/WgAyexP4CikzleMUUAZXYE05T1JJpgb1JGaN+D0J+h5rI1JweOv6UueOoqJXzkE5HXinA474+ooAkx9B2zSEEN9fejdxnIxTid3cdKBDAM5HBPrmnAcn6UDGDjb7+9P4JHOB/OgCNcDPIp6jOM0DhsBh6YpSeePSnckVSO5H+FNf1x70qE9M9PahzycAke9K4DM9ckDH40vQjac8flSN2AIHenYPXmmOxKhIOB1qdScYIH51APcHipV6jG36mmhE5PTH86QHGRjJ9PSmgjPReMnFGRwflxTAcM++eeM0o7Z49s00AbiRt/A0oGSMYOaAHDPzYHTjOcUHHsKFAxyRnPNIPXOfoKBDsgDNMOTgjJxT8nIPJ7U0k8nBzQAg5K+p9aljK4IYDp3qJTwCcc+vWng4GCeD7UAS5yQc49wOtOJXgkkDnHFMzkHLZz04p+cAgljzTEAPPDd+eKTHLHJH0p59SD+IoYf72cUXADggZJPsKAeOrYoxhl+X8c0hHJyKBCHhc4yfekydpJAFKeo+UYHrScD0z7CqAdnJPzY9OKcoIOTu6cUw8knnGM8jrSk9ePxzQBIpPAAP50dScAUwHpjbwOM06Ns91z04oEPJJB6DjtR64IA+lG44xgntwKQcgD+dAwU4PA5JoLEAngYo43DAB+ozQScHjvSENzn29KRSSAOTQDjPPemg/MN2PzpFD88Z7+pNIvXJwKF4U47ml+bAwDQAxic4HY4peMEc9aGwT1/WlIAQYxj0p2ATJ7YzzQ3QHH5UpC5znmmk8g5x7YosAEkZx0PvTRnPOcdqUgHPp1JpMgHtQA4Hsc4puOCM9OwNLjjFIB+WfSgBuQAQelKCKQNtzg/Sg9CMHj3oAb/EPYU0j5v8TSv24x+NGfTj2AoAY2DximuCTx+PanN39evWmsCD1H50gGkAE4w1Jn6g/pSjtjHHp3ppyQSQeKYB/CT2oprHGQMUUrAZAOBkbuR/nFKT7HPc4qJSe2eOlSHJU5yec+lQaXHYG7PPSlLAAY3cVHz2HWnkHGc8/WgRKrDAPzH8KerDIHJA9qh54GCfxp2CQpU9+maAuSBsEf4U7cDjr+WKaoO4cUKpGcg/nQBICMjO49+lO4C87gQPSmEEY3D9aeOh6cDJ/wAaQB6lifp0ppT16GoVv7LzNn2y2Z/7olUn+dWVXIyDlT3Xp+dK99imiM9c55IwD604cgHk59aVlJUdz2yelJjAB4NMkkB6dPx5p6HrggZ9BSDBXg9O+KVAc8k1SETMeRzxg9sUZIGMjn0FHJHRhz0JpASD0/EmgB4+8wz/AOO07O4Z5+uKapyTz9TmnZGDwDQApDYyD9c0hGBnPPXrTl4B6ZzQ2MqQeM46UCGdFGMDjIPpTTgjoBz2p5GeO2KR+AeTu78UAIp6jIzj0p6E4wP5UzkMRz9eM04DB5C0ICQHnk/0qTtyffrUAIxyF49D0p6fdHAwfWmImAyTgfrSkcY4PHPNMHJXP4YpxJK5+bOOaAADnoMj2pWHXggHngUgztPLcc80YJz7+9MAAGOSc+wxSYGB19OtO2/SkYAr1Ax3oAauOqgYFLjJ6/pSY784zzTgpB+6wpiEGSAQf0p4JHOeppoUAAEdc8etKcY5IxQAvIboOevPWgHnOT6cCgjHA5/CjDd/ryaAHAjIyTz7U0/ewBxnvTiMFeRyeRRgDOB+VMBhHpgdsgUoBOD14z0pecDOTigA8ZHJosAoAIPUcetNbjO3ke5qTAyRkZ/GmHGaAGEnJPT+lGTj69KGyDx+lKRxzQAhz1yc0EccZznNOHocUxvbAJoGIc85zijnpzTj746+lNwCCeMfSkAYwDnp7UgPUCjH40p4HBPNMBn4YzQ36Uv55FKQcYAODSAibgDg0Hjvx7mnMF2pwMg0EZB6ZpARv098fnTR16k/QU4rgrgmhV5wMZoGRgDAPzfTNJt5HAGOxqT64pDwxOAOaAIW6nJ9+lFOGcYzk0UCMDjAJ6ipRhlGf1NIB26kinAZI4H5dKg0HbRu5A5pycDJwBnpRjGMDnvxTvm2+nfpRcQIME1IoGOQDzSLk/8A6qeQSB1zSuOxIo+fp264oPX8fShcg8U75j/D+lIYiDPA6/SvN/E2rXmp392lvGJNLsn8owElRO38RJHf0Br0scMDjO32rzW70+40i/vo2mMYmnaaN+zq3t6joa5cXKUYXRth0nLUx0stNlTNrMtuW5MU4xg+mehqzapq1l82nXTgDtDMCP8AvmiXMmS8FpL/ALSNtJ/Cq8kdurY+z7W7BJsn9BXlKUr6Ha0ram7B4v1m0AW9tY5lHHzRlD+YrTtvHtkwAu7KeI9zGQ1czbWl7J/x6W2okHod+B+orRi0DXphnyQoP/PWRc/yrspzxPRM55Ro9TpoPF+hyD5rmSMjtJGRV+HXtGkIMWp2xz2L4x+dcivhLV5Bkvaj6rmn/wDCH6mR88tt/wB8rXVGeJ6xRi40f5jvI7u0kXKXVsw7ESg08zQc4nhAPo4NcB/whWodpYM+gVajk8GaqOVlg/74U/1rRVK38n4kctL+b8D0T7Tbg5M8X5ini8tRn/SYhn3FeYv4S11RhbhB7CI/0aqcvh7X4zzIuPVopB/jSdSt/J+IctL+Y9XbU7KPrdxfgaqXHiLTYefOZiOoHFeUNZavESsrWTj0aYp/6EBU0NpdgK8+k3G1TnfZ3IIP4c5rKVetH7BcaVJ/aPRP+Ekjk5ijRkPQtJzUw11WGDbrnrkSVzMdzbSRqEUwBUxteLo+Dx16cD8qUyW5RT5o3BvnXy8BgOv8qXt6u7Q/Zw7nTrrSH/ljjPP3xT11iM9YD+DCuUHkqNpkB+bPT+EEd/8AgJ/KnR+WPLHmIuwgNjkg8f8AxJ/Kn9Yqdheyh3OsGqwn/llIPowqRdVgx/qpf++hXJr8sQUyRjHP4cf4H8qIVdnj3SwjjDbnx2/z+VV9Yn2F7KPc68atCBzHKB9c05dVgPJE2T7VyKIxdiJBtGSGz14P/wBaryWsr/MxU9sbsE4Df5/KhYifYTpR7nRrqlv6ScD+5Txqtp3Mg/7Z1gm0kMwHksVU/MBkE8nJ/IH8qke2kCnbbsBg4J4xzj8cYP5e1P6zLsJ0l3Nv+07PJ/eP/wB+zS/2pZtx5rD6qRWDDbEsfNjkVQVDc/TP54b9anito8L5h+cDn9594cZPtjB/Oq+sPsL2S7mwL+0z/r0x75pwv7XPzXEfB681mW+nwtAzPc5blcrIMbgM4x68dPetKLQrOZVC3beYVJG2TcG+9joOOg+uRT+s+QvZLuOF9aFuLiKnm7tSD+/jyPcChPDNs73I/tJSU3bAjA54cj/0Fcf71aEPg2zkbH9oqRzhvMGDgv8Apwv+TTWJv0D2XmZ32m3J4niP/AxThNDtys0IIOfvjNakfgW2eHeNQXIcA/MPulsdPxFWYvh5bTFRHdAhpOHDD7vycYI/2zzT+s+QvZeZjLJGW4kj/BhSkj+8DzgDcKvJ8PGlgWRLjO4rlflHBCcf+PHn2FUbj4f3amXDhtoyuAPmGP8A6x/Sn9ZXYPZeYAjPUH6HNOVSBkYP/AaoX3g24s7dWMkpl3MpAA25BYcf98/zrF1dJfDI82W7mjgbBJ2HIJZlAK9+gJx60nioxV5IFScnZM6tx8x4I3cUxlODjg1x1v4zhbG67gkH+2jKTV6PxbaMMMYz7rJ/9ahYyi/tDeHqLodEydAMH+lKQcZOPyrFXxXYcGRgBjrvFP8A+Er0cHm5A/WtFiaT+0ifY1P5Wa54OMZ/CkAwRwTisr/hKdEYcahGD9DUR8U6Hk5voz6YQmn7en/MvvF7KfZmyVO7hSaCpPIBxWMfFmhZP+mr0/55tzTf+Es0L/n/AFAP/TNv8KXt6f8AMvvH7OfZmxtGBkfnTtvJyMc4x1zWKfFegkf8hFM/7jf4UHxZoRI/4mUY+qt/hR7en/MvvF7OfZmzgZ7+9NYdD/Ssj/hKdCb/AJiMOffd/hTl8R6Iwx/aloOeMsRR7am/tL7x+zn2NIjofT1NI+0HoSO9EEsVzEstvKksLjcrochh6g08nggEnj861I2GEc8AdaaRgEnOPSpQuV5A/OmsB0GM0AM753UjDjIP50vOe+D6UpG7BGaQyNQSOcY7DFFO7c8DNFAGGgO7GTwMYp4+6fekU4PsaeuPXp6VkaCkDZ1P4mlGCPfFJ2685o/h70gJFAxnA/KgDtnrxSLhlIPUVKgz249aYAV+btTlxng/pSqvr+dSY7gnHY00IYf85qO5ghuEKzqjr6MM1OBn1xSZ6ccUCMRvDekE5+wwH0Hzf41etdNtLTHkW0UXuEq31AABxSk9Mjnr1pJJbDbb3ADAXOQOmAKenytt/PikXGV4z29aeg5JB49aYh4GT1wO1OYDaM9uvFNUkjr15qQduf1piGlRknI9cYNNZM7uOCPSpOQee445NGMeh/DNAhnlnrzzxUjIMDBIx70qYz0H5VMfQjkHnC07gVZog4KyYdSOQwyD+BrNutD02dt72qRyjjfCTGw/FcVt4O7J6d+KjZeeppk7HLy+FrZ3JN3dk9V3hWP545pv/CKWvT7XIM/9MlNdTsyMjnI4pPLwOp/Olyx7Du+5y58KxseLx8gc/uF/xpp8KJ8+Lpjkk8wgevv7mupKEDjHHqaPLzgjpn17Ucsewc0u5zJ8Kgci7QEj+KL/AOv70z/hF5R927tz/vRN/jXWNGDnC5/CnBDkdvwo5I9hc0u5yi+HLlW+W4ss8dUfH8/anjQ9QChEm08Dsdkma6doTu6jj3p6x8gt396OSPYOZ9zmjpuqgl1msgDnO0yAdCP6077LrO0Dz7fBOT+9cevt/tGuiZMry3T3NL5YOCf5UckewczMJRrkfmDNoUkJzmVjyc+o9z+dEK63BN5qR2jNnGDJkHofT2/U1umMgZGcilWEcnOce9Hs4dg55HPzjWZF5sbIn+95q5PT2/2f1NVPs2rg4XT7cYGPlnQZHH+ArrfIBWgQ5ztH50vZw7ApyOOSz1RB/wAeC8H+Gdf8fp+VI9nqL7h/Zzr2/wBauP5/5xXZG35HQYpy2/XOaPZQ7D9pI4cWeqI2Utrlcj+Fx/8AFULBrSKVjh1Be5Ac/wDxVdx9nXtnimi3JDdcZo9jAftJHGiTxGqlc6oVxjG49BnjrTv7Q8TrnEmqAZyeWrsBBgZ6nvzzR5J9MY96PYQD2kkcmms+KVT/AF2phenJY49RyKgnsNa1xY21R75wjFow8gTbn73zH1x2rtVhz7596kjRcD5TgdKTw9N7j9rJbHFr4ODKu9LVMf7bs34kHmnf8INZN80hTPU4Vz/Nq7YpjBHXPamsPc01QpL7KE6k31OQXwPpnORnjj5P/r1KvgvSAPmiOfbArqsADBwTS4zjjjpnHWn7Kn/Khc8+5y58GaOcYgf3+akbwVpBGRFIv0eup257UHlOtDo0/wCVfcNTmurOSfwPpW0YNxz/ALVRP4F0zHElyP8AgVdgV4wcYpGU4HAHHrUuhSe8UP2s/wCZnEv4CsCMrcXI9+KjbwBZ9ry5Hr8o4rtgBj/Gkf7uB1+lT9Wpfyoftqnc4hvh/a9r+fnn7oqM/D63zzqE+PaNa7rB24J/Sk4Ax29KPqtH+Uar1O5T0zToNN0+CztFIhhGBuOSSepP1NWNpzwPepADg8n2zxTDjPXp9a2SSVkZ3vqxo38dMU04znPFSFf72D9KawHHH5d6YEZXntSjgkZHX0NOIIHBJFMIyCQWoGNboepFFOIJHOB6c0UAYSY7AcU9clQRnk0xPuk4x9aepBb5fSuc1HKeADyTQVyR6UuOB605cE5Y9DmmIBx8vp+tSY+TPy56UiDrjv8ArTuFAxmmhMeoXPRaefu44NNUcdSaU528Z/KqELhc9sj3o4zk4FICCOpz16UHv1wOaAEYYHOBmlUYHvj0oI4IOTgU4DgY54655pAHIxkZ/GnLg9cfWmA8YOODxTzn5fX2FAiSPGPWnjoMZ4zjimLgDr7YzTui5GMUxD+WB+9zQmQvfHpmjCgjsewpQeQOMfSmAIwGckY9z3p64bqFNMA6nOBn0p245GM0CAlSBwAO3tR7sB78c0hBzyppcgnGGx6UADYGTwT9OtKowoAGBj0peqg5IP1oA4AbPPfNAAEwCACSfal6g9e2cmgIF/H9aUcfeweOvXFMQY4IYcfWnKMcKVpgc4IOBz6daVAOmccdDSAcBwO+O+KkQZX+IegpnYe/FOHy47/QUxA2MDP4ZNDDIGNu72FKwPYZ57Che4ORTAULwduTzwAMU447nGOtJ0A6cfWhjuwRycdu9ABwTxg5HpT+D1Jx7CmkErg5GKGGGzxigB24FQMYPTGetPBJHbr35qJc4I/HpmkGdx+8McfWmBMOvQn6CgDHb8CcUzBCggge+aG45yMigB6gLu5z+OKRyAAM9fU9KaGOT1/LrSOxII5x7CmAAgnpml27gDikBDZB3D8elPB57YNACKMg8fWm4I7EfjT8gDnaD3HJpBzjAAzx3oAaD2z+tIRjuCKTIGemD2xRnPBPPtQAEHP3h9KQDBIxx1zTmwOBnpnNNAzk5HvnrQA4ZOQCTijJzgZI9aQA+vSggng/UcUgGA/KB796Q9/TtzTm6g4/+tTdx64OT60DI25TkgY6YoxweeT7UEAdyM8Uq9sYFMBCD0Jx6ZpqnAPPTrzSt0wdoyfSg8N/LNIBpbqQc+tDkEEqR0pCTk8GlJyoyD055oAYfmOTjr35prAZ6D8s04j5QcE/jSHr0H54oGMIIyATRT37dM0UXA54ds9O9SK2O/HSowCP/r07ccLk9PSsDVkwI47n6Uq46c9aiQ84IwM8YNPBH09KYiZDxnH60c9Mceuc0xGzwCKfu7cAn0ppCJk6j0+tO/hPP61Ep+UZIzT0bjaWU8UwE4HHFGeeDQTx6DNICd33jjHpQA8OCTggA08gkDGPTgVDu+bg8ewp3O04DfTNICQg+hyOBSj74GPmpisfM9T0p64PO5c/WmhDu4BOBmnLySN2QByMUxWJwc8elPyc5yeeDTEPDHPVscGnkMRwWqNc5I+b2FPPA6HHXJPegQoyfuhsdeaANuOAD9aByMsAAD1JpSQM4wD1xQAOeAAKVfmyMKD/ACpWzj7wwPanKeOmSe2KAEXBA7GlA5xng+3Snbj/ABZPpS5wMnJz79KBDBjkMTz7dqXbx3wfSlAw3Gfpml/hAwcDnBPWi4DADhvlJz3P9Kdj+8FHGDSHb6du/NPXk9s9sCgBMgLwefQCnbcjGSSeRQM9i2fpS4wD6fWmIMENyP1peMjPXp0zTBjC4K896epYjvgegoAVcAfjTm6DAJOMZzimjcQTtYenI5pWwuMbR+OaYDs4XBAwRjFKCO2eeeFpAT7cjgYpDnrh8e5oAd83IBbP9KANvp1780xgDnAGfz4pVxs7Y9AKaAcOM5YDtgChhnpnk0MeMAE4Pc4pDjBBAA9zQIcORnnp0zTVyQflApy49APqKRT97p/3zzTAOMDhfUUZ4GAMjuKGbvg+3FMLEnOCMe+KAHFhj6e1ITljjdjOelIPvdM+2aZxkD5fQ0APGTjlqQZBxnJ680hIz/DxRu9MDnjigZJ164P0qPOcdCfXHSlDD3OKRixOdpNACkEnPOPemqecn+dGcEnb34560hIIONuKAHMBuxjH48UhHTOOPemsxPIAGOlIGJJ9f50gFyNpGBntmkyccHjPYU0Ng9Dj2pSfl5Ix65pjGngYG6m45xx+fWgkZyTj0oJ47Z9cUABwWA4/WjPy9Fz274pHIBGCPejOeh/KkMQsAMcH6U0EEjsPTFPPYEE8VG2cdMds5oAVugA6H2ophY4565zRSAwQfpkUvTqcimgj6YFKjDhgSD1IrE1H9+M4py88DOffpTQe+DTjjJ2g0xDkJGeBxT1Y4bOMUwfQYz60o4U4PvTETLjsQKcoBXqPyqJWOSeSP6U8EgDrQAu7GOT0oDepY/hTWOSOWz25rD1DxTpGn3klrdXZWdDhlUZ2n0J9aTkoq7BJvY3l/E/hSn7gwMg1gQ+KdMm+a2dph/ssn9WFSnxBDxtsrtv93yz/AOz1m69P+ZF+zl2NtSM9B+NOBIJ6AjrxWA3iNV/5hWqN/uxKR/6FTJfFkCHdJpeqK3uij+tL6xS/mF7KfY6RJcnG449cVIDkfKSfxrj28caajDzLW+XnuAP61oaZ4l0q95SXySTgCQ4z+PSmsRTf2gdGa6HSgnPHH4ilz0O0fnVeOVHUFZI244IbNTBh13KM9ia2uZkhA3ZwOvPXmnA8DOc/TFQNPCoLNKo5/vCmtfWgbm5jGD3ai6CzLXbkkDrThkDAJ47VR/tKwRcm6i/76pr61pa5/wBMi7epqeePcOV9jTwSCcdPehlyvO3kdM1jnxHpaA/6SGJ7hDTP+Eq00fdaQ/RKTqwX2kV7Ob6G1gbv4cduDTiAQ3brkisVPEFvMwEFvLLnssiA/kTU41diCRpd2eTn94lL2sHsxezkuhpchQfTuOKcDt6HnHHNZZ1Unrplz6f61OtOfVAgU/2fcHd6SIf60/aw7i9nLsae7GMbcnrSjGATjvWfDqiHlre5QHnqhx+tKur25B3JMD6Ejn/OaPaw7h7OXYvDAAxnOfSngkDrk+5qhFqdq+dwlTnHzAH+VT/bbPAzcoCcdB0zj/Gn7WHcPZy7E+AFPc5/yKc2C2ecd8DpVUajZ84uCwJz6fj9OetNOqWgOMuwJHK8in7WHcPZy7F5c49c56mkPQAgZ+nSoUuw0Qkjtbt+fuiPmorrVFhAMlhqC5PUxgUe1h3D2cuxbPXgMMHIwKVRnsefcc1hy+J7KMnzLe9X6gZH61H/AMJdpoABhuyR22Dp+dP2sO4ezl2OhwBg8AfnSDHHAFc83jHTypxDdkdM4Qf1qOTxppqlQba99ONp/rR7WHcXs5djqM5GcnBpBlScE49zXLr420vbu+zX+B/0zH+NKvjTTWJ222oHPYRL+nNP2sO4ezn2OlYcZ+UfjQoyAQFyB61zg8Z6eTtFjqhPoIl5/Wnr4tsiCBZ6iB0OUUf1o9rDuP2cuxvjG8gf1ppHA6Y9hWKPE9meRbXoA9Qo/rR/wkllnPkXWRzzt4/Wn7WHcXs5djZxjjPGfSkGcHJJ5rHXxHYswBguF56/Lj+dTPrVooDeVOQR2Kntn1o9rDuHs5djRx8yjPf1pD9/p+tZh12yIP7q4Gf9kY/nSf29a5B8m5P0C0e0h3HyS7Gnxkk4oyAcZ7+lZba9aDpBde2QtRPr9ru/497sgfTpR7SHcOSXY19wyRzyO1GeeS3TjnrWN/b1sW+WyvCfwpRrcJUg2d3xxyBij2kO4ezl2NZskHgfnSIw24x+Xas2LV4pZo4zbzxhuNzrx/8Aq6VfywznjFNSUthOLW47cO2PwFNPbBb60bgDnI/OgEduv1piA4POGz70gOCeCT9aU4I4I/nUbMMHhfpQMdvAPQdaaT7dOnFNZvmAIJHpikbdk8kAjrQAE8HufYUUhYgHkjHfFFIDnA/A5BqRWyevPfiqocYOP5U5Hwe5z3rE1LqvzycZp45quhyoIqRCOg65oAmQ89Rj35xTlYdz1HaogQSScf40/eQe+TVCHnrjn0p64zwBzx0qPfj19OaXqOgHvQInUqGGVBxz9K831vwnJLeTSG2uJmZi3mQMPnBORkHvXoZZQew+tKSN3ByDWVSmqis2XCbjseTt4RY5zpupH3wtNXw35LZ/s3UM9ty5/kK9bXlupxUhA2jPr1rB4SL+0zRVmuiPJ1srqPG211NP90EfyoknuoVKmPViO5w3+Fesqq5GTigL1AY9fzqfqEO7K+tS7Hjc97IF2m2uxz1lVj+mKdptjquqOw0+yfZn5pJV2KPz617GV5OG5z70qLhuWPAxjFXHBU1qyZYmbWiPO4fBmrBBvv44zj7sK8VYbwlqrQiP7cMZ+9tG78677APXJ96UDDH5Sfqa2VCn2MvbVO55q/g3WB0vePfH+NQy+EdbT/l6DZ6bYy38jXqJQcnbQF5HIGfUc0vq1LsP29TueRyeGNeTq3Hq0Lj/ABqu+ha2oz5kOPdXH81r2Vc8A7jkHFSAMVOC/wBM9aX1Wl2D6xU7nhzaVq4OPMsyfQzAfzpp0vWuqx2zf7kyH+te4NEHzuRTn+9zUc1latw1tbE9sxqf6UfVKfYPrEzyzSF1e3QI1hDF/trIqv8AwZOec/c/M1qpJqYaNvI5RUXmcYIURjpjqfL/AFrtLjSNOcjdZ2p/7Zj+lRjQtL76fb8nGAlWqCWwvby6nJQXGpRmEtb7njdW3faew2cdP9j9aiUakjxMluoMeMfvx1Hl+3+wfzrs/wCxNLA/5Btv/wB8/rSjQ9L/AOgfb8eop+x8w9szko5dVAUNCDgJ0mHJXy+2P9g/nU9vd6pDcxSCKQqrAlTMpzgIOeP9k/nXTHQ9L5xp1r+VINB0knjTrfr2U/40eyJdW5zkN9fxtHmCZvlCn9+vGNvIP4Gr9lreoW5U/ZrkttCsftCnOAoPOOQdtav9gaWD/wAg6Db67T/jTzoOk4GdNts/Q/40/ZeYucba+L7+CZWFlclQS2DOhwSAAenbHSug074mahaMuNMm2eWEZfMj5bu/TqePyrAbQNJLf8g+2+m05/nSroGlbc/2dAfz/wAabp3Fz2PRbX42XIP73Qptm7+GdOF59uvI/L3rQX432ksojfQrqMHozzR4H1ryxNB0rPOnQD65/wAaR9B0nH/IOtz7Yb/GoeHTKVax6DdfG/S58H/hHrzeCP8AltGOB17Hr6VX/wCF3aWHAfw3dyqQQwd4iv8AKuEHh7ScZGnwH8Dn+dL/AGFpIbjTLbGO4P8AjS+reZXtvI7K4+M2kPgr4RmYEEMp8oY+h2nnr+dZ7fGGx8xwfBsbqPu/vI8gfw/wf5ya5w6BpGDjTbb8mz/Og+H9JOP+Jbb/AIBv8af1bzF7byN7/haeitMZ5/B6rNvJ8xJUIC4PIUrgNz+vtWL4j8e22pDOm+HAm9dskrssbMck5AQYHXB9aaPDukAA/wBm2/4g9fzpV8P6RnnTrfPpg/40LDeYe28jm5dbvH3D7DIF3sR+9GcEk46e4pE1y9RMf2d82F2t5w+XGPb2xzXSjQtJ76bb/gD/AI03+wdK7adbe/BP9af1Zdw9t5HNPrt7uQixKYwWAlUg/c7Y/wBmkXxDehFVrLJAUD94O2z2/wBn9a6ZvD+lZwNMt8duD/jR/wAI7pY/5hlsD64P+NL6ou4/rD7HNReIr2MxD7G25O/nA+nTjnp3qOHxBdKNsto/PJPnDk4YenvXUjQdJAx/Ztvn/dpy6FpQz/xLbX8V4o+qLuHt32OaHiG43Kws24Vgf34Gc7/bj7/6Uk3iG6kaRmtmBeQyf6/gZ3cdP9oflXS/2JpgA/4ltr/37pW0TTc8ada9v+WdL6mu4/bvscoPEFwZQ6QHcpXAMucAEH09sUi6zMI0TyWG05OJsbh8mP8A0H9a6waLpmf+Qfa+x8sUjaPpxAxp9qD/ANcxR9Uj3D277HIrq9ysu8DjbtI8/j7u3/E/jSvrt19naNmyCQcmbuN//wAX+ldf/ZWn9rC1z7RCnJptoCcWVsB1/wBSv+FH1Rdw+sPschbajeX95b29uuXcqpw+QAGySfb/AAr0CQ7pZGGMEk/Tmq8FvHAp8mGKLI5MaAf0qYn3Ofr0ranSVO9iJzc9xCepH4fSnFsqOo5qNuoz9OTTQQDyBg+9WRYcW+9tyCPemMcn8KRSA38Jz3ppIPUg4oAcSOp7c8cU1jwOMD60jdgBnAphPynKqM0DHh/U8/Wiotw6AfpRQBzKtgn09+lPR/f2xVNHGTz1qRH55P5Vz3NjQjYHjjpU0eSScZFU42xjAzUisQw9B6mqRLLiNjrjJ9Kd5mD1NVlfnv14zUoYc9aYidWyejY9c0oIyM/zqJO3Ge1OGMdAMdsUAPLHPBHI+vNPDZHQ/hUOfl608n8fx70gHjlhnr35qRT2J/SoNyg44qVTgjGcigCZTnv2+lKp4Oc/Wo8/eyc59aN3OMdaAJSQR3+melOUd+fz6VGG+7159qUnC8D36UxEo5PXOPejqM5yPrTVycc4GeeOtLnJwCc+5oEScdxg/Wmnhh3HfikB54PTtmng5OM9aAEHQ5JJ/lSjnHP60mct26UoOOy/SmKxIAAvONw4zSjGM5GfpzTCRgYxjHak3ccZ44zQA7GRzSDpnk80pPz8k4pOc4PA96YrARkdD70KpHQL+JoGMZwDz3pc4z0HpgdKYWFxnOcevAoXr/iaOScBjg9qB1PAP160CFxnnP5mlXAIOQcHil4B6rikB65b9KAsLtHGAeaFUEAYIP1pTkgcDHSkHQgqKYWE78gD8M04HhuTkjjim7s85Oc9hTycHBGeOtMBBzzg8DuaVV4HQDFIMYPC5HOfWjK4479MUBYX1O7LdaCpJI6ClI/2mH6UmSTzg/jRcVhduR2x7mlIweTSZ29SPwGaXsMcEU7jEXG7OTihUBGFOT6dKTnfwc596AcDJI465NAC44AbGR1NB6ZJBx0NNLEYIOQe+KUcjGDnr7UwFB5/HHApAdrjg9aaTyOM9uvShj1PH50APYY69O1IccYNMLehA9RSlgQRk+tACc7fX3x+lIwx1B64IpS5K8Z96QngcfrSGAz2HH1o7jp17mmjkc8D0zQT0x1+lACg88nBHb1pN2BnjJPpSEdT83rg0jYAOCTj0oAa7AgMMfiKCeOQfXpTNx6dj19qYT852+uMk0hji3oDnOaRm+b+gpisSOelN3L7UgHljxyce1NJyTnr+dNbHbA+lITswcLjvjvQAoc4YnNFM7nODmigDjVk+XrjFTK2RjNUoyeowKlV/XPWuZM3ZoI/I5zU6uM9RVCNgcEdPep0Pr0qkyS6h5znj2FShznPP4VUVh69fapg49Tn3qhFlSMHjp6ml3dvU+tQD2xnrUm4H6UCJgR659qUnOOehqJWz2Jx71ICOnGTQBICCwH9KevQnByaiRuR0P6U+PGcjr70ASrnB/xpQ2TgH8DUYPytgjPWlBwxzn8qBEoYZHXpwKXPP07UwDKjr/SnE8g8daYExPAJPbrmlJHGMZPtUZOCMYHvQc7uuPagB+QKeGzzzwc9KiAJPv0605cjB/r0oESZGM849uKf1HJ5NR5GD04p28ABSRn6UAPyMc/oaUKCOevXrTCQQMEEfSnB+2entQBJtx3AB4PNIyYTA7dqcHBPI5PtSsRs5PFMRFgbQoNOG70OMdDS7cZzn8aUJ8/YCmAgOAM+nFN7k4BJ/SnjGRnkU043L/KgQAnOQT+XWlzk5+YD6Ug5HGePU0vOegBB7mmA5SDjPH1NN7HJHPpRkcnHPpjmlUem7FAAfvdDx3zjFBPI27fxpT1I7Zxye1M3nPb8qAFGc9QPwpd2AeKaeo4Y59qXOBnApgKPUAZx3NIj8kZHtgUgbjH1pMn+Hdkc8UwsPDkdcn9KU4Pp19ajxknrRyAQMY9qAH5AC80hOOp54OfSmMTjHP5UHryTnHemA8tnJOTSZyoG0A/WmEjBGD+JpAwzg4zQA4HPQgE0mTk5b8cUZAzjpnPSg8dMk0ABZuCGP4Uo5PPr1Jpi8gdeO+aUH72AOeaAAHjjbTh0HIx61GQcA4HvS9sn9BQA/cT35xQATyRnvTO/GcY5pWbg4BPGQTSAc2AuRxg9AajdwCVXH40m4kEgL75PSo8nPPT2ouMCeOSPwFNbPbqeaVmPTOP6UzceeeO3FK4Dc8gg8+tAyH+bv2oGM9eKQnBzzn16mkAm7I7flSk8E8DjsKafx9aYxwoxmgYrEgg5Jz7UUwn5u+KKA0OGRwO/0qYNnpzmqUZNTKeAcnrXKjcto2B1qyrnj5qoqcenPep0PAIxjsc1aYi6r5Hp34qZWBOcVTQg9D27GpUOeTTuTYuA9CMVMrKTweneqiv93IytSg+rZGeMUwLG7K8ipFOeegqAHjuadGcZxx3yaBFkHPPOcdqehOD8uCahVsHAORUikdselMRKp4zkDPtRkZ4JpoOQeg9qcDnPPSmIXPAHJ9qVeTnBB96ax54yfpQcDGc0CJQeOoxTwxJHX6VDn8AeKPT7x560ATg7fvA8+p7UKRgZ4I45NMGOnzYNKCBggYHuaYEpIUjaRS7vm4JIxzUeflK5ANBxnnke1CEWAw44OelKMgkc5qAHAHH504N3xge5pATbgecH86kBwOnB4+tQAkEZIqQE7jyMHvimMcGAycYpQ+BnjJpqHgFsZpCenoB6UxEwkGVyeR3ApT1BAPvVcc8807txjB96AJRsDckAVJ8pbgj8qq5I6np6U4E7SefxpgWAAOOWPr6UgXn+9UKdz0PpmlBwB+dAhzYCj5l9qb2PJP0oZsqBwDn0ob7xByR69KYwOdvH86OSOg6c5po+7jHHXk0vdeg45NAhF6jaevtQ3XuRjqKXPGc0HGcnP8qYA3QYGKQAYA4FLngHA9T70oORjIzQAh4zznHemMejYODUjHcByfemkcAlR9SaAG8Y98d/Sg9ByOnanEZzjH07UijJxg0wBCeQCfyozkD5WPrRjjkcGheMYHGOOaAG4JYZXg8cmlUDccDBpenQD8aaWwf4TjtjNIYmOA2ePYUpbC4AbINITz1GOegqNupHf3oELkEEEjPpSAqDgEZNJluRuUZ7GgH8/pQMVSexwORikPJ+tNLc5HrQxx1JJ+lIBSFYjqKjPGeuB1yOlPzxxn3pjZB/+vSGNOTzzjrmmHtjn60rfMDx79elNY8enHHNACkgEHJPtnrURBI4z9KUnPULTHOemPwNIQrZzz9cUUxmGckZH1ooGcCpz2xUwYY+vpVRDzz2qdD7ZrkR0ltCCMd+tSp6Y4qshyRzVhT+NUmKxYXp15qdeVA6nNV0YAZHSplYH61SYiZevB/WpBuXj8KhUjrzge1SK5AznrVEsnRicCpVfgEj2qGMnI6+tSKVyMc+57UIROrDn1qYEbAT19qroR6jGO386mXO3rk1RJIhOT0APSpN3OC35CokGXBz2py54BYn0GOBTESMxIHU5oYZOefzoxkY59aQDnGMgigQ4r7jFIc7VIPGaQn+7jNKGJAySfp2oAcSOME9acW5qM/Mo4Oc9qcSOOo/XFAD1+6OADS8he2fao+AP4fxp4cYPI49PSmIcCfUggYxSnOAcdPXtTCScfrRxtwRwPWgCRD0LADmpkb1qt156U9DyPQ+tK4FnJwDnnNLn5R1z34qIMAcZGP5U/PHqaoB/cnH64pQcDGAPemqw7qfXmgtxyfagBSenOM8mlwMA8sBTSfu5K/Snuc5zj2A6UxCLtyRjA96UAcdAaO3AHTvSBjxnA9aBj+MY6k9aRunTrS/xZHH4UHlcEkn6UwG4PPHHvTuAuTjINNwS2BuP1704EhBjA9MUCGgkk/McUEZI4z9aUAnAJ4pvYDHHfNMBeTnpkU7djJyMjjgUwEZbG3pwTSDjq3btQMfuznvjpSfeBxQe2Rk9M00g4+7jtzQIcWweoGPSmFzgAk0E4IJxzxx2pD+XtQAvXtSKORwAc0cDoDz+FIVHqMe5oAeSSDwBTGbuG46ggUA4IORzx60056g/gKBik8E55HtTSMk5A980mO200mOmRg9KAAnAxgZ6/SkzwM5z6ClIxwBg03ORz+lIBDj/wDXQcdhk4ozz349RTMc4GT9KAHjGOc8HPFMYd8A4P40DHQKenJ9aRjyNuQPrUjGtjPQD2phxnnGPbtT3I4qI5GTkZ/lQAgORjpjpxTXGTxxijcQG6Y96blsdR0oBCFscjH1NFNY7h94HvRQB56hxUynOOKqxtzmplb9a4jqLcbZA5yKnVs+tU42A61NHJkdatCLkbZ9Pep1YbBz+VU1btVhGAGO9UhFhXz7ipVY9xyB6VWRuxNShvQ9uMU0ySyh468VKCMgd/eqyEcA9cVOrkEc96pCJ0LZ6DHvVhTleoHNVEbFTK3BAyM1SIZYQ8YWnqTt56A9qgR/fipl5Tp9CKYh5IxjdgU4dRg8+5qI9CCQAKf1bGfwFADzyexPqaQ8854FGBjj8fejJ4IOMelAhxYbfXFAAGeOaaDgckke3eg4x/FjHOaAY7bt4PGKcSMHDceopg6dPf60cDgeuaYh4G7qcn6UuOpA+bHemg9ee+aUnnPJpABGMYGfbPSkBOBxx060E56jnNKCeTjPP40wHhscKoqRZOew9xUJwQOBjpS+mP50ATh1IIJJpdxLDAqAHb94gewp+4bc5zTETjJHIApcnuaiDE8heP0p287sEjjrTAkLA9cn+tOBJJ4BHXiolIJI3Z54p6EDOMgimA7cSckgDP1pw2kEHI/Coi3GRjmnBwc5YnHtxQA8444PPenYxGcBRjmmAhuAT15pd3ZefqaAEBB78GhzlBwT9aQMR0PNKemBnnmmAA5PTk0mRzk4/Cm4KkfKfb0FOPDg9vegBDjOOaQkgnOAPenBzxg8D0pDzghTj69aAA5HPGPagYB+8SaM9MY9hTN2eB3/AFoGOBzkEA/U0wAYGQB9e9Kucnjg9OaT1xgd6BCAgY9c0hPODk5o3YPUfhTSe+SR6UAL19Tx3ppPPAHGODxSkgN3J6Cm8kH5en60hisOuAAOlMY8ZIx9KcTgZ9PWo2yxz1A6UALnggZxSPw/Q4GDRnd69Ofc0hzzkfWkApAPByB7U3OCOOR3oY+xxnnJpGIyMD8M9KBjc/kDSeueO9DdT8o/HvRn/wCvSAjLZJJ6fpTGPA5pxBPoBUZbgihjEcg8du1FNcniikB5z06VKnWiiuJHSPUnLc1ZiGV5ooq0ImUkH8amH38dqKKpCLEfzEg9qmHCnHrRRTe4iRD836VOnHHvRRTJZIvHT2qZCcLzRRVolkvRSRxT1/1ZPeiiqJJlAwT6Yp6kkUUUAJ1APvTwAMjt1oooBbiSfKOOOlIGJ6miigAjJ3H0xUjjBXHpRRTRI0k5/Gkydp5oopAIWORz2FSAcfjRRQxDu2e+adgbW46dKKKfQAzhlHvSBiH49KKKaGTR8qCeeO9CgArjv/hRRQIP+WYPfrT4zuZt3OOlFFUMkUDrgdPSlIAHFFFAEYY7Tz3NPXmTB6YFFFJAPKgKMDtUcrEDgkcZooqhDWJz1PepF5fkk0UUxgeAccUn8B9qKKQIGUBOB3pjnA44oooAbgE4I4p20FRn6UUUAMBIPFMZiHUA8UUUhCxjJ5pdoy3tnFFFAxo+5imk/Ow7DtRRQIjZiFGD2NN3Ejk9s0UUDG5J601j8gPfNFFIa2FUkjJ5oPY96KKkCI8EgdKZJxkDpRRQCIXPOO2KKKKBo//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_61_37855=[""].join("\n");
var outline_f36_61_37855=null;
